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ABSTRACT
Due to its common dysregulation in epithelial-based cancers and the extensive characterization
of its role in tumor growth, epidermal growth factor receptor (EGFR) has long been an attractive
target for monoclonal antibodies. Intense research has culminated in the approval of two
antibody-based drugs against EGFR for cancer treatment, with numerous others in clinical trials.
However, therapeutic efficacy of these drugs has been disappointingly low due to autocrine
signaling, receptor mutation, and transport limitations, necessitating novel antibody designs and
mechanisms of action. Recently, it was reported that treatment with combinations of antibodies
can induce receptor clustering, leading to synergistic receptor downregulation and anti-tumor
activity. The aim of this thesis is to elucidate the details of this phenomenon and to exploit this
mechanism to design more effective therapeutic antibodies targeting EGFR.
We first illuminate several key aspects of combination antibody-induced clustering. By
screening a panel of pairwise combinations, we show that the most potently downregulating pairs
consist of two non-competitive antibodies that target EGFR extracellular domain 3. We further
find the mechanism underlying downregulation to be consistent with recycling inhibition.
Lastly, in contrast to the agonism associated with ligand-induced downregulation, we
demonstrate that combination mAb-induced downregulation does not activate EGFR or its
downstream effectors and it leads to synergistic reduction in migration and proliferation of cells
that secrete autocrine ligand.
To enhance antibody binding and induced receptor clustering, we design multispecific antibody-
based constructs that engage up to four distinct epitopes on EGFR. We engineer two classes of
constructs: one consisting of a full EGFR-specific antibody fused to the variable domain of a
second anti-EGFR antibody and the other consisting of a full EGFR-specific antibody fused to
one or more EGFR-targeted tenth type three domains of human fibronectin. Both classes of
constructs induce robust receptor clustering and downregulation in the absence of signal
activation. In vitro downregulation correlates well with in vivo inhibition of tumor growth in
several mouse xenograft tumor models and mutational analysis demonstrates that the efficacy of
our fusions is attributable to both signaling effects and antibody-dependent cell-mediated
cytotoxicity. Our multi-epitopic strategy may be readily applied to other receptor systems to
form the basis for a new category of antibody-based therapeutics.
Thesis Supervisor: K. Dane Wittrup
Title: C.P. Dubbs Professor of Chemical & Biological Engineering
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1. Background
Epidermal Growth Factor Receptor Structure and Signaling
The epidermal growth factor receptor (EGFR, also known as ErbB 1), is one of four members of
the ErbB family of transmembrane proteins, which is responsible for mediating the effects of
growth factors such as epidermal growth factor (EGF), transforming growth factor-a (TGF-a),
amphiregulin, and neuregulins (1-3). The four ErbB receptors (EGFR, ErbB2, ErbB3, and
ErbB4) are prototypical receptor tyrosine kinases that homo- and heterodimerize in the presence
of ligand to form ten functional signaling complexes. Receptor interaction results in trans-
phosphorylation of tyrosine residues in the constituent receptors' intracellular domains,
recruiting phosphotyrosine-binding adaptor proteins which in turn activate downstream
pathways. Each ErbB receptor has distinct ligand-binding and dimerization propensities; For
instance ErbB2 does not bind to any known ligand and ErbB3 has an inactive kinase domain,
making both of these receptors dependent upon heterodimerization for signaling. Notably,
ErbB2 is the favored heterodimeric partner of the other ErbB family receptors and its preferred
interaction partner is ErbB3, resulting in a potently signaling heterodimer (4).
The interplay between ErbB family members creates a horizontal and vertical signaling network
that leads to activation of a variety of pathways, including the mitogen-activated protein kinase
(MAPK) pathway, the protein kinase C (PKC) pathway, and the phosphoinositide 3-kinase
(P13K) pathway. Activation of these pathways ultimately converges on transcription factors,
whose modulation leads to an array of cellular responses including growth, adhesion, migration,
differentiation, and apoptosis. The ErbB family signaling network as it is currently understood is
summarized in Figure 1.1 (2). This diagram encapsulates the complexity of the network, yet
eloquently abstracts ErbB family signaling into an input layer of ligand binding, a signal
processing layer of adaptor protein recruitment and transcription factor regulation, and an output
layer of cell behaviors.
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aFigure 1.1. Schematic of the ErbB signaling pathway including stimulating ligands, ErbB family receptors, effector
proteins, and downstream transcription factors regulated by the indicated signaling cascades, from (2), reproduced
with permission. Note that the diagram is abstracted into input signal, signal processing network, and output
response layers.
Among the members of the ErbB family, EGFR is by far the best characterized. EGFR is a 170-
kDa protein that is 1186 amino acids in length. Over 20% of the receptor mass is contributed by
N-linked glycosylation, which is requisite for both localization and function (5). Like the other
ErbB family receptors, EGFR consists of an extracellular region (domains I-IV), a
transmembrane (TM) domain, a juxtamembrane (6) domain, a tyrosine kinase domain (TK), and
a carboxyl-terminal region (CT), as shown in Figure 1.2. ErbB family members share 37%-49%
sequence identity and the three-dimensional folds of ErbB receptors are similar, except for
possible divergence in the C-terminal domains (7).
151 312 481 621 644 687 955 1186
D2 D4 TM CT
Figure 1.2: Schematic of the four extracellular domains, the transmembrane domain, and the intracellular domains
(tyrosine kinase and c-terminal domain) of EGFR. Numbers represent amino acid positions along the receptor.
11
The EGFR extracellular region is composed of four domains. Domains 1 and 3 are often called
LI and L2, respectively, since their fold resembles that of the leucine-rich domain of receptors in
the insulin growth factor family (8). Ligands bind between these two leucine-rich domains (9-
11). Domain 3 was identified as the predominant ligand binding domain by epitope studies that
showed EGF and TGF-a have sub-micromolar affinities for an EGFR fragment containing only
L2 and small adjacent sections of domains 2 and 4 (12, 13). Domains 2 and 4 are often referred
to as CR1 and CR2, respectively, as their sequences are cysteine-rich and consist of numerous
short segments linked by disulfide bonds. Domain 2 plays a key role in dimerization, as the CR1
domains of partner receptors directly interact in EGFR homodimers (11).
The crystal structures of both the monomeric (9) and homodimeric (11) forms of the extracellular
domains of EGFR were recently solved, although domain 4 was either disordered (9) or missing
(11) from the crystallized protein. The dimeric structure was solved conjugated to EGF and
TGF-a. EGF ligand binds to the receptor in two different states: a high-affinity state (10-50 pM)
and a low-affmity state (1-2 nM), possibly differing in dimeric conformations or activity (14).
EGF ligand interacts with domains 1 and 3 of the tethered receptor monomer, distal from the
dimerization interface. It is believed that binding of a growth factor induces a 1300 rigid body
rotation that transitions EGFR into the dimeric conformation, as shown in Figure 1.3 (15).
2
130'
2
IV IV'qi
Donwir' IV
A mxkdaes3- 7
0604to I N
Tethered Monomer Extended Dimer
Figure 1.3: Crystal structures of the tethered monomeric (9) and extended dimeric (11) forms of the EGFR
extracellular domains. Domain 4 has been added to the dimer for context using its coordinates from the monomer.
Domain 1 is shown in red, domains 2 and 4 are colored green, and domain 3 is shown in blue and red. EGF ligand
is shown in teal. The domain 2 dimerization contacts between interacting receptors are marked with asterisks.
Figure reproduced with permission from reference (15).
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EGFR dimers exist in 2:2 receptor:ligand complexes, although dimerization is entirely receptor-
mediated. The dimerization interface is localized to domain 2, as shown in Figure 1.3. Residues
242-259 of each EGFR molecule contact and interact with domain 2 residues of the partner
receptor (15). Additional domain 2 contacts occur between residues 193-195, 204-205, and 279-
280 of partner receptors (11). Domain 4 may play a role in the dimerization interface as it has
been reported that peptides that mimic modules 6 and 7 of this extracellular domain can disrupt
EGFR homo- and heterodimerization (16). Also, domain 4 mutations have been shown to
obstruct ligand binding and tyrosine phosphorylation, but the role of domain 4 in dimerization
has yet to be fully elucidated due to the inability to crystallize this region (17). The orientation
and interacting residues in the EGFR dimer are depicted in Figure 1.3.
Although the structure of the extracellular domain and its rearrangement upon ligand-mediated
dimerization are now well understood, the mechanism of kinase activation was, until recently,
poorly defined. Conflicting structural data showed the active kinase domain crystallized in both
symmetric and asymmetric formats (18, 19). Further mutational and biochemical analysis by
Zhang and colleagues demonstrated that dimerization of the extracellular domain relieves the
autoinhibition of the intracellular kinase domain through formation of an asymmetric kinase
dimer in which the C-terminal lobe of one kinase domain interacts with the N-terminal lobe of its
partner receptor in an analogous manner to the interaction between cyclin and cyclin-dependent
kinases. This interaction exposes the active site on one receptor, allowing for kinase activity.
The two receptors can dynamically switch positions to enable trans-phosphorylation of both
receptors, as shown in Figure 1.4 (19).
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i ( '
Figure 1.4. Schematic of EGFR kinase domain activation following EGF activation. Ligand-induced symmetric
extracellular dimerization (pink) effects the rearrangement of intracellular tyrosine kinase domains to relieve
autoinhibition and enable activation in a structurally similar manner to the cyclin/cyclin-dependent kinase
interaction. The active kinase domain then trans-phosphorylates its partner receptor. The two receptors may switch
positions to allow for activation of both molecules. Figure reproduced with permission from (19).
EGFR signaling is critical for epithelial cell development and its knockout in mice results in
death either in mid-gestation, at birth, or postnatal day 20, depending on the genetics of the
particular mouse strain (20-23). In contrast, mice show much less sensitivity to the absence of
EGFR ligands, suggesting extensive redundancy in their function. Knockout of EGF and
amphiregulin have no palpable effects on mouse phenotype (24) and knockout of TGF-a results
only in slight abnormalities in the eye and in hair follicles (25). Even simultaneous knockout of
EGF, amphiregulin, and TGF-a results in relatively mild defects including slight growth
retardation and irregularities in the small intestine (26).
EGFR Trafficking
The structural and signaling properties of EGFR are intimately linked to its trafficking kinetics.
In the absence of ligand, the vast majority of EGFR is localized to the cell surface (80-90%), but
it is constantly shuttled in and out of the cell with an internalization halftime of 30 minutes and a
rapid rate of recycling (27). Since the metabolic half-life of EGFR is 10-14 hours in fibroblasts
and epithelial cells and 20-48 hours in transformed cells, receptors cycle through the endocytic
pathway dozens of times with little risk of degradation (Figure 1.5) (1, 28, 29).
Once a ligand binds to and activates EGFR, the rate of internalization increases 5-10 fold and the
degradation fraction is augmented at the expense of recycling (27, 30). This phenomenon,
14
known as receptor downregulation, is thought to be a negative feedback mechanism to attenuate
growth factor signaling.
Oe~deton u I M Wd bne*e
............ 
Figure 1.5. Schematic of EGFR trafficking with
known time constants labeled. EGFR is
constitutively shuttled in and out of the cell with
an internalization halftime of 30' and a high
probability of rapid recycling. Upon ligand
stimulation, internalization is accelerated five- to
tenfold and recycled fraction is dramatically
reduced, shunting receptors to late endosomes
and, ultimately, degradation in the lysosome. This
figure is reproduced with permission from (1).
interact with the receptor. Cbl family
Acceleration of endocytosis rate is a direct
consequence of recruitment to the clathrin-
mediated endocytosis pathway compared to basal
internalization routes. Clathrin-mediated
endocytosis is by far the fastest means of receptor
internalization and is the predominant endocytic
route for activated receptor under physiological
conditions (31). However, additional modes of
internalization involving lipid rafts, caveolae,
membrane ruffling, and pinocytosis have also been
described (32-36). Unlike clathrin-mediated
internalization, though, these alternative
mechanisms do not accelerate EGFR endocytosis
compared to constitutive kinetics. Also,
accumulating evidence shows that these pathways
are active only in the presence of extremely high
concentrations of EGF, well above those observed
physiologically (37-39).
Immediately following activation of EGFR, Cbl
proteins bind to the EGFR phosphotyrosine
domain through complexation with the adapter
protein Grb2 or a presently uncharacterized protein
(referred to as "X" in Figure 1.6), both of which
proteins, which have E3 ubiquitin ligase activity,
monoubiquitinate EGFR with the assistance of E2 ubiquitin conjugating enzymes (31). These
proteins are in turn phosphorylated by Src, increasing their interaction with the Cbl-interacting
protein CIN85. CIN85 is constitutively associated with endophilins, which regulate clathrin-
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mediated endocytosis, suggesting a role for this protein in internalization. However, the role of
CIN85 in trafficking of membrane-bound EGFR remains undefined as its presence has not yet
been detected in coated pits.
Ubiquitinated EGFR is recognized by ubiquitin binding domains (UBDs) of the EGFR pathway
substrates 15 (EPS 15) and 15R (Eps 15R) as well as epsin, which collaborate to recruit clathrin to
the cell surface and facilitate the formation of a complex between the tetramer AP-2 and the
receptor to be internalized. AP-2 drives clathrin assembly and thus the formation of the 0.2-tm
vesicles known as clathrin-coated pits. Receptors enter these pits and are pinched off from the
membrane with the aid of dynamin (40). The internalized clathrin-coated vesicle is subsequently
uncoated and fuses with an early endosome.
It should be noted that there is evidence of a ubiquitination-independent route of clathrin-
mediated endocytosis. Mutation of the EGFR ubiquitination sites did not impact internalization
rate, implying that Cbl-mediated ubiquitination is not strictly required for rapid endocytosis (39,
41, 42). Also, siRNA knockdown of the UBD-containing epsin, Eps 15, and Eps 15R failed to
inhibit clathrin-dependent internalization of EGFR (32, 43). Ubiquitin- and Grb2/Cbl-
independent mechanisms of EGFR recruitment to clathrin-coated pits are currently being
investigated.
In contrast with ubiquitination, kinase domain activity is requisite for clathrin-mediated
endocytosis. Mutation of the kinase domain's catalytic lysine and competitive inhibition of
kinase activation result in significant reductions in endocytosis rate in the presence of ligand (on
the order of basal endocytosis) and inefficient recruitment to clathrin-coated pits (44-48). Thus,
accelerated endocytosis through clathrin-coated pits requires intact kinase activity.
From the early endosome, a receptor may be sorted for recycling back to the surface (known as
quick recycling). Unbound receptors are typically shunted to this pathway whereas active EGF-
bound receptors are rarely recycled and remain in the endosome as it matures into the late
endosome, also known as a multi-vesicular body (MVB). Within the MVB, activated
ubiquitinated EGFR forms a complex with ESCRT-0 (consisting of STAM, signal transduction
16
adaptor molecule, and HRS, hepatocyte-growth-factor-regulated tyrosine-kinase substrate)
through its UBDs. The receptor is then encapsulated into the intraluminal vesicles of MVBs,
which subsequently fuse with lysosomes, where protein degradation is carried out by hydrolases
(49). Small amounts of recycling (known as late recycling) also occur from MVBs. The EGFR
internalization pathway and approximate timescales for relevant events are summarized in Figure
1.5 and a more detailed depiction of the endocytic pathway is provided in Figure 1.6.
Ubiquitin
C a W e UBIDChi x Phosphorylated tyroine
' AP-2 binding site
Figure 1.6. Model of EGFR endocytosis and intracellular trafficking following ligand stimulation. Briefly, EGF or
TGF-a binding to EGFR (blue) induces dimerization and phosphorylation. The Grb2-Cbl adaptor protein complex
is then recruited to phosphotyrosine sites in the C-terminal domain of the receptor. The RING domain of Cbl in turn
recruits E2 enzymes to ubiquitinate the receptor. Ubiquitinated receptor is recognized by ubiquitin binding domains
(UBDs) of epsin, Eps15, and Epsl5R, which are associated with AP-2 and clathrin heavy chain, the principle
constituent of clathrin-coated pits (CCPs). Note that there may also be Grb2-Cbl complex-independent modes of
CCP recruitment. CCPs containing EGFR fuse with early endosomes (EEs) and receptor may either be rapidly
recycled or remain encapsulated in endosomes as they mature into multivesicular bodies (MVBs). Ubiquitinated
EGFR that remains in MVBs interacts with the UBDs of the ESCRT-O complex (consisting of HRS and STAM) as
well as Eps15b, resulting in its localization to internal MVB vesicles. MVB then fuses with primary lysosomes,
where vesicle-bound EGFR-EGF complexes are degraded. Figure reproduced with permission from (31).
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Internalization has historically been viewed exclusively as a mechanism for quenching receptor
signaling, but it is now known that most if not all EGFR in endosomes is capable of signal
transduction (50, 51). However, the signaling pathways that are activated and the duration of
activation differ for internalized receptors compared with their surface-bound counterparts (52).
While PLC-y and P13K pathway activation are reported to be restricted to surface-bound
receptors, the ras-dependent MAPK can be activated from both surface-bound and intracellular
receptors (53, 54). Endosomal signaling has also been linked to tumor development. For
instance, nuclear localization of EGFR has been observed following endocytosis and this
localization is enhanced in cancer cells, but the role that nuclear EGFR plays in signal
transduction or cancer development has yet to be established (55).
Aside from receptor internalization, an additional mechanism for signal attenuation is
dephosphorylation of internalized EGFR at the endoplasmic reticulum by protein tyrosine
phosphatase-1B (PTP1B) (56). However, the relationship between receptor deactivation and
sorting is unclear at present (57).
EGFR trafficking and internalization are also affected by heterodimerization. All other ErbB
family members exhibit slower internalization and less efficient degradation sorting than EGFR
(58-61), resulting in modulation of EGFR trafficking kinetics depending on dimer distribution.
In particular, ErbB2 is the preferred heterodimerization partner of EGFR and the formation of a
complex between these two ErbB family members results in enhanced affinity for EGF, but
reduced internalization and degradation (20, 27). Consequently, EGFR downregulation is
decreased and EGFR signaling persists for longer time periods in the presence of excess ErbB2.
Linking EGFR to Cancer
For the past three decades, EGFR has been under intensive study due to its common
overexpression in epithelial-based tumors. EGFR expression is found at increased levels in
many head, neck, breast, bladder, prostate, kidney, non-small-cell lung cancers, and gliomas
(57). Between 33 and 50% of human epithelial tumors overexpress EGFR and this aberrant
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expression has been linked to poor clinical outcome, making EGFR a particularly attractive
target for anti-cancer therapeutics (62, 63).
In addition to aberrant expression, mutations of the EGFR gene that dysregulate receptor
signaling are often detected in cancer cells. Heterozygous somatic mutations including deletions,
insertions, and point mutations have been observed in the EGFR kinase domain, particularly in
lung cancer patients (64-66). These mutations strengthen receptor interactions with ATP,
amplifying autophosphorylation and boosting cell survival (67, 68).
Numerous non-kinase domain EGFR mutants have also been observed, particularly in tumors
with EGFR gene amplification. Mutants with deletions, sequence duplications, and defective
kinase regulatory signals have been reported. As many as 20% of glioblastomas express EGFR
variants (69, 70), the most common of which is EGFRvIII (71), a splice mutant that deletes
residues 6-273 of the receptor (most of extracellular domains 1 and 2). Due to the absence of
domain 1-mediated tetheringin EGFRvIII, it is locked in the extended dimeric conformation.
The TK domain is thus constitutively active, independent of ligand binding (57). Other non-
kinase rearrangements within the ErbB 1 gene such as large deletions, point mutants, and
insertions are also common, particularly in gliomas (72).
Finally, ErbB receptors have been linked to cancer in the context of autocrine signaling.
Expression of an ErbB receptor in conjunction with an excess of its ligand can lead to
unregulated cell growth. Autocrine production of TGF-a and EGF in cancer patients is
correlated with increased mortality (73, 74). Also, autocrine signaling by neuregulin has been
shown to induce uncontrolled proliferation of human vestibular schwannoma cells (75). Thus,
anti-cancer therapeutics must often compete with high concentrations of endogenous ligands in
vivo.
Anti-EGFR Therapeutics
Extensive overexpression and dysregulation of EGFR in a wide variety of cancer forms make
this receptor an attractive therapeutic target. The two main compounds that have been used for
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targeting EGFR are small-molecule tyrosine kinase inhibitors (TKIs) and anti-EGFR monoclonal
antibodies (mAbs).
TKIs block activation of the EGFR TK domain by binding to the intracellular Mg-ATP binding
site, obstructing ATP binding and subsequent autophosphorylation. The best-characterized TKIs
are gefitinib and erlotinib, both of which are synthetic anilinoquinazolines that inhibit EGFR TK
activity with nanomolar IC50 values. Complementing its primary action of blocking ATP
binding, gefitinib has also been shown to indirectly reduce angiogenesis (76). Treatment with
gefitinib or erlotinib inhibits tumor cell proliferation, probably through induction of cell cycle
arrest or apoptosis, and both drugs were recently approved by the FDA in the treatment of non-
small-cell lung cancer (77, 78). There are several other TKIs in clinical trials, including
canertinib, lapatinib, AG-1478, and HKI-272 (57).
mAbs are Y-shaped homodimeric proteins that consist of two identical heavy and two identical
light chains. The structure of a standard immunoglobulin G (IgG) is shown in Figure 1.7. The
heavy and light chains contain an N-terminal variable fragments (VH and VL, respectively).
Each variable fragment has a beta barrel structure with conserved beta sheets (the framework
regions) separated by three hypervariable loops known as the complementarity determining
regions that confer specificity to a target antigen (79, 80). In addition to variable domains,
antibody heavy chains consist of
three constant domains (CH1, CH2,
and CH3) and the light chains
include one constant domain (CL),
all of which are uniform for a
particular antibody isotype. The
Figure 1.7. Schematic of the assembly and structure of IgG heavy chain CH2 and CH3 constant
antibody. The structure of the heavy (left) and light (midde) chains domains are collectively termed the
are presented. These chains assemble via four disulfide bridges to
form the symmetric 2:2 dimer shown at right. Note that the heavy Fc region, and interact with
chain consists of an N-terminal variable domain and three constant
domains whereas the light chain consists of an N-terminal variable complement or Fcy receptors found
domain and one constant domain. on several types of leukocytes,
including natural killer cells, macrophages, and neutrophils, to elicit an immune response (81).
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Antibodies assemble into 2:2 heavy:light chain complexes, linked by four disulfide bonds: One
between CHI and CL of each arm and two in the hinge region (N-terminal end of the CH2
domain). Crystallization of a full, intact human IgG revealed substantial asymmetry emanating
from the extensive flexibility in antibody structure (82). Their ability to specifically target an
antigen of interest and to foment an immune response have made mAbs attractive therapeutic
molecules. In cancer treatment alone, there are ten clinically approved antibody-based drugs,
with 165 others currently undergoing clinical trials (6).
mAbs specific for EGFR function both by recruiting cytotoxic lymphocytes or other white blood
cells to enhance the immune response to cancer in a process known as antibody-dependent cell-
mediated cytotoxicity (ADCC) (81) and by directly inhibiting EGFR signaling. The first
antibody-based EGFR therapeutic to receive clinical approval was cetuximab (humanized form
of murine mAb 225) (83). Originally isolated from immunized mice, mAb 225 was
reconstructed as a chimeric human Immunoglobulin GI (IgGl) for clinical use. With a 100-fold
greater affinity for EGFR than the native EGF ligand, mAb 225 directly competes with ligand
binding to domain III, blocking dimerization and autophosphorylation (84, 85). Its binding has
been shown to enhance EGFR internalization and degradation in some cell lines (86, 87). mAb
225 treatment has been shown to induce Gi-phase cell-cycle arrest and enhanced apoptosis in a
range of human tumor cell lines (88, 89). Incidentally, mAb 225 also inhibits vascular
endothelial growth factor (VEGF), further enhancing its anti-tumor activity (90).
Following successful phase III clinical trials, mAb 225 was recently approved to treat metastatic
colorectal cancer (91) and squamous cell carcinoma of the head and neck (92, 93). Other
monoclonal antibodies targeting the EGFR ligand-binding domain include the FDA-approved
panitumumab and several compounds undergoing clinical trials, including matuzumab and hR-3
(94, 95).
A monoclonal antibody (mAb 806) that specifically targets EGFRvIII was recently discovered
(96). mAb 806 binds to a cysteine loop at the end of EGFR extracellular domain II, a
conformational epitope that is exposed only when the receptor transitions into the open
conformation upon dimerization (97-99). Since this antibody is not competitive with compounds
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targeting the ligand-binding domain, it is undergoing clinical testing for both monotherapy and
combination therapy. A recent phase I clinical trial of mAb 806 demonstrated specific targeting
of the mutant receptor and no significant toxicity (100).
Despite recent advances in the development of monoclonal antibody therapeutics against EGFR,
large deficiencies remain in the efficacy of these drugs. For instance, mAb 225 showed an 11%
response rate as a monotherapy and a 23% response rate in combination with chemotherapy in
metastatic colorectal cancer and showed a response rate of 13% in squamous cell carcinoma of
the head and neck (Erbitux@ prescribing information). The other clinically approved anti-EGFR
antibody, panitumumab, had only an 8% response rate in metastatic colorectal cancer (Vectibix@
prescribing information). It should also be noted that these antibodies are ineffective against
EGFRvIII and tumor cells that secrete high levels of autocrine EGFR ligands due to their
reliance on ligand competition for efficacy. In addition, poor tumor penetration, autocrine
signaling, acquired resistance, and receptor mutation hinder drug performance (101). It is
therefore of interest to develop complementary therapeutic strategies to enhance mAb efficacy.
Antibody-Induced Clustering
It was recently established that particular combinations of non-competitive anti-EGFR mAbs
synergistically reduce surface receptor levels both in vitro and in vivo. This downregulation of
receptor is independent of tyrosine kinase activity and leads to enhanced tumor cell killing and
prolonged survival in mouse xenograft models of cancer (102-105). Consistency between
downregulation levels and combination efficacy in mouse models was also reported for ErbB2
(106). Friedman et al proposed that antibody synergism results from the formation of large
clusters of crosslinked receptors on the cell surface following combination mAb treatment (102).
Biochemical evidence for the formation of higher-order clusters of EGFR was presented by Zhu
et al using the tyrosine kinase inhibitor decorin (107).
In particular, inclusion of the 806 monoclonal antibody in combination antibody treatments
could be of significant utility in targeting EGFR. Due to its selectivity for mutant or overactive
receptors and its neutralizing activity, it may be able to evade some of the shortcomings of mAbs
that compete with ligand binding (96, 98). In a recent study, it was demonstrated that EGFR
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undergoes synergistic downregulation in the presence of mAb 806 and mAb 528, an antibody
with similar specificity and binding affinity to mAb 225 (103). This study points again to the
possibility of receptor crosslinking and clustering, which can impact both trafficking and
downstream signaling.
We hypothesized that receptor clustering could lead to downregulation through internalization
enhancement or degradation fraction augmentation. We note that the endocytic machinery is
saturable (37), thus improving the efficiency of internalization via simultaneous entry of multiple
clustered receptors could enhance the rate of receptor internalization compared to that of
untreated cells. Additionally, whereas unoccupied single receptors are rapidly recycled back to
the membrane following internalization, oligomeric receptors are preferentially retained in
endosomes through maturation and lysosomal fusion (31, 108), which could potentially result in
enhancement of EGFR degradation.
Receptor clustering could be advantageous in that it would complement existing therapeutic
mechanisms by downregulation of EGFR and its signaling. Also, a clustering strategy would be
independent of ligand binding, allowing for efficacy in constitutively active systems involving
mutated receptor or dysregulated ligand, which resist treatment by currently approved
therapeutics. The characterization and, ultimately, the exploitation of antibody-mediated
clustering holds promise as a novel strategy for therapeutic EGFR targeting in cancer.
Thesis Contributions
At the outset of this thesis work, the idea of antibody-induced clustering was just beginning to be
explored. The objective of our project was to characterize the reproducibility and scope of this
phenomenon and to isolate its mechanistic basis to gain insights that would inform design of
EGFR-downregulating compounds for therapeutic applications. In the work described herein,
we identify the requirements for antibody-induced downregulation, elucidate its kinetic
mechanism, and evaluate its efficacy in a simulated tumor environment. We then apply our
insights to the design of two novel classes of multispecific antibodies that show therapeutic
promise in both in vitro and in vivo models of cancer.
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In Chapter 2, we illuminate several crucial properties of combination antibody-induced
clustering. By screening a panel of pairwise antibody combinations, we show that co-treatment
with non-competitive mAbs targeting distinct epitopes on EGFR elicits up to 80% receptor
downregulation. Receptor downregulation induced by mAb combinations is found to be
inversely proportional to receptor density and requires bivalency of both constituent antibodies.
We further find that mAb pairs consisting of two non-competitive antibodies that target EGFR
domain 3 show the highest downregulation activity. The mechanism underlying downregulation
is found to be consistent with recycling inhibition. Importantly, in contrast to the agonism
associated with ligand-induced downregulation, we find that combination mAb-induced
downregulation does not activate EGFR or downstream signaling pathways and that it leads to
synergistic reduction in migration and proliferation of autocrine ligand-secreting cells.
After establishing the parameters for combination mAb-induced downregulation, we attempt to
enhance antibody binding and induced receptor clustering through avidity effects. We employ
two novel design approaches for our multispecific antibodies: (1) Fusion of the a full anti-EGFR
antibody with the variable domain fragment of a second EGFR-targeted antibody (described in
Chapter 3) and (2) Fusion of a full EGFR-specific antibody fused to one or more EGFR-binding
variants of the tenth type three domain of human fibronectin (detailed in Chapter 4). We
demonstrate that both classes of constructs induce robust receptor clustering and reproducible
downregulation on a range of cancerous cell lines. We also establish that these multispecific
fusions downregulate both through blockade of receptor recycling and via acceleration of
endocytosis and that downregulation is independent of receptor surface density. To motivate
therapeutic application, we show that multispecific compounds do not agonize EGFR signaling
and that they inhibit motility and growth of cells that aberrantly express autocrine ligand.
We present evidence in Chapter 5 that both of our multispecific strategies effectively curtail
growth in tumor xenograft models that resist treatment with standard of care antibodies and that
in vivo inhibition of tumor growth channels in vitro receptor downregulation. In particular, we
show dramatic control of tumors that contain genetic mutations in effector proteins downstream
of EGFR (raf and ras). Through mutational analysis, we demonstrate that ligand inhibition,
receptor inhibition, and effector function all contribute to therapeutic efficacy.
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In summary, we have rigorously characterized and defined requirements for antibody-induced
downregulation and applied this information to the design of novel classes of EGFR-targeted
antibody-based therapeutics. The modularity of our constructs and the generality of our system
suggests extensibility of the multi-epitopic strategy to other ErbB family members and, more
generally, to receptor proteins of therapeutic interest.
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2. Characterization of Receptor Clustering and Downregulation Induced by Combination
Antibody Treatment
Introduction
As discussed in Chapter 1, epidermal growth factor receptor (EGFR) is a member of the ErbB
family of single-pass transmembrane receptor tyrosine kinases (RTKs). Under normal
conditions, EGFR activation is tightly regulated by its native ligands, epidermal growth factor
(EGF) and transforming growth factor a (TGFa), which bind to the receptor extracellular
domain (1). Ligand binding induces conformational changes in EGFR that stabilize homo- or
hetero-dimerization, leading to autophosphorylation of its intracellular domain. Phosphorylation
of selected tyrosine residues activates signaling effectors in downstream pathways, including the
MAPK and P13K pathways, eliciting responses such as growth, migration, differentiation, and
apoptosis (2). The primary mechanisms of signal attenuation are receptor deactivation via
phosphatase activity and receptor degradation following endocytosis (3). Ligand activation
accelerates receptor endocytosis and simultaneously decreases the recycling to degradation ratio
to terminate EGFR signaling (4).
Dysregulation of EGFR leading to unregulated growth has been observed in a variety of cancers.
Means of dysregulation include receptor overexpression, which occurs in one-third of all
epithelial-based tumors (5), mutation, aberrant localization, autocrine ligand secretion, and
obstruction of endocytosis (3). Due to its prevalence and altered expression in cancer patients,
several therapeutic strategies have been employed to target EGFR, one of which involves the use
of monoclonal antibodies (mAbs) that bind the receptor ectodomain. mAbs act through multiple
mechanisms including immune cell recruitment, toxin delivery, and direct inhibition of receptor
signaling via ligand competition, obstruction of dimerization, or modulation of trafficking (6).
Both clinically approved mAbs targeting EGFR (cetuximab and panitumumab) bind domain 3 of
the EGFR ectodomain, directly competing with ligand and thereby preventing dimerization and
activation (7-9). Unfortunately, the monotherapy objective response rates of cetuximab and
panitumumab are tepid: 11% (10) and 8% (9, 11) respectively in the treatment of metastatic
colorectal cancer. Although these rates improve when mAbs are used in combination with
chemotherapy, poor tumor penetration, autocrine signaling, acquired resistance, and receptor
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mutation hinder drug performance (12). It is therefore of interest to develop complementary
therapeutic strategies to enhance mAb efficacy.
It was recently established that particular combinations of non-competitive anti-EGFR mAbs
synergistically reduce surface receptor levels both in vitro and in vivo. This downregulation of
receptor leads to enhanced tumor cell killing and prolonged survival in mouse xenograft models
of cancer (13-16). Consistency between downregulation levels and combination efficacy in
mouse models was also reported for ErbB2 (17). Friedman et al proposed that synergism results
from clustering of receptors on the cell surface following combination mAb treatment (13).
Preliminary evidence for the formation of such clusters was presented by Zhu et al using the
tyrosine kinase inhibitor decorin (18).
In order to gain deeper mechanistic insights motivated by these exciting results and to inform the
development of more potent antibody-based therapeutics, we investigated binding and trafficking
processes underlying combination mAb-induced downregulation. Our findings establish a
connection between binding epitopes and downregulatory activity of mAb pairs and show that
synergistic downregulation results from receptor recycling inhibition. We further demonstrate
that unlike EGF-induced downregulation, mAb-induced downregulation is not agonistic and it
coincides with reduced migration and proliferation of autocrine ligand-secreting cells.
Results
Combinations of anti-EGFR mAbs reproducibly downregulate surface receptor in both normal
and transformed human cell lines
Using a panel of six anti-EGFR mouse mAbs, we compared the ability of pairwise combinations
to downregulate receptor on seven normal or transformed cell lines, whose origins and receptor
densities are detailed in Table 2.1. Note that the surface EGFR levels span more than an order of
magnitude, ranging from 1.0x10 5 to 2.8x10 6 receptors per cell.
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HT-29 Colorectal adenocarcinoma 1.0 x 101
Hela Cervical adenocarcinoma 1.7 x 10'
U87 Glioblastoma 1.9 x 105
HMEC Human mammary epithelial tissue 4.5 x 105
CHO-EG Chinese hamster ovary (EGFR-GFP transfected) 1.6 x 106
U87-SH Glioblastoma (mutant EGFRvIII transfected) 1.6 x 106
A431 Epidermoid carcinoma 2.8 x 106
Table 2.1. Cell line origins and surface receptor densities. The source and EGFR expression levels are provided for
the seven normal and transformed cell lines assessed in our pairwise antibody downregulation screen. Note that
U87-SH contains 1.4x 106 transfected copies of the EGFRvIII mutant and 1.9x 105 endogenous wild type EGFR per
cell (19, 20). Also, CHO-EG cells express 1.6x 106 transfected GFP-fused EGFR per cell (21).
The steady state (13 h) surface receptor levels following treatment with each pairwise mAb
combination are displayed in Figure 2.1 A. In general, mAb pairs downregulate more effectively
than does single mAb treatment and the relative performance of each combination is fairly
consistent across cell lines. Also, downregulation extent decreases as receptor density increases.
This trend parallels that for ligand-induced downregulation (Figure 2.1B) and is suggestive of
endocytic machinery saturability (22).
0.6
EGFR per Cell (x106)
Figure 2.1. EGFR surface
downregulation across seven cell lines
following pairwise mAb treatment. (A)
The indicated cell lines were treated with
the denoted antibody pairs for 13 h at
37*C. Cells were then detached with
trypsin, acid stripped to remove bound
antibody, washed, and relabeled with
murine 225 and an anti-mouse
fluorescent secondary antibody to detect
surface EGFR. Receptor levels relative
to those of untreated cells were analyzed
via flow cytometry. Values presented on
the heat map represent the averages of
three independent experiments. (B)
Comparison of the 13 h surface EGFR
levels following treatment with either
225+H11 (0), 111+565 (0), or EGF
(A) plotted against receptor density for
each of the seven cell lines analyzed
6 (*SD, n=3).
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To confinm that differential downregulation extent between cell lines resulted from divergence in
receptor abundance and not coincidental genetic variability, these assays were reproduced in a
series U87 cell lines transfected with varying numbers of receptor (Table 2.2) (19, 20). As
shown in Figure 2.2, the trend of decreasing downregulation efficiency with increasing receptor
abundance was recapitulated in the U87 system. EGF was not included in this panel since it does
not downregulate the EGFRvIII mutant receptor (19).
Cell Line wtEGFR/cell EGFRvIII/cell Total EGFR/cell
U87 1.9x10- 1.9x10,
U87-M 1.9x105 5.0x10 6.9xl05
U87-DK 1.9x105 8.lx10 1.0x106
U87-H 1.9x105 1.1x106 1.3x106
U87-SH 1.9x101 1.4x106 1.6x106
U87-WT 1.9x106 -_1.9x106
Table 2.2. U87 cell line surface EGFR (wild type and mutant) densities. Wild type (wt) and transfected mutant
(vII) surface EGFR expression levels as determined by flow cytometry. M = medium, DK = dead kinase (Inactive
kinase domain due to K721M mutation in transfected EGFRvIII), H = high, SH = super high, WT = wild type
overexpressing.
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Figure 2.2. Receptor density versus
downregulation extent in U87-derived
cell lines. U87 cell lines transfected
with varying numbers of mutant
EGFRvIII receptors were subjected to
combination mAb treatment (either
225+H11, blue circles, or 111+565,
red squares) for 13 h at 37*C. Surface
receptor levels were then measured by
flow cytometry. Remaining surface
EGFR signal (relative to that of
untreated cells) is plotted as a function
of total receptor number per cell (±SD;
n=3).
Intriguingly, downregulation does not require kinase activity, as the transfected kinase defective
mutant form of EGFRvIII in U87-DK cells is downregulated as effectively as transfected
EGFRvIII with an intact kinase region (Figure 2.2). This distinguishes antibody-mediated
downregulation from EGF-induced downregulation and hints at an alternative mechanism of
action.
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From our pairwise screen, we note that one specific mAb combination, that of 225 (the murine
version of cetuximab) and H 11, downregulates significantly better than other pairs, particularly
in cell lines with high EGFR expression levels. Downregulation by the combination of the
domain 3-directed 225 and H 11 mAbs also exhibits less sensitivity to receptor density than do
other combinations (Figures 2.1, 2.2).
To determine whether or not surface EGFR downregulation coincides with total receptor
downregulation, we examined the abundance of a transfected EGFR-GFP fusion on CHO-EG
cells following combination antibody treatment. As shown in Figure 2.3, the observed reduction
in surface EGFR directly corresponds to a reduction in total EGFR, albeit on a delayed timescale
due to the additional requirements for endosomal maturation, lysosomal fusion, and protein
degradation. EGF-induced downregulation parallels this trend, although with much more rapid
kinetics (t1/2, EGF = 0.35 h versus t1/2 , 225+HL1 = 1.5 h for surface EGFR and t1 /2 , EGF = 0.51 h versus
t1/2, 225+H1 = 2.4 h for total EGFR).
120 100
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Figure 2.3. Surface vs. total EGFR downregulation kinetics. CHO cells stably transfected with an EGFR-GFP fusion
(denoted CHO-EG) (23) were treated with the 225+H1 1 mAb combination (blue circles) or EGF (green triangles)
for the indicated time periods at 37*C. Cells were then acid stripped and relabeled with 225 to detect surface EGFR;
GFP signal was used as a readout for total EGFR expression. Cells were analyzed via flow cytometry and the
relative surface (closed symbols) and total (open symbols) EGFR levels compared to those of untreated cells are
plotted over the 24 h time course (±SD; n=3). The extrapolated curves show nonlinear least squares regression fits
to single exponential functions. The inset enlarges the first 3 hours post-treatment to resolve EGF behavior at early
time points.
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Combinations of domain 3 binders downregulate receptor most efficiently
To examine the correlation between downregulation and epitope, we mapped the binding
domains of the tested mAbs. By sorting a randomized EGFR ectodomain library displayed on
the surface of yeast, we identified residues that were critical for the binding of each mAb (Table
2.3) with the exception of 225, for which a crystal structure was available (8) and which our lab
had previously mapped by this method (24).
mAb Mapped Residues Domain(s)
199.12 S137, K165 1/2
EGFR1 R141, Q193 1/2
225 Q384, Q408, H409, K443, K465, 1467, N473* 3
HI S356, H359 3
111 R353, S356, H359 3
565 K322, N328, N331 3
Table 2.3. Binding epitopes of anti-EGFR mAbs. The epitopes for the antibodies characterized in our pairwise
downregulation screen (Figure 2.1) were determined via yeast surface display-based technique (24). *Epitope
obtained from published crystal structure (8).
A B
900i
Figure 2.4. Mapped epitopes of anti-EGFR mAbs. Using a yeast library of EGFR ectodomain mutants, the binding
domains of five mAbs were determined. Domains 1 (orange), 2 (yellow), 3 (green), and 4 (cyan) are displayed in the
monomeric (A) and dimeric (B) forms of the receptor. EGF ligand is shown in black in the dimeric structure.
Epitopes for EGFR1 (dark green), 199.12 (magenta), HI 1 (25), 111 (pink), and 565 (blue) are shown as spheres.
Starred residues are part of both the H 11 and 111 epitopes. The 225 epitope identified in the published crystal
structure is shown in gray (8). The monomeric and dimeric structures are adapted from inq1 (1) and livo (26),
respectively.
Figure 2.4 depicts the locations of the mAb epitopes on EGFR in its monomeric (1) and dimeric
(26) forms. Consistent with the structural data, 111 and H1 1 crossblock, as do 199.12 and
EGFR1. Also, 225, H111, 111, and 565 compete with EGF ligand. The most active combination
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of downregulating mAbs identified from Figure 2.1 (225+H 11) consists of two constructs that
bind to extracellular domain 3, the ligand-binding domain, but are non-competitive (Figure 2.5).
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Figure 2.5. mAb and EGF competition assays. HMEC cells were pre-blocked for 1 h at 4*C with the indicated
concentration of unlabeled competitor: 199.12 (A) (A), EGFR1 (*) (B), 111 (E) (C), HI 1 (U) (D) and (F), or 225
(K), HI 1 (0), 111 (E), 565 (@), and EGF (0) (E). Fluorescently-labeled mAb or EGF (20 nM) was then added:
EGFRI (A), 199.12 (B), 111 (C), H 11 (D), EGF (E), or 225 (F) and incubation proceeded at 4*C for 30 min.
Fluorescence was analyzed via flow cytometry and signal intensity (relative to that in uncompeted cells) is plotted as
a function of competitor concentration (+SD; n=3).
Amongst the antibodies tested, combinations consisting of two non-competitive domain 3
binders downregulate receptor more effectively than both competitive combinations and
combinations with one domain 3 binder and one domain 1/2 binder (Figure 2.6), implicating
stereospecific dependence of downregulation. The downregulation activity of each antibody
combination the seven cell lines we examined is ranked in Table 2.4. Preference for antibodies
targeting non-overlapping epitopes is consistent with receptor clustering, as competitive mAbs
cannot form chains of crosslinked receptor.
41
(Increasing downregulation extent
HT-29
HeLa
U87
H MEC
CHO-EG
U87-SH
A431
* 3-3 * 1/2-3 [ Competitive
Figure 2.6. Epitope dependence of combination
mAb-induced surface EGFR downregulation. The
15 pairwise mAb combinations in our six by six
panel were ranked in order of EGFR
downregulation extent for each of the seven
indicated cell lines. Pairs consisting of two non-
competitive domain 3 binders (blue), pairs
consisting of one domain 1/2 and one domain 3
binder (green), and competitive pairs (yellow) are
denoted.
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Table 2.4. Comparison of mAb combination performance in seven EGFR-expressing cell lines. The fifteen
pairwise mAb combinations are ranked in descending order of downregulation potency for each cell line examined
in our pairwise downregulation screen. Pairs consisting of two non-competitive domain 3 binders (blue), pairs
consisting of one domain 1/2 and one domain 3 binder (green), and competitive pairs (yellow) are indicated.
Receptor downregulation requires two bivalent antibodies
In an effort to determine whether or not hypothesized antibody-mediated clustering plays a role
in the observed receptor downregulation, we digested the full IgG constructs from our most
actively downregulating combination of antibodies (225+H1 1) into Fab fragments. Fab
fragments consist of a single variable and constant domain of each chain and are consequently
monovalent binders. As shown in Figure 2.7, Fabs by themselves or in combination do not
substantively reduce surface EGFR levels. Also, single mAb treatment or combination of a Fab
and a mAb do not elicit downregulation. However, the combination of two full IgGs markedly
reduces surface EGFR levels on all seven cell lines examined, indicating the requirement for
bivalency to effect receptor downregulation, suggestive of a clustering mechanism.
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Figure 2.7. Two bivalent IgG molecules required to achieve receptor downregulation. The 225 and H 11 antibodies
were digested into their respective monovalent Fab fragments using the enzyme ficin. The indicated Fabs, full IgGs,
and combinations thereof were incubated with the seven cell lines shown for 13 h at 37*C. Cells were then
detached, stripped of antibody, and relabeled for surface EGFR via flow cytometry. Surface EGFR levels
normalized by those of untreated cells are presented for each condition.
Antibody treatment results in punctate clustered distribution of EGFR
We visualized receptor distribution on A431 cells following single versus combination antibody
treatment via deconvolution fluorescence microscopy. As evidenced in Figure 2.8, the receptor
distribution (tracked by fluorescent 225) changes dramatically upon the addition of H11.
Compared to the diffuse surface-staining pattern we observe following 225 monotherapy,
treatment with 225 and H 11 results in a punctate EGFR distribution both intracellularly and
extracellularly, indicative of receptor clustering. Clustering is observed as early as 1 h post-
antibody administration and endures throughout the 6 h timecourse.
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Figure 2.8. Visual evidence of combination antibody-induced clustering. A431 cells were treated with
fluorescently-labeled 225 in the presence or absence of Hi1 for the indicated time periods at 37*C. Cells were
washed to remove free antibody and imaged on a DeltaVision deconvolution microscope. Images reflect projections
of deconvolved 0.15 pm thick z-sections through the cell monolayer. Scale bars = 30 pm.
mAb-induced downregulation is significantly slower than EGF-induced downregulation
The kinetics of antibody-induced EGFR downregulation treatment were compared to those of
EGF-induced downregulation. Both combination mAb treatment and EGF treatment ultimately
result in a maximum of 80% downregulation, although EGF reduces surface receptor expression
much more rapidly (Figure 2.9).
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Figure 2.9. Surface EGFR downregulation kinetics. HeLa (left) and HMEC (right) cells were incubated at 37*C in
the presence of 225+H1 1 (0), 111+565 (M), or EGF ( ). At the specified time points, surface receptor was
quantified via flow cytometry. Surface EGFR levels relative to those of untreated cells are plotted as a function of
time (±SD; n=3).
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Downregulation halftimes for the potent 225+H1 1 pair, the moderately effective 111+565 pair,
and EGF are provided in Table 2.5. Note that the mAb-induced downregulation timescales are
independent of receptor density and consistent across cell lines, typically ranging from 0.5-2.5 h.
Cell Line 225+H11 t1/2 (h) 111+565 tin (h) EGF tin (h)
HT-29 4.88 2.15 0.02
HeLa 2.12 2.39 0.13
U87 1.84 0.81 0.14
HMEC 1.86 1.22 0.02
CHO-EG 1.50 0.55 0.35
A431 1.40 * 0.02
Table 2.5. Surface EGFR downregulation rates. Receptor downregulation halftimes were measured on the six cell
lines shown. Kinetic downregulation data were fit to a single exponential using non-linear least squares regression.
* 111+565 did not reduce A431 surface EGFR levels.
Combination mAb treatment downregulates surface receptor by abrogating recycling
We next sought to elucidate the kinetic rate processes underlying EGFR downregulation. To this
end, we considered a simple material balance for receptor trafficking (Figure 2.10). A full
derivation for our trafficking model is provided in Appendix A.
Solving for the steady state surface (Rs) and internal (RI) receptor levels, we find that:
Psyn
ke
kre
kdeg)
and R 1 =
Pksyn
kdeg Equation 2.1
Figure 2.10. Modulation of EGFR
trafficking via combination mAb
treatment. A basic model of receptor
clustering and trafficking following
treatment with non-competitive EGFR-
targeted mAbs is shown. Note that two
bivalent antibodies are required to cluster
surface EGFR via crosslinked chains.
Relevant rate parameters and species are
labeled. EGFR can be surface-bound (Rs)
or internal (R1). Receptor is synthesized
with a rate Psy, internalized with rate k.,
recycled back to the surface with rate kre,
and degraded with rate kdeg.
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Surface receptor levels can thus be lowered by (1) decreasing synthesis, (2) increasing the
endocytosis rate constant, (3) decreasing the recycling to degradation ratio, or by a combination
of these factors.
Cells treated with and without the protein synthesis inhibitor cycloheximide (27) exhibit similar
downregulation kinetics (Figure 2.11), implying that altered receptor synthesis is not responsible
for the observed drop in surface EGFR. Furthermore, the relatively slow downregulation rate
(on the order of the constitutive endocytosis rate) indicates that first-pass endocytosis is certainly
not accelerated in treated cells (Figure 2.9).
Figure 2.11. Impact of synthesis inhibition on EGFR levels. (A) CHO-EG cells were incubated at 37 0C with (blue
circles) or without (black squares) 225 and H11 in the absence (open symbols) or presence (closed symbols) of the
receptor synthesis inhibitor cycloheximide (40 gM). At each time point, cells were detached and total EGFR content
(based on GFP fluorescence) was measured via flow cytometry. GFP signal relative to that of untreated cells is
plotted against incubation time (+SD; n=3). "+" = With and "-" = Without cycloheximide.
We then considered the possibility that mAb treatment inhibits recycling. Assuming that
synthesis and degradation rates are unchanged, the model predicts the fractional surface receptor
remaining after treatment to be:
Equation 2.2
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where "u" and "t" represent the untreated and treated cases, respectively. Thus, downregulation
extent depends on the ratio of the untreated and treated endocytic and recycling rates. Also, there
is predicted to be a lower bound on EGFR levels, even if recycling is completely blocked by
treatment (i.e. Rst # 0 even when krec,,t = 0). This is consistent with the 80% downregulation limit
observed in our panel and the fact that treatment with 225+H1 1 plus additional monoclonal and
polyclonal antibodies does not drive downregulation further (Figure 2.12).
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Figure 2.12. Effects of supplementing 225+H11 combination with additional monoclonal and polyclonal antibodies.
(A) HT-29 cells were treated with the indicated mAbs (66 nM for single treatments and 33 nM each in combination)
for 13 h at 37*C. Surface EGFR levels relative to those of untreated control cells were determined through flow
cytometry and are displayed for each treatment condition (+SD; n=6). (B) CHO-EG cells were treated with (0) or
without (0) the 225+H1 1 mAb combination (33 nM each) and incubated at 37*C for 30 min. An anti-mouse
polyclonal antibody was then added at the indicated concentration and incubation proceeded for 13 h at 370 C.
Surface EGFR was analyzed by flow cytometry and receptor levels relative to those of untreated cells are plotted as
a function of polyclonal antibody concentration (+SD; n=3).
To determine whether receptor recycling is hindered by mAb treatment, a pulse-chase quenching
assay was performed. Briefly, A431 cells were pulsed with Alexa 488-labeled 225 in the
presence or absence of HI 1. Surface 225 was then quenched by the addition of Alexa 488
quenching antibody. Cells were subsequently chased in the continued presence of quenching
antibody so that any incremental drop in signal during this period would result from internal 225
recycling to the cell surface, a surrogate for receptor recycling. As shown in Figure 2.13A, 488
signal drops during the chase period in the absence but not in the presence of H 11, implying that
combination treatment blocks the recycling that is observed following single mAb treatment. To
independently confirm this result, cells were treated with or without the recycling inhibitor
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monensin (28) in the absence or presence of the 225+H111 combination. As shown in Figure
2.13B, treatment with monensin alone evokes essentially the same response as 225+Hl 1
treatment with or without monensin, consistent with the hypothesis that combination treatment
substantively vitiates receptor recycling.
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Figure 2.13. Inhibition of EGFR recycling via combination mAb treatment. (A) A431 cells were pulsed with Alexa
488-conjugated 225 for 2 h in the presence (0) or absence ( ) of HI 1. Surface receptor signal was then quenched
by adding 25 pg/mL Alexa 488 quenching antibody and cells were chased at 37*C in the continued presence of
quenching antibody. Total fluorescence was determined at each time point and signal relative to the unchased
control is plotted versus time (±SD; n=3). (B) HT-29 (left) and HMEC (right) cells were incubated at 37*C with
(circles) or without (squares) 225 and H 11 in the absence (open symbols) or presence (closed symbols) of the
recycling inhibitor monensin (200 pM). Surface EGFR levels compared to those of untreated cells are plotted
against incubation time (±SD; n=3).
Less potent mAb combinations induced greater receptor downregulation in the presence than in
the absence of monensin, indicating that recycling was less dramatically impaired in these
treatment conditions compared to the 225+Hl 1 administration (Figure 2.14).
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Figure 2.14. Impact of recycling inhibition on EGFR levels of combination antibody-treated cells. (B) HeLa cells
were incubated for 13 h at 37*C with the indicated antibody combinations in the absence (light gray) or presence
(dark gray) of the recycling inhibitor monensin (200 pM). Cells were detached and analyzed for surface EGFR.
Surface receptor levels relative to those of untreated cells from the 0 h time point are plotted against incubation time
(+SD; n=3).
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mAb treatment does not agonize EGFR or activate downstream signaling effectors
Since EGFR signals actively from endosomes following ligand stimulation (29), we examined
whether or not mAb-induced internalization was similarly agonistic. We first evaluated EGFR
activation in A431 cells at eight known phosphosites in the intracellular domain using in-cell
western assays (Figure 2.15A). None of these phosphosites were stimulated by single or
combination mAb treatment, including three major autophosphorylation sites (Y1068, Y 1148,
and Y1 173) (30), one minor autophosphorylation site (Y1086) (31), and targets of Src tyrosine
kinase (Y845) (32), Ca-calmodulin-dependent kinase II (S 1046) (33), protein kinase C (T654)
(34), and MAPK (T669) (35). In contrast, most sites were activated two- to threefold by EGF.
Bead-based immunosorbent assays were also conducted on A431 cells to test for activation of
downstream pathway effector MAPK (ERK). As Figure 2.15B demonstrates, incubation with
225 and H 11 singly and in combination failed to phosphorylate MAPK above control levels.
To obtain a more global perspective of cell response, we used an iTRAQ-based mass
spectrometry screen to assess phosphorylation following treatment with an isotype control mAb,
225, Hi 1, 225+H1 1, or EGF. Lists of all phosphoproteins identified from the mass spectrometry
screen and their relative signals compared to control treatment are provided in Appendix B.
Figure 2.15C focuses on the relative phosphorylation of proteins associated with two critical
pathways downstream of EGFR: the MAPK and P13K cascades. In agreement with our
phosphotyrosine mass spectrometry screen, neither single nor combination mAb treatment
activates any of these signaling effectors based on a cut-off of 1.7-fold background.
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Figure 2.15. Downstream signaling implications of combination mAb treatment. (A) In-cell western assays were
performed on A431 cells for eight known EGFR phosphosites. Activation profiles are shown for EGF (0), 225 (0),
H1 1 (E), and 225+H1 1 (0). Phosphoprotein fluorescence was normalized by DNA fluorescence and signal relative
to that of untreated cells is plotted versus time (tSD; n=3). (B) The timecourse of ERK 1/2 activation in A431 cells
following mAb or EGF treatment was measured via bead-based immunoassay. Normalized phosphoprotein signal is
plotted for cells treated with EGF (U), 225 (0), HI 1 (0), 225+H1 1 (9), and an antibody-free control (A) (+SD;
n=3). (C) Serum-starved A431 cells were incubated with 225, HI 1, the 225+H1 1 combination, and EGF at 370 C for
15 min (36) or 60 min (bottom). EGF stimulation was held constant at 15 min for both screens. Cells were then lysed
and relative protein phosphorylation was measured using an iTraq-based mass spectrometry screen. Phosphorylation
levels were normalized by total protein content and signal strength relative to that in cells treated with an isotype
control mAb is presented for MAPK and P13K pathway components. Repetition of the 60 min screen yielded
consistent results for proteins identified in both cohorts.
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Downregulating mAb combination impedes cell migration and proliferation
We further explored the therapeutic promise of the most efficacious downregulating combination
by examining its effects on migration and proliferation of cultured cells. An artificially
constructed autocrine HMEC cell line (denoted ECT) that sheds surface-expressed chimeric EGF
chimera at a fractional release rate of 0.3 hI (23) was tested. This autocrine model simulates a
tumor environment in which growth factor expression is dysregulated (37-39). In ECT cells, the
225+H 11 combination significantly (P<0.01) reduces the extent of cell migration compared to
both untreated cells and cells treated with either mAb alone. In contrast, migration is not
significantly further inhibited by combination treatment compared to 225 monotherapy in normal
HMEC cells (Figure 2.16A). The same trend of selective inhibition of autocrine-expressing cells
was observed for cell proliferation in the ECT and HMEC lines (Figure 2.16B), demonstrating
that combination treatment is more effective than monotherapy in a system that aberrantly
overexpresses EGF ligand.
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Figure 2.16. Cell migration and proliferation following mAb treatment. (A) Migration of HMEC (dark gray) and
HMEC-derived autocrine EGF-secreting ECT (light gray) cells was assessed using a scratch wound healing assay.
Confluent monolayers were wounded and subsequently incubated with the indicated mAbs for 24 h at 37*C.
Relative migration is shown as fractional wound replenishment compared to that of an untreated control (±SD; n=6).
(B) Proliferation of HMEC (dark gray) and ECT (light gray) cells was measured using the MTT assay. Cells were
treated with the specified mAbs for 72 h at 37*C. Relative proliferation is presented as viable cell abundance
compared to that of untreated cells (±SD; n=6). Asterisks denote P<0.0 1 for the 225+H1 1 combination relative to
treatment with either mAb alone.
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Discussion
The use of non-competitive antibody combinations to engage multiple therapeutic mechanisms is
an increasingly popular and attractive strategy for enhancing drug efficacy (6). Understanding
the biophysical and biochemical bases for antibody synergy will be helpful for designing the next
generation of combination and multispecific treatments. The work discussed herein offers
insights into the structural dependence and molecular mechanism of synergy.
Despite limited prior physical evidence for formation of receptor clusters, there had been
extensive speculation that combination mAb treatment induces clustering, leading to
downregulation (13, 15, 18). We show that two bivalent antibodies are required for
downregulation (Figure 2.7) and present images of punctate receptor distribution following
combination mAb treatment (Figure 2.8). This corroborates recent observations of punctate
receptor distributions following treatment with a cocktail of non-competitive EGFR-targeted
antibodies developed by Symphogen (15) and supports a clustering-dependent downregulation
model.
From our pairwise combination screen, we observed that all mAb pairs that were examined elicit
some level of downregulation, although the most effective combinations include two mAbs
against EGFR extracellular domain 3, the ligand-binding domain (Figure 2.6). In particular, the
combination of one antibody that binds proximal to the EGF epitope (225) and a second antibody
that binds upstream in domain 3 (H1 1) appears to out-perform all other combinations in the cell
lines examined (Figures 2.1, 2.4, 2.6). This finding is congruous with previous observations of
domain 3-targeted mAb synergism (13, 16). In general, the extent of downregulation induced by
a mAb pair may depend on the structure of the bound receptor and the degree to which its
orientation facilitates clustering.
Observed saturability of downregulation manifested in downregulation dependence on receptor
density is consistent with previous findings in cell lines expressing elevated levels of EGFR (22).
The inability to improve upon receptor downregulation by supplementing the 225+Hl 1
combination with additional monoclonal and polyclonal antibodies (Figure 2.12) is consistent
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with a mechanism reliant on recycling inhibition, as surface levels are determined by the steady
state balance between synthesis and constitutive endocytosis.
Combining our kinetic model with experimental findings (Figs. 2.9 - 2.14), we deduced that
synergistic EGFR downregulation is a consequence of a decrease in the ratio of the recycling to
degradation rates. Treatment with the most effectively downregulating combination completely
blocks recycling in the three in vitro systems examined (Figure 2.13), consistent with the
formation of internalized clusters incapable of returning to the cell surface through recycling
endosomes. Extending this result, less potent combinations may fail to efficiently cluster
receptors, thereby only partially obstructing recycling (Figure 2.14).
Our finding that the downregulation mechanism operates intracellularly to reduce endosomal
recycling resonates with previous experimental and theoretical analyses of endosomal sorting
outcomes (40, 41) and agrees with our further observations that downregulation is antibody-
dependent and saturable (Figures 2.1, 2.2). There is no evidence of endocytic rate acceleration,
as occurs in clathrin-mediated endocytosis stimulated by EGF (4, 42). We speculate that
internalization following combination mAb treatment does not occur through clathrin-coated
pits, but rather through basal membrane turnover or via lipid rafts such as caveolae. Indeed, Zhu
and colleagues demonstrated that receptor clustering effected by decorin led to caveolin-
mediated internalization of EGFR and, ultimately, its degradation.
Encouragingly, contrary to ligand-induced internalization, mAb-induced internalization does not
activate EGFR or its downstream effectors (Figure 2.15). Lysosomal targeting of the receptor is
expected to require ubiquitinylation (43), but if so we find it to be independent of kinase activity
(Figure 2.2). This is consistent with previous work showing that EGFR and its effector pathways
are differentially activated by distinct liands and mAbs (16, 44). Our results support a therapeutic
strategy that utilizes endogenous trafficking machinery to reduce surface EGFR expression
without activating downstream signaling pathways.
While combination therapy did not affect migration and proliferation relative to monotherapy in
normal cells, it inhibited both processes in a cell line that exhibits autocrine ligand secretion, a
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common means of EGFR dysregulation in cancer (Figure 2.16). This suggests selective
sensititvity of transformed cells to combination antibody therapy.
In vivo, others have shown correlation between receptor downregulation and drug efficacy in
mouse xenograft models (13, 14, 17), offering promise for the therapeutic potential of
synergistically downregulating mAb pairs identified in our screen. Also, the observation of
ErbB2 downregulation by mAb combinations (17) suggests that clustering receptor may be an
effective approach for targeting other ErbB family receptors and receptor tyrosine kinases in
general.
Overall, our work demonstrates that combinations of anti-EGFR mAbs reproducibly reduce
surface receptor levels in a structurally-dependent fashion by inhibiting receptor recycling. These
mAb combinations show therapeutic promise in that they do not agonize signaling and they
hamper the migration and proliferation of cells that secrete autocrine EGF.
Based on the successful application of our combination downregulating strategy to an in vitro
model of the tumor environment, we engineered novel antibody fusions to encapsulate the multi-
epitopic strategy in single therapeutic molecules. The two formats we pursued for these
constructs were: (1) Bispecific antibodies containing a full EGFR-specific IgG fused to the scFv
of a second non-competitive anti-EGFR antibody and (2) Multispecific antibody-fibronectin
domain fusions consisting of a full EGFR-targeted IgG fused to one or more EGFR-binding
variants of the tenth type 3 domain of human fibronectin. The design and preliminary
characterization of these constructs are detailed in Chapters 3 and 4, respectively and their
therapeutic efficacies are evaluated in vivo in Chapter 5.
Materials and Methods
Cell lines and antibodies
The transfected CHO-EG (21), U87-MG-derived EGFRvIII-expressing lines (20), and ECT (23)
cell lines were established as described previously and all other lines were obtained from ATCC
(Manassas, VA). Cells were maintained in their respective growth media (from ATCC unless
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otherwise indicated): DMEM for A431, U87-MG, U87-MGSH, and CHO-EG cells, McCoy's
Modified 5A media for HT-29 cells, EMEM for HeLa cells, and HuMEC Ready Medium
(Invitrogen, Carlsbad, CA) for HMEC and ECT cells. U87-MG, U87-MGSH, and CHO-EG
media were supplemented with 1 mM sodium pyruvate (Invitrogen) and 0.1 mM non-essential
amino acids (Invitrogen) and transfected lines U87-MGSH and CHO-EG were selected with 0.3
mM Geneticin (Invitrogen). ATCC media was supplemented with 10% fetal bovine serum
(FBS). 225 was secreted from the hybridoma cell line (ATCC). EGFR1 (AbCam, Cambridge,
MA) and H 11 and 199.12 (LabVision, Fremont, CA) were purchased. 111 and 565 were
prepared as described previously (13).
Unless otherwise noted, all washes were conducted in PBSA (PBS containing 0.1% BSA) and all
mAbs were used at a concentration of 40 nM for single treatment and 20 nM each for
combination treatment. EGF (Sigma, St. Louis, MO) was dosed at 20 nM. Trypsin-EDTA
(Invitrogen) contains 0.05% trypsin and 0.5 mM EDTA.
Receptor quantification
Cells were serum starved for 12-16 h, washed, digested in trypsin-EDTA (20 min at 37*C),
neutralized with complete medium, and labeled with 20 nM 225 for 1 h on ice. They were then
washed, labeled with 66 nM phycoerythrin (PE)-conjugated goat anti-mouse antibody
(Invitrogen) for 20 min on ice, washed again, and subjected to quantitative flow cytometry on an
EPICS XL cytometer (Beckman Coulter, Fullerton, CA). Receptor density was calculated based
on extrapolation from a curve of identically labeled anti-mouse IgG-coated beads (Bangs
Laboratories, Fishers, IN).
Receptor downregulation assays
Cells were seeded at 5x 104 per well in 96-well plates, serum starved for 12-16 h, treated with the
indicated mAbs in serum-free medium, and incubated at 37*C. At each time point, cells were
washed and treated with trypsin-EDTA for 20 min at 37*C. Trypsin was neutralized with
medium (10% FBS) and cells were transferred to v-bottom plates on ice. They were then
washed, acid stripped (0.2 M acetic acid, 0.5 M NaCl, pH 2.5), and washed again prior to
incubation with 20 nM 225 for 1 h on ice to label surface EGFR. Cells were then washed and
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labeled with 66 nM PE-conjugated goat anti-mouse antibody (Invitrogen) for 20 min on ice.
After a final wash, plates were analyzed on a FACS Calibur cytometer (BD Biosciences, San
Jose, CA). Cell pelleting was conducted at 1000xg.
Antibody and EGF competition assays
mAbs were labeled using an Alexa 488 microscale labeling kit (Invitrogen). Alexa 488-labeled
EGF was purchased from Invitrogen. HMEC cells were seeded in 10 cm culture dishes and
grown to confluence. They were then serum starved for 12-16 h, washed in PBS, and incubated
with trypsin-EDTA for 20 min at 37*C. The trypsin was then neutralized by the addition of rich
medium and cells were transferred to 96-well v-bottom plates (1xi05 per well) and incubated on
ice for 1 h with the specified unlabeled competitor mAb or EGF at the prescribed concentration.
The indicated Alexa 488-labeled mAb or EGF was then added to a final concentration of 20 nM
and cells were incubated for an additional 30 min on ice. After the cells were washed (PBS, 0.1%
BSA), 488 signal was analyzed via flow cytometry, as described for receptor downregulation
assays.
Fine epitope mapping of anti-EGFR mAbs
A mutagenized library (average of one mutation per clone) of yeast expressing the EGFR
ectodomain followed by a c-myc tag was generated, induced, and sorted as previously described
(24). The library was subjected to two rounds of selection: One against the mapped mAb and for
c-myc binding and one for simultaneous 225 and c-myc binding to select for properly folded,
full-length clones. Selected clones were sequenced to identify residues that interact with the
mAb.
Digestion of IgG to form Fab fragments
The 225 and HI 1 murine IgGi mAbs were digested into their respective Fab fragments using the
immobilized ficin mouse IgGi Fab preparation kit following the manufacturer's protocol
(Thermo Fisher Scientific, Waltham, MA, Product # 44680). Fab was isolated from CH2-CH3
domains using protein A affinity chromatography. Fabs were reconstituted in PBS using Zeba
desalting columns and recovery was quantified via 280 nm absorbance (Thermo Fisher
Scientific). Purity was confirmed via SDS-PAGE analysis.
56
Live cell deconvolution microscopy
mAb 225 was labeled with Alexa 488 using a fluorescent labeling kit (Invitrogen). A431 cells
were plated at 50,000 per well in 8-well microscopy chambers and allowed to settle overnight.
Cells were serum-starved for 8-12 h and incubated with 20 nM fluorescently-labeled 225 in the
absence or presence of 20 nM mAb HI 1 for the indicated time lengths at 370, 5% CO 2 . Cells
were immediately washed and reconstituted in phenol red-free medium (Invitrogen) for imaging
on a Delta Vision inverted deconvolution microscope at 60X magnification (oil immersion lens).
Deconvolution and projection of 0.15 Im z-slices and image analysis were performed using the
Softworx software package. All compared images were obtained using identical settings with
normalized brightness and contrast levels set.
Cycloheximide synthesis inhibition assays
CHO-EG cells were seeded at 5x10 4 per well in 96-well plates and serum starved for 12-16 h.
They were then reconstituted in serum-free medium in the presence or absence of 40 [LM
cycloheximide (Sigma) to block de novo receptor synthesis. After 20 min incubation at 37*C, the
indicated mAbs were added to each well and incubation at 37*C proceeded for the specified
length of time. Cells were then washed with PBS and the medium was replaced with trypsin-
EDTA. After 20 min incubation at 37*C, the trypsin was neutralized by the addition of medium
containing 10% FBS. Cells were then transferred to 96-well v-bottom plates, washed (PBS, 0.1%
BSA), and analyzed for GFP content via flow cytometry, as detailed for receptor downregulation
assays.
Polyclonal antibody treatment downregulation assays
CHO-EG cells were seeded at 5x10 4 per well in 96-well plates and serum starved for 12-16 h.
They were then reconstituted in serum-free medium with or without 33 nM each of mAbs 225
and H1 1. After 30 min incubation at 37*C, goat anti-mouse polyclonal antibody (Invitrogen) was
added at the indicated concentration and incubation at 37*C continued for 13 h. Cells were then
detached, acid stripped, relabeled for surface EGFR, and analyzed as in receptor downregulation
assays.
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Alexa 488 quenching pulse-chase assays
225 was labeled using an Alexa 488 microscale labeling kit (Invitrogen). A431 cells were
seeded at 5x10 4 per well in 96-well plates and serum starved for 12-16 h. They were then pulsed
with Alexa 488-labeled 225 with or without H1 1 in serum-free medium and incubated at 37*C
for 2 h. Cells were subsequently treated with 25 [g/mL anti-Alexa-488 quenching antibody
(Invitrogen) for 30 min on ice and chased at 37*C for the indicated length of time in the presence
of quenching antibody. Cells were returned to ice, washed, incubated with trypsin-EDTA for 30
min, and neutralized (DMEM, 10% FBS). They were then transferred to v-bottom plates,
washed, and analyzed on a FACS Calibur cytometer (BD Biosciences). Percent unchased signal
was calculated relative to cells that were not returned to 37*C after quenching (45, 46).
Monensin recycling assays
Cells were seeded at 5x 104 per well in 96-well plates and serum starved for 12-16 h. They were
then treated with or without 200 [xM monensin (Sigma) in serum-free medium and incubated at
37*C for 20 min. The indicated mAbs were then added and incubation proceeded at 37*C. At
each time point, surface EGFR was analyzed as in receptor downregulation assays.
In-cell western assays
A431 cells were seeded at 4x 104 per well in 96-well plates and allowed to adhere for 24 h.
Following 12-16 h of serum starvation, cells were treated with the designated mAbs in serum-
free medium at 37*C for the specified time length. All subsequent incubations were performed
at room temperature. Cells were fixed for 20 min (PBS containing 4% formaldehyde),
permeabilized via four 5 min incubations (PBS containing 0.1% triton), blocked for 1 h in
Odyssey blocking buffer (Licor Biosciences, Lincoln, NE), and labeled for 1 h with 15 nM anti-
phosphosite antibodies (Genscript, Piscataway, NJ) in blocking buffer. Cells were then washed
three times with PBST (PBS containing 0.1% Tween-20) and labeled with 66 nM 800-
conjugated goat anti-rabbit antibody (Rockland Immunochemicals, Gilbertsville, PA) and 400
nM TO-PRO-3 DNA stain (Invitrogen) in blocking buffer for 30 min. After three final PBST
washes, wells were aspirated dry for analysis on a Licor Odyssey Scanner (Licor Biosciences).
Signal was normalized to cell abundance by dividing 800 (phosphoprotein) by 700 (TO-PRO-3)
channel fluorescence.
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Luminex (bead-based immunosorbent) phosphoprotein quantification assays
A431 cells seeded in 96-well plates at 3x 104 per well were allowed to settle for 24 h prior to 12-
16 h serum starvation. Cells were then incubated with the specified mAbs in serum-free medium
at 37*C. At the indicated times, cells were lysed using the Bio-Plex cell lysis kit (Bio-Rad,
Hercules, CA). Phosphorylated ERK1/2 abundance was quantified using the Luminex bead-
based immunoassay, performed with the Bio-Plex Phospho-ERKi/2 (T202/Y204, T1 85/Y1 87)
bead kit and the Bio-Plex Phosphoprotein Detection Reagent kit on the Bio-Plex 200 platform
(Bio-Rad).
Global phospho-mass spectrometry screens.
lx106 A431 cells per well were seeded in 6-well plates, grown to confluence, and incubated with
the appropriate mAbs in serum-free medium at 37*C for 15 or 60 min. Cells were washed once
with chilled PBS and lysed at 4*C (8 M urea, 1 mM Na 3VO 4). Protein concentration was
measured via bicinchoninic acid assay (Pierce, Rockford, IL). Lysate reduction, alkylation,
trypsin digestion, and peptide fractionation were performed as previously described (47).
Samples were labeled separately with 8 isotopic iTRAQ reagents (Applied Biosystems, Foster
City, CA) for 2 h at room temperature, combined, and concentrated. Immunoprecipitation with
pooled anti-phosphotyrosine antibodies (4G1O (Millipore, Billerica, MA), pTyrI00 (Cell
Signaling, Beverly, MA), and PT-66 (Sigma)) proceeded for 16 h at 4*C using protein G agarose
beads (Calbiochem, San Diego, CA) in IP buffer (100 mM Tris, 100 mM NaCl, 1% Nonidet P-
40, pH 7.4). Phosphopeptide enrichment by IMAC and analysis and quantification of eluted
peptides were conducted via ESI LC/MS/MS on an LTQ-Orbitrap (Thermo Fisher Scientific).
Phosphopeptides were identified using Mascot analysis software (48) and spectra were manually
validated (49). Signal intensities were normalized by total protein levels and compared to isotype
control treatment.
Migration assays
HMEC and ECT cells were seeded at 5x10 4 per well in 96-well plates and grown to confluence.
Monolayers were wounded with a pipet tip, washed with PBS, and placed in complete medium
with the indicated mAbs. Scratch area was measured immediately and after 24 h incubation at
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37*C using Image J software analysis of images from a Nikon confocal microscope (Nikon
Instruments, Melville, NY). Percent migration was calculated as the fractional reduction in
scratch area in the treated wells divided by that of the untreated wells.
Cell proliferation assays
HMEC and ECT cells were seeded at 5x10 3 per well in 96-well plates and allowed to adhere for
24 h. They were then treated with the indicated mAbs in complete medium and incubated at
37*C for 72 h. Cell viability (relative to an untreated control) was assessed using the [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay (Invitrogen) (50).
Statistical analysis
Heteroscedastic two-tailed student's t tests were performed on migration and proliferation assay
results to compare combination and single mAb treatment.
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3. Design of Multispecific Antibodies Targeting Both Wild Type and Mutant EGFR
Introduction
As discussed in Chapter 1, the first antibody-based EGFR therapeutic to be clinically approved
was cetuximab, the chimeric human IgGI form of the murine mAb 225 (1). With a 100-fold
greater affinity for EGFR than the native EGF ligand, mAb 225 directly competes with ligand
binding to domain III, blocking dimerization and, consequently, receptor activation (2, 3).
Cetuximab can also exert effects via alternative mechanisms including antibody-dependent
cellular cytotoxicity (4), induction of receptor internalization and degradation (5), induction of
G1-phase cell-cycle arrest, enhanced apoptosis (6, 7), and inhibition of vascular endothelial
growth factor (VEGF), although these effects vary between cell lines. Other monoclonal
antibodies targeting the EGFR ligand-binding domain include the FDA-approved panitumumab
and several compounds undergoing clinical trials, including matuzumab and hR-3 (8, 9).
As discussed in Chapter 1, the approved therapeutic mAbs have not lived up to their promise in
the clinic. The monotherapy objective response rates of cetuximab and panitumumab are just
11% and 8%, respectively, in the treatment of metastatic colorectal cancer (10-12). These
response rates approximately double when the drugs are used in combination with
chemotherapeutics, but there is still much opportunity for the improvement of EGFR-targeted
antibody therapeutics. The tepid clinical response of cetuximab and panitumumab can be
attributed to delivery limitations, acquired resistance, and receptor mutation (1). Specifically,
antibody penetration into solid tumors is limited by transport and catabolism. Also, tumors may
develop resistance to mAbs, often through genetic mutation of EGFR. Heterozygous somatic
mutations including deletions, insertions, and point mutations have been observed in the EGFR
kinase domain in some lung cancer patients (13-15). These mutations strengthen receptor
interactions with ATP, amplifying autophosphorylation and boosting cell survival (16, 17).
Furthermore, rearrangements within the ErbB 1 gene such as large deletions, point mutants, and
insertions are also common, particularly in gliomas (18). As many as 20% of glioblastomas
express EGFR variants (19, 20), the most common of which is EGFRvIII, a constituitively active
truncation mutant that lacks the entire domain I and the majority of domain II of the EGFR
extracellular domain to lock the receptor in the active conformation (21). Tumors may also
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exhibit antibody resistance through abnormal expression of the ligand, for instance through
autocrine production or through increased spatial accessibility as a result of aberrant
colocalization of the receptor and ligand (22, 23). Due to their reliance on ligand competition for
efficacy, the current clinically approved antibodies targeting EGFR are ineffective against tumor
cells that express mutants such as EGFRvIII and those that dysregulate EGFR ligands.
Consequently, there is a dire need for effective EGFR-targeted mAbs that operate through
complementary mechanisms to inhibit receptor signaling.
Based on our kinetic characterization and in vitro proliferation and migration analysis of
combination antibody treatment, we established that antibody-induced receptor clustering and
downregulation provides a novel and effective therapeutic strategy for targeting EGFR. We
demonstrate the ability to modulate trafficking through recycling inhibition by targeting multiple
epitopes on the EGFR extracellular domain (24). Encouragingly, this mechanism does not
agonize receptor activity or downstream effectors in contrast to EGF-mediated downregulation.
Others have shown that synergistic EGFR downregulation leads to inhibition of xenografted
tumor growth (24-27). Antibody-induced clustering thus provides an alternative strategy to
ligand inhibition that could be of particular utility in systems that resist ligand competition
treatment, such as autocrine tumors or constitutively active mutations such as EGFRvIII.
An alternative mechanism to ligand inhibition exploited by approved EGFR-targeted antibodies
involves binding to cryptic epitopes that are exposed only in mutant or activated receptor. This
strategy offers the advantage of selectively binding to transformed cells, thus minimizing off-
target effects. As discussed in Chapter 1, a monoclonal antibody that specifically targets the
truncation mutant EGFRvIII, mAb 806, was discovered in 2002 (28). As shown in Figure 3.1,
mAb 806 binds to a cysteine loop at the tail end of EGFR extracellular domain II, a
conformational epitope that is exposed only when the receptor transitions into the open
conformation upon dimerization (29-31). The residues implicated in the 806 epitope are
provided in Table 3.1. Since this antibody is not competitive with currently approved anti-EGFR
mAbs, it is undergoing both monotherapy and combination therapy clinical trials. A recent
phase I clinical trial of mAb 806 demonstrated robust pharmacokinetic properties, effective
therapeutic, targeting and no significant toxicity (32).
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Figure 3.1. Epitopes of mAb 225 and 806 on EGFR ectodomain. The binding epitopes of the two antibodies that
comprise BS28 are depicted on the EGFR monomer (A) (3) and dimer (B) (33). The 806 epitope is shown in red
spheres (31) and the 225 epitope is shown in gray spheres (3). The EGF ligands are shown in black in the 2:2
ligand:receptor dimeric conformation. Domains 1 (orange), 2 (yellow), 3 (green), and 4 (cyan) of the EGFR
ectodomain are depicted. Note that 225 and 806 are noncompetitive and that while 225 competes with ligand, 806
does not. The 806 epitope is exposed only in the active dimeric conformation.
Construct EGFR Binding Domain Epitope
mAb 225 3 Q384, Q408, H409, K443, K465, 1467, N473
mAb 806 2 C287, E293, D297, G298, V299, R300, K301, C302
Table 3.1. Binding epitopes of 225 and 806. Residues implicated in the 225 and 806 epitopes from the published
crystal structure of the bound Fab fragments of the respective antibodies are shown (3). Note that the epitopes are
non-overlapping and 225 is competitive with ligand, whereas 806 is not.
mAb 806 could be informative for developing the next generation of antibody-based EGFR
drugs. Due to its selectivity for mutant or overactive receptors and its distinct mechanism of
action, it may be able to circumvent some of the shortcomings of antibodies that act through
ligand inhibition alone. In a recent study, it was demonstrated that EGFR undergoes synergistic
downregulation following combination treatment with 806 and mAb 528, an antibody with
similar specificity and binding affinity to mAb 225 (25). This study points to the possibility of
receptor crosslinking and clustering, which have been shown to impact both trafficking and
signaling (24, 26).
To harness the power of both combination antibody-induced clustering and preferential targeting
of mutant or activated EGFR, we sought to combine the 225 and 806 mAbs for therapeutic
development. In an effort to attain and potentially enhance mAb-induced downregulation and
enhance tumor cell selectivity, we created an immunoglobulin-based bispecific antibody that
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incorporates the variable domains of both 225 and 806. As shown in Figure 3.2, such an
antibody would be capable of crosslinking EGFR in the same manner as does a mixture of two
antibodies.
A B
Figure 3.2. Bispecific antibodies induce receptor clustering in analogous manner to mAb combinations. Like
combinations of monoclonal antibodies targeted to non-overlapping epitopes on a single receptor (A), bispecific
antibodies that engage multiple non-redundant epitopes on a single receptor (B) have the potential to induce
clustering.
In addition to promoting crosslinking to complement endogenous mAb effects, the bispecific
antibody format enhances clustering through avidity effects. By bringing two EGFR binding
sites into proximity of one another and of other receptors, bispecific antibodies increase the local
concentration of antibody and augment the likelihood of epitope presentation. This strategy is of
particular utility in the case of mAb 806, which recognizes a cryptic epitope on EGFR.
Enhanced clustering capacity renders bispecific antibodies superior to existing therapeutic
compounds or mAb combinations in terms of targeting EGFR and inhibiting its signaling.
Additionally, the presence of the 806 variable region renders this treatment effective on both
wild type and mutant versions of the receptor. The modular structure and design of our multi-
epitopic compound could also form the basis for a new generation of antibody-based therapeutics
against EGFR and other receptor tyrosine kinases that operates through a distinct clustering
mechanism.
In general, bispecific antibodies are constructed to target two different antigens to improve
selectivity of targeting and binding affinity. Bispecific molecules have also found utility in
multi-step targeting strategies involving toxin administration or engagement of immune cells, for
instance through T cell receptor specificity (35-37). Our strategy differs from conventional
bispecific therapeutic strategies since rather than endeavoring to engage multiple unique proteins
with our construct, we aim to target a single receptor at two distinct epitopes to modulate its
trafficking and, ultimately, its expression.
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There are currently in excess of 35 different bispecific antibody formats in pre-clinical or clinical
development. These formats comprise seven classes of constructs: (1) Asymmetric IgG-like
antibodies, which contain all constant and variable IgG domains but contain distinct variable
regions on either arm to confer dual specificity; (2) Symmetric IgG-like antibodies, which have
two specificities within a single variable domain, allowing for molecular symmetry; (38) IgG
fusions, which conjugate additional variable domains at one or more termini of the IgG light or
heavy chain; (4) Fc fusions, which stabilize single-chain variable fragments (scFv's) or diabodies
by linking them to constant domains CH2 and CH3; (5) Fab fusions, which connect two distinct
Fabs using a chemical crosslinker or a flexible linker sequence; (6) ScFv- and diabody-based
antibodies, which consist of two different variable domain fragments either independently or
fused to a stabilizing protein such as human serum albumin; and (7) IgG/Non-IgG fusions, which
link antibody constant and variable domains to naturally-occurring or chimeric cytokines or
receptor proteins (39).
For our bispecific antibody design, we wished to establish a stable, non-immunogenic construct
with built-in flexibility at variable domain joints. Consequently, we chose to mimic the antibody
format by engineering an IgG fusion consisting of the full 225 human IgG1 with an 806 scFv
(heavy and light chain variable regions linked head-to-tail) fused to the light or heavy chain at
the N or C terminus. Flexible (G4S)2 linkers were used between the scFv and IgG components.
This bispecific format had been previously established with a dual-targeted anti- 1,4,7,10-
tetraazacyclododecane- 1,4,7,1 0-tetraacetic acid (DOTA), anti-carcinoembryoinic antigen
antibody (40).
Preliminary work has shown that the bispecific antibody is stably secreted in the scFv fusion
format. Also, binding of this bispecific compound is improved over the binding of both
constituent antibodies and, in some cases, binding is enabled in cell lines that do not show native
interactions with mAb 806. Multi-epitopic binding results in formidable and reproducible
downregulation by bispecific antibodies across a panel of eleven cell lines expressing both wild
type and mutant EGFR. These promising in vitro downregulation results motivated the in vivo
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characterization of our lead bispecific construct in the treatment of the EGFRvIII-expressing
glioblastoma cell line U87-SH (41), the results of which are detailed in Chapter 5.
Results
mAb 806 binds weakly to most wild type EGFR-expressing cell lines
We examined the binding of mAb 806 to a series of EGFR-expressing cell lines that contain
l.Ox 105 to 2.8x 106 receptors per cell, as
60 described in Chapter 2. We found that
mAb 806 showed strong selectivity for
N40
EGFRvIII, which was expressed only on
U87-SH cells (41) in the panel shown in
O H-I- U8- HMEC Figure 3.3. U87-SH cells express 1.7x 105
HeLa Cell Une U87-SH A431 wild type and 1.4x106 mutant EGFR per
Figure 3.3 Binding of mAb 806. The proportion of 806- cell (24). Binding to all other cells lines
binding receptors was determined in six EGFR-expressing
cell lines. Saturating concentrations (20 nM) of both 225 was weak or absent, with the exception of
or 806 were incubated with the indicated cell lines. Cells
were then washed, labeled with fluorophore-conjugated A43 1, which is known to have a maximum
secondary antibody, washed again, and analyzed via flow of 10% of EGFR in the active dimeric
cytometry. The 806 signal relative to 225 signal is
presented for each cell line, representing 806 binding as a conformation in unstimulated cells due tofraction of total surface EGFR binding (±SD, n=3). Cell
lines are listed in increasing order of receptor density. extensive EGFR overexpression (28).
Bispecific antibodies consisting of the full 225 IgG and an 806 scFv are stably secreted in HEK
293 mammalian expression system
Antibodies were designed using a modular format that fused the 225 mAb with the 806 scFv.
Constructs consist of a full human IgG1 backbone with the 225 variable domains with an 806
scFv conjugated to either the light chain or heavy chain at the N- or C-terminal ends. Due to
symmetric assembly of the IgG heavy and light chains, these bispecific constructs are bispecific
and tetravalent. 225-806 bispecific antibodies will henceforth be designated BS28 followed by
the location of scFv fusion, as depicted in Figure 3.4.
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BS28-HN BS28-HC BS28-LN BS28-LC
Figure 3.4. BS28 bispecific antibody structure. A human IgGI isotype backbone is used as a scaffold for
engineering BS28 constructs. The heavy chain consists of three constant domains (CHI, CH2, and CH3) and one
variable domain (VH), whereas the light chain consists of one constant domain (CL) and one variable domain (VL).
Constant domains are shown in orange and variable domains are displayed in red. The 806 scFv (blue) is fused to
the heavy or light chain at the N or C terminus with a flexible linker and the fusion constructs are named as
indicated. Antibody light and heavy chains are assembled in vitro in 2:2 complexes, linked by three disulfide bonds.
Full sequences of the four BS28 constructs that were designed are provided in Appendix C.
Bispecific antibodies were secreted from HEK 293F cells co-transfected with the appropriate
heavy and light chain expression plasmids derived from the gWiz mammalian expression vector.
The sequences for the four bispecific plasmids as well as the unconjugated 225 heavy and light
chain plasmids are provided in Appendix C. All constructs include a Kozak consensus sequence
immediately upstream of the leader sequence to enhance yield (42). Although not essential, our
modular bispecific format allows for the insertion of an epitope tag to facilitate labeling and/or
purification. As proof of principle, a cmyc tag was fused to the C-terminal end of BS28-LC.
Note that the BS28 constructs are approximately 1.3 times the size of the 225 antibody.
For the preparation of each bispecific construct, one chain was conjugated to an scFv of the 806
antibody and the other chain was identical to that of the unmodified 225 antibody. The
molecular weights of each of the constructs are detailed in Table 3.2.
Construct Heavy Chain MW Light Chain MW Full Antibody MW (g/mol)(g/mol) (g/mol)
225 51082 25629 153422
BS28-HN 77218 25629 205640
BS28-HC 77634 25629 206471
BS28-LN 51082 52423 206955
BS28-LC 51082 53510 209129
Table 3.2. Molecular weights of BS28 constructs. The molecular weights (MWs) of the heavy chain, light chain,
and fully-assembled antibody are provided for the unmodified 225 mAb and the four secreted BS28 constructs.
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HEK 293 cells were co-transfected with the designated heavy and light chain plasmids in the
Non-Reducing Reducing presence of 2 tg/mL polyethylinimine.
'225 HN HC LN LC 225 HN HC LN LC Following transfection, cells were
incubated for 7 days at 37*C and 5%
a CO2 . Secretions were then harvested,
ao purified via protein A affinity
chromatography, and reconstituted in
phosphate buffered saline. Purity was
4
evaluated via SDS-PAGE analysis. As
displayed in Figure 3.5, the molecular
H 4weights of the fully assembled BS28
constructs and their respective heavy
Figure 3.5. SDS-PAGE analysis of secreted BS28 constructs. and light chains matched expectations
The four secreted and protein A-purified BS28 constructs and the purity of these antibodies was(denoted by orientation as shown in Figure 3.4) were
characterized by SDS-PAGE analysis under non-reducing high, with no visible aggregates or
(left) and reducing (right) conditions. The unconjugated 225
IgG is shown for reference. degradation products.
Engineered bispecific antibody yields ranged from 2 to 1383 pg/L depending on scFv
orientation. A comparison of the yields for each BS28 format is provided in Figure 3.6. Note
that the heavy chain N-terminal fusion secretes the most robustly. Comparison with secretion
levels of the 225 IgG shows that BS28-HN secretes with a yield of nearly two-fold that of the
base antibody. In contrast, the light chain N-terminal scFv fusion secretes poorly. Due to the
low levels of BS28-LN secretion, this construct was omitted in subsequent characterization and
analysis.
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Figure 3.6. Bispecific antibody yield summary. BS28 antibodies were secreted from HEK 293F cells in the four
orientations shown in Figure 3.4 and the resulting yields of the protein A-purified products are presented. Note
that HN secretes best (1383 pg/L), followed by LC (305 pig/L), HC (125 [tg/L), and LN (4 pig/L). Secretion levels
of the 225 base antibody (731 pig/L) are indicated by the dashed line.
Bispecific antibodies bind EGFR with higher affinity than constituent monoclonal antibodies
The interaction between the bispecific constructs and their target antigen, EGFR, was
characterized on the surface of A431 cells. Since the 806 variable domain only binds to 10% of
surface EGFR in the A431 cell line (Figure 3.3), we might not expect to see enhanced binding of
the bispecific antibody relative to the unconjugated 225 IgG. However, as shown in Figure 3.7
and Table 3.3, we observe that the affinity of the Ab-Fn3 fusion is 4-6 times greater than that of
the unmodified 225 antibody at endosomal pH (6.0) and ten- to twenty-fold greater than that of
the unmodified 225 antibody at physiological pH (7.4). This is a direct consequence of avidity
effects emanating from the bispecificity of the BS28 construct. Hence, from an interaction
standpoint alone, we observe that multispecificity confers binding of 806 to wild type EGFR in
cell lines that show little interaction with this antibody in the monoclonal format.
We further observe from Table 3.3 that binding affinity is roughly equivalent between
endosomal and physiological pH and that both Kd values are in the tens of picomolar range. The
insensitivity of binding to pH reduction indicates that the compound will remain bound to EGFR
following internalization, as does the 225 base antibody.
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Figure 3.7. BS28 binding kinetics. BS28-HN (light blue), HC (medium blue), and LC (dark blue) were titrated on
the surface of A431 cells at pH 6.0 (A) and pH 7.4 (B). Due to avidity effects resulting from the bispecificity of
these constructs, all three have a higher affinity for their target antigen, EGFR, than the unmodified 225 antibody
(green). Nonlinear least squares regression fits to a 1:1 binding isotherm are shown for 225 and BS28 constructs
(solid lines).
Construct Kd (pH 6.0, pM) Kd (pH 7.4, pM)
225 370 1284
BS28-HN 76 47
BS28-HC 97 100
BS28-LC 59 86
Table 3.3. Equilibrium dissociation constructs of BS28 constructs. Using nonlinear least squares regression, the
titration curves shown in Figure 8 were fitted to binding isotherms (% bound = [L]/([L]+Kd where [L] is antibody
concentration and Kd is the apparent equilibrium dissociation constant) and the Kd values were were determined.
Compared to unmodified 225 mAb, bispecific constructs have four-to-six-fold tighter interactions with EGFR at pH
6.0 and ten- to twenty-fold tighter interactions with EGFR at pH 7.4.
Bispecific antibodies induce surface downregulation of both EGFRvIHi and wild type EGFR
Improved receptor clustering manifests itself through enhanced surface EGFR downregulation.
We hypothesized that bispecific antibody-induced clustering would be more efficient than
combination antibody-induced clustering based on avidity and effective concentration effects, so
we sought to examine clustering efficiency by quantifying surface downregulation following
treatment with monoclonal versus bispecific antibodies.
To demonstrate the advantage of using a bispecific, and in particular one that includes 806 to
target mutant receptors, we measured surface EGFR downregulation in a series of cell lines
derived from the U87 glioblastoma line that express various numbers of EGFRvIII (41, 43). All
six cell lines express 1.7x 105 wild type EGFR and variable amounts of transfected EGFRvIII
(24). Note that the U87-DK (dead kinase) cell line is transfected with EGFRvIII possessing the
K721M mutation, which is known to inactivate the tyrosine kinase domain (43), and the U87-
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WT (wild type) line is transfected with wild type EGFR (41). The receptor densities of each of
these cell lines are provided in Chapter 2, Table 2.2.
To quantify surface EGFR downregulation, cells were treated with 20 nM total of either mAb
225, mAb 806, mAbs 225 and 806 combined, BS28-HC, or BS28-LC for 13 h at 37*C. This
allows for the receptors to achieve a new steady state in the presence of antibody. Cells were
then acid stripped to remove surface antibody, relabeled with an anti-EGFR antibody followed
by a fluorophore-conjugated secondary antibody, and quantified via flow cytometry.
The six U87-derived EGFRvIII-expressing cell lines tested were virtually unaffected by mAb
225 and mAb 806 treatment (Figure 3.8), consistent with the results of single antibody treatment
in our combination antibody downregulation panel (Chapter 2, Figure 2.1). In particular, 806
had no effect on any of the lines, even though all but U87 and U87-WT express EGFRvIII.
Interestingly, the combination of mAbs 225 and 806 did not significantly alter surface EGFR
levels. However, all three bispecific constructs tested elicited 50-80% downregulation of surface
EGFR on the six cell lines examined.
I0
Figure 3.8 Surface EGFR downregulation in U87-derived cells following BS28 treatment. Six U87-derived cell
lines (listed in increasing order of EGFR expression level) were treated at a total concentration of 20 nM of the
indicated antibodies for 13 h at 37*C. They were then acid stripped, labeled with an anti-EGFR antibody and a
fluorescent secondary antibody, and analyzed via flow cytometry to quantify remaining surface receptor relative to
that of untreated cells.
Notably, bispecific antibody orientation impacts the extent of downregulation. Specifically, the
fusions with a greater spatial separation between the 225 and 806 variable domains (HC and LC)
downregulate more potently than the construct with adjacent variable domains (HN).
75
Additionally, the LC construct performs slightly better (average downregulation = 72%) than the
HC construct (average downregulation = 65%), suggesting an optimum spacing between the 225
variable domain and the 806 scFv.
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Figure 3.9. Mutant EGFR downregulation extent i
independent of initial receptor number. Downregulation dat
from each cell line shown in Figure 3.8 is plotted agains
receptor density. Surface receptor remaining is presented a
a percentage of the untreated control (2SD, n=3).
Recall from Chapter 2 that pairwise mAb
downregulation extent was inversely
correlated with EGFR density, particularly
in the case of less potently
downregulating combinations. In
contrast, downregulation extent is
uncorrelated with receptor expression
s levels for BS28 constructs; These
a antibodies perform consistently well in allt
ssix cell lines tested (Figure 3.9).
Finally, we note that downregulation of the U87-DK cell line is as effective as downregulation of
other U87-derived cell lines, indicating that kinase activity is not required for bispecific
antibody-induced downregulation. This is in accord with the findings of our group and others for
combination antibody treatment (24, 26).
Although 806 does not bind to wild type EGFR unless it is in the activated conformation, the
enhancement in binding affinity conferred by the fusion of the 806 variable domain to the 225
IgG suggested that antibody binding and downregulation of wild type EGFR could be enhanced
in the case of bispecific treatment. Consequently, we examined steady-state receptor levels on
five wild type EGFR-expressing cell lines (characterized in Chapter 2, Table 2.1) following
single, combination, or bispecific antibody treatment. The U87-SH mutant EGFR-expressing
cell line was included with this panel for reference.
As was the case for mutant EGFR-expressing cell lines, single or combination mAbs had
minimal effects, whereas BS28-HN, HC, and LC decreased surface receptor levels by 50-80% in
the six cell lines that were tested (See Figure 3.10). While all three BS28 constructs
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reproducibly effected downregulation, BS28-HN was notably less active than the HC and LC
constructs, as was observed for the U87 panel. Also consistent with the U87 data, BS28-LC
(average downregulation= 64%) was slightly more potent than BS28-HC (average
downregulation = 53%).
HT-29 HeLa U87 HMEC U8-S A43
:122S+806 60H
BS28-HN 40
Bispecftc BS28-HC 20
LBS28-LC l 0
Figure 3.10 Surface EGFR downregulation in U87-derived cells following BS28 treatment. Six U87-derived cell
lines (listed in increasing order of EGFR expression level) were treated at a total concentration of 20 nM of the
indicated antibodies for 13 h at 37*C. They were then acid stripped, labeled with an anti-EGFR antibody and a
fluorescent secondary antibody, and analyzed via flow cytometry to quantify remaining surface receptor relative to
that of untreated cells.
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Figure 3.11. Wild type EGFR downregulation extent is
independent of initial receptor number. Downregulation data
from the cell lines shown in Figure 3.10 is plotted against
receptor density. Surface receptor remaining is presented as
a percentage of that of untreated cells (±SD, n=3).
As was observed for U87-derived cell
lines, BS28 constructs substantively
downregulate wild type EGFR-expressing
cell lines regardless of receptor
expression level (See Figure 3.11). This
result reinforces the distinction between
mAb combinations and bispecific
constructs in terms of downregulation
dependence on initial surface EGFR
levels.
Taken together, the mutant and wild type EGFR downregulation results are suggestive of greatly
enhanced receptor clustering in the presence of the bispecific antibody compared to mAb 225,
mAb 806, or the combination thereof.
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Discussion
We have demonstrated that use of a bispecific format for administration 225 and 806 results in
synergy between these two mAbs in a system where combination monoclonal antibody treatment
is insufficient. Although combination treatment does not induce receptor downregulation,
bispecific constructs reduce EGFR surface levels by 50-80% in both mutant and wild type
EGFR-expressing cell lines (Figures 3.8, 3.10). In contrast to combination antibody-induced
downregulation, BS28-induced downregulation is insensitive to receptor density (Figures 3.9,
3.11), suggestive of potent, reproducible elimination of EGFR from the cell surface. These
findings argue for the importance of considering antibody structure, orientation, and valency in
therapeutic design, particularly when pursuing a mechanism of action that involves receptor
clustering and downregulation.
There are clear physical advantages to the administration of bispecific antibodies over mAb
combinations in the context of receptor clustering. As described in Chapter 2, receptor clustering
can be induced by using a combination of antibodies with non-overlapping epitopes. However,
this requires alternating receptor binding, as shown in Figure 3.1. The advantage of the
bispecific antibody is that every molecule displays both EGFR-targeted paratopes, reducing
transport limitations and facilitating receptor crosslinking, since every antibody molecule is
capable of extending the growing receptor-antibody chain.
Bispecific constructs also have enhanced binding compared to monoclonal antibodies, as shown
in Figure 3.7 and Table 3.3. This is the result of the cooperativity of binding that stems from
avidity effects. The presence of multiple antibody interactions increases the probability of
binding and reduces the probability of dissociation since the likelihood of multiple interactions
terminating simultaneously is low. Furthermore, if one paratope of the tetravalent antibody
dissociates from the receptor while the three other paratopes may remain bound to surface
receptors, the local apparent concentration of the free paratope in the vicinity of surface-bound is
drastically inflated. In all likelihood, the dissociated paratope will rebind, strengthening the
apparent affinity of the antibody for its target receptor.
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In the particular case of the 225-806 bispecific construct, binding is not only enhanced, but
enabled through avidity effects. Recall that the 806 epitope is only exposed when EGFR is in its
active conformation (28-31). However, due to thermodynamic fluctuations of the receptor, the
806 epitope can be exposed even when the receptor is in the tethered monomeric state. If the
225 paratope is already bound to EGFR, the range of the 806 paratope is constrained, increasing
the apparent concentration of 806 paratope to which the receptor is exposed and increasing the
probability that 806 will bind when its epitope is exposed. Thus, the 806 paratope on the
bispecific antibody is much more likely to capture its epitope in the 225-bound constrained state
compared to the unconstrained state in free solution. Improved 806 binding in the bispecific
state is evidenced by the affinity enhancement of BS28 constructs compared to mAb 225 in
A431 cells at physiological and endosomal pH. The 806 monoclonal antibody only binds to
approximately 10% of EGFR in A431 cells (the activated fraction), yet in a bispecific with 225,
it improves the affinity of the monoclonal 225 antibody at pH 7.4 by more than an order of
magnitude (Figure 3.7B and Table 3.3). This improved 806 scFv binding also facilitates
crosslinking, thus augmenting receptor clustering.
In addition to the therapeutic advantages of using a bispecific antibody as opposed to a single
antibody or a drug cocktail, there are commercial advantages to the development of multispecific
compounds. From a logistical standpoint, combining two therapeutics into a single compound
facilitates preparation on the production side and administration on the clinical side. Also,
clinical testing of a bispecific compound may be expedited compared to a drug cocktail since one
would only be required to characterize the properties of a single compound as opposed to
multiple compounds (36, 37). Lastly, the presence of multiple antibody variable domains and
the recruitment of multiple therapeutic mechanisms within a single compound along with the
binding and clustering advantages of a bispecific antibody combine to make multispecific
antibodies more potent than their monoclonal counterparts. As a result, drug dosage is reduced
for bispecific compounds, potentially reducing off-target effects.
Our comprehensive study of the class of single scFv fusions for 225-806 bispecific design
(Figure 3.4) offers insight into the structural bias of antibody-induced downregulation.
Specifically, we find that fusion of the scFv in the HN position enhances antibody secretion
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(Figure 3.6), but does not optimize downregulation. The HC and LC fusions, which further
separate the two variable domains, more effectively reduce surface EGFR levels, with the LC
spacing showing a slight advantage over the HC orientation (Figures 3.8, 3.10).
The ability of our BS28 constructs to downregulate both EGFR and EGFRvIII is significant
since the two FDA-approved antibody drugs that target EGFR are ineffective against this mutant,
as they rely significantly on ligand competition for therapeutic efficacy. The recruitment of a
mechanism that is independent of ligand binding implies that BS28 would also have a
therapeutic advantage in cases where EGFR ligands are overexpressed or otherwise
dysregulated. Clearly, BS28 constructs have the potential to complement the effects and
overcome the limitations of currently approved antibodies targeting EGFR.
In our combination mAb studies discussed in Chapter 2, clustering was shown to abrogate EGFR
recycling, thereby decreasing surface receptor expression and activation of downstream signaling
pathways (24). By altering the trafficking of EGFR using the endogenous endocytic machinery,
clustering reduces the steady state surface levels of EGFR, thus reducing the number of receptors
available for signal activation. Importantly, receptor clustering was found not to be agonistic,
achieving downregulation without activating downstream pathways. We also found combination
antibody-mediated downregulation to coincide with inhibition of the migration and growth of
transformed cells (24). Based on the similarity in mechanism and downregulatory capacity
between mAb combinations and our engineered bispecific antibodies, we predict that our BS28
series would exhibit an analogous correlation between receptor downregulation and efficacy in
the absence of agonism.
The therapeutic promise of our BS28 bispecific antibodies has been confirmed in vitro through
surface EGFR downregulation assays on human cancer cell lines. Previous work has
demonstrated tumor inhibition by EGFR downregulating constructs (25-27, 44, 45). Based on
these results, we pursued in vivo characterization of our most potently downregulating bispecific
antibody (BS28-LC) via mouse xenograft studies, as described in Chapter 5.
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Use of the bispecific construct we have developed offers numerous therapeutic advantages over
current clinically available treatments. The strategy of administering a bispecific antibody with
two variable domains targeting non-overlapping epitopes on a single receptor tyrosine kinase can
also be generalized as a robust therapeutic option. The modular format of the bispecific
constructs we have developed allows for the presentation of any antibody variable domain with
engineered specificity for multiple non-overlapping sites on any antigen of interest. This
provides a generalized scaffold for eliciting receptor clustering, which could be extended to other
members of the ErbB family or to other receptor tyrosine kinases. The IgG backbone will allow
for superior retention in the bloodstream via neonatal Fe receptor recycling (46) and the
molecular specificity of the two variable domains will minimize off-target toxicity. This novel
targeting approach has the potential to complement existing therapeutic mechanisms such as
ligand competition, immune recruitment, and angiogenesis inhibition to enhance drug efficacy
via clustering, receptor downregulation, increased binding affinity, and selective targeting.
Additionally, compared to administration of a cocktail of antibodies, the bispecific approach
enhances or, as is the case for 225 and 806, enables synergy between its constituent antibodies.
The primary commercial application we envision for BS28 constructs is use as a targeted
therapeutic in multiple forms of epithelial-based cancer. Although 806 specifically targets
EGFRvIII, our in vitro downregulation data suggests that BS28 may be effective on a wide range
of cancer cell lines with varied wild type and mutant receptor densities, even those that do not
bind to the 806 monoclonal antibody (Figures 3.3, 3.8, 3.10).
A further application of BS28 constructs could be as delivery agents for multi-step targeting
applications. Fusion to toxins, endosomalytic species, siRNA, or other cell disruption agents
would direct these molecules to wild type and mutant EGFR-expressing tumors and allow for
their rapid internalization. Through formation of large depots of clustered EGFR-antibody
complexes in the cytoplasm, bispecific molecules could provide high local concentrations of
toxin or to selectively destroy transformed cells. Furthermore, conjugation of BS28 constructs to
fusogenic peptides could facilitate disruption of the endosomal membrane and allow for
diffusion of conjugated toxins into the cytosol, enhancing therapeutic efficacy.
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Finally, aside from their potential as therapeutic agents, BS28 constructs could be developed as
research and diagnostic tools. With picomolar affinity for EGFR (Figure 3.7 and Table 3.3) and
targeted recognition of the mutant EGFRvIII with the 806 moiety, BS28 antibodies tightly and
selectively bind EGFR, providing accurate and highly sensitive detection for tumor diagnosis
applications.
Materials and Methods
Cell lines and antibodies
The transfected CHO-EG (47) and U87-derived (41) cell lines were established as described
previously and all other lines were obtained from ATCC (Manassas, VA). Cells were maintained
in their respective growth media (from ATCC unless otherwise indicated): DMEM for A43 1,
U87-MG, transfected U87-MG, and CHO-EG cells, McCoy's Modified 5A media for HT-29
cells, EMEM for HeLa cells, and HuMEC Ready Medium (Invitrogen, Carlsbad, CA) for HMEC
cells. U87-MG, transfected U87-MG, and CHO-EG media were supplemented with 1 mM
sodium pyruvate (Invitrogen) and 0.1 mM non-essential amino acids (Invitrogen) and transfected
U87-MG lines and CHO-EG were selected with 0.3 mM Geneticin (Invitrogen). ATCC media
was supplemented with 10% fetal bovine serum (FBS). Murine 225 was secreted from the
hybridoma cell line (ATCC).
Unless otherwise noted, all washes were conducted in PBS containing 0.1% BSA and all mAbs
were used at a concentration of 20 nM for single treatment and 10 nM each for combination
treatment. EGF (Sigma, St. Louis, MO) was dosed at 20 nM. Trypsin-EDTA (Invitrogen)
contains 0.05% trypsin and 0.5 mM EDTA. Cell pelleting was conducted at 1000xg.
225 and 806 mAb binding assays
To characterize mAb 225 and 806 binding to cells, the indicated cell lines were grown to
confluence and subsequently serum-starved for 12 h. Cells were then trypsinized, washed in
PBSA, and incubated with 20 nM mAb 225 or 806 (human IgG 1) in a 96-well plate on ice for 1
h. Cells were then washed and labeled with 66 nM PE-conjugated goat anti-human antibody
(Rockland Immunochemicals, Gilbertsville, PA) for 20 min on ice. After a final wash, plates
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were analyzed on a FACS Calibur cytometer (BD Biosciences, San Jose, CA). 806 fluorescence
intensity was normalized by 225 fluorescence intensity to determine the fraction of surface
EGFR molecules that bind the 806 mAb.
Production of mAb and BS28 constructs via HEK cell transfection
The human IgG1 heavy and light chains of each BS28 construct and the 225 and 806 mAbs were
inserted into the gWiz mammalian expression vector (Genlantis). The sequences for all 225,
806, and BS28 plasmids are provided in Appendix C. Constructs were verified by sequence
analysis. HEK 293F cells (Invitrogen) were grown to 1.2 million cells per mL and diluted to one
million per mL. Miniprepped DNA and polyethyleneimine (Sigma) were independently diluted
to 0.05 and 0.1 mg/mL in OptiPro medium and incubated at 220 for 15 min. Equal volumes of
DNA and polyethyleneimine were mixed and incubated at 22* for 15 min. 500 mL of cells in
FreeStyle media and 20 mL of DNA/polyethyleneimine mixture in OptiPro were added to a 2 L
roller bottle and incubated at 370, 5% CO2 on a roller bottle adapter for seven days. The cell
secretions were then centrifuged for 30 min at 15,000xg and the supernatant was filtered through
a 0.22 [tm bottle-top filter and purified via affinity column chromatography using protein A resin
(Thermo Fisher Scientific, Waltham, MA). The eluted bispecific antibodies were concentrated
and transferred to PBS and then characterized by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis. For reducing SDS-PAGE, samples were treated with 0.6
M dithiothreitol.
BS28 and mAb cell surface affinity titrations
To characterize bispecific construct binding affinities, A431 cells were grown to confluence and
serum-starved for 12 h. Cells were then trypsinized, washed in PBSA and incubated with
various concentrations of Ab-Fn3 or mAb 225 in a 96-well plate on ice. The number of cells and
sample volumes were selected to ensure at least tenfold excess Ab-Fn3 relative to EGFR. Cells
were incubated on ice for sufficient time to ensure that the approach to equilibrium was at least
99% complete. Cells were then washed and labeled with 66 nM PE-conjugated goat anti-human
antibody (Rockland Immunochemicals) for 20 min on ice. After a final wash, plates were
analyzed on a FACS Calibur cytometer (BD Biosciences). Fluorescence intensities are
normalized to the maximum value for a give construct. The minimum and maximum
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fluorescence and the Kd value were determined by minimizing the sum of squared errors
assuming a 1:1 binding interaction (% Bound = [L]/([L]+Kij) where [L] is bispecific antibody
concentration and K1 is the apparent equilibrium dissociation constant of the BS28 construct.
Titrations were performed at both pH 6.0 (endosomal pH) and pH 7.4 (physiological pH). All
curve fitting was implemented in MATLAB (Mathworks, Natick, MA).
Receptor downregulation assays
Cells were seeded at 5x10 4 per well in 96-well plates and allowed to adhere overnight. They
were then serum starved for 12-16 h, treated with the indicated mAbs or BS28 constructs in
serum-free medium, and incubated at 37*C for 13 h. Subsequently, cells were washed and
treated with trypsin-EDTA for 20 min at 37*C. Trypsin was neutralized with medium (10%
FBS) and cells were immediately transferred to v-bottom plates on ice. They were then washed,
acid stripped (0.2 M acetic acid, 0.5 M NaCl, pH 2.5), and washed again prior to incubation with
20 nM murine 225 for 1 h on ice to label surface EGFR. Cells were then washed and labeled
with 66 nM PE-conjugated goat anti-mouse antibody (Invitrogen) for 20 min on ice. After a final
wash, plates were analyzed on a FACS Calibur cytometer (BD Biosciences). Results are
presented as fluorescence intensity of treated cells divided by that of untreated control cells.
Each value presented in the heat maps and downregulation versus receptor density graphs
represents the mean downregulation extent in triplicate wells averaged over three independent
experiments.
References
1. Martinelli E, De Palma R, Orditura M, De Vita F, & Ciardiello F (2009) Anti-epidermal
growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol
158(1):1-9.
2. Grunwald V & Hidalgo M (2003) Developing inhibitors of the epidermal growth factor
receptor for cancer treatment. JNatl Cancer Inst 95(12):851-867.
3. Li S, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor
by cetuximab. Cancer Cell 7(4):301-311.
84
4. de Bono JS & Rowinsky EK (2002) Therapeutics targeting signal transduction for
patients with colorectal carcinoma. Br Med Bull 64:227-254.
5. Ennis BW, Lippman ME, & Dickson RB (1991) The EGF receptor system as a target for
antitumor therapy. Cancer Invest 9(5):553-562.
6. Prewett MC, et al. (2002) Enhanced antitumor activity of anti-epidermal growth factor
receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11)
against human colorectal tumor xenografts. Clin Cancer Res 8(5):994-1003.
7. Ciardiello F, et al. (1999) Antitumor activity of sequential treatment with topotecan and
anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res
5(4):909-916.
8. Mateo C, et al. (1997) Humanization of a mouse monoclonal antibody that blocks the
epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology
3(1):71-81.
9. Sebastian S, et al. (2006) The complexity of targeting EGFR signalling in cancer: from
expression to turnover. Biochim Biophys Acta 1766(1):120-139.
10. Cunningham D, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl JMed 351(4):337-345.
11. Cohenuram M & Saif MW (2007) Panitumumab the first fully human monoclonal
antibody: from the bench to the clinic. Anticancer Drugs 18(1):7-15.
12. Van Cutsem E, et al. (2007) Open-label phase III trial of panitumumab plus best
supportive care compared with best supportive care alone in patients with chemotherapy-
refractory metastatic colorectal cancer. JClin Oncol 25(13):1658-1664.
13. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl JMed
350(21):2129-2139.
14. Paez JG, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response
to gefitinib therapy. Science 304(5676):1497-1500.
15. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from
"never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proc NatlAcad Sci USA 101(36):13306-13311.
85
16. Tracy S, et al. (2004) Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung
cancer cell line H3255. Cancer Res 64(20):7241-7244.
17. Sordella R, Bell DW, Haber DA, & Settleman J (2004) Gefitinib-sensitizing EGFR
mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687):1163-1167.
18. Ekstrand AJ, Sugawa N, James CD, & Collins VP (1992) Amplified and rearranged
epidermal growth factor receptor genes in human glioblastomas reveal deletions of
sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA
89(10):4309-4313.
19. Ekstrand AJ, et al. (1991) Genes for epidermal growth factor receptor, transforming
growth factor alpha, and epidermal growth factor and their expression in human gliomas
in vivo. Cancer Res 51(8):2164-2172.
20. Liu L, et al. (2005) Clinical significance of EGFR amplification and the aberrant
EGFRvIII transcript in conventionally treated astrocytic gliomas. JMol Med 83(11):917-
926.
21. Wong AJ, et al. (1992) Structural alterations of the epidermal growth factor receptor gene
in human gliomas. Proc Natl Acad Sci USA 89(7):2965-2969.
22. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, & Sugimachi K (1990)
Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the
human lung. Cancer Res 50(21):7077-7080.
23. Hirai T, et al. (1998) Clinical results of transhiatal esophagectomy for carcinoma of the
lower thoracic esophagus according to biological markers. Dis Esophagus 11(4):221-225.
24. Spangler JB, et al. (2010) Combination antibody treatment down-regulates epidermal
growth factor receptor by inhibiting endosomal recycling. Proc Natl A cad Sci USA
107(30):13252-13257.
25. Perera RM, et al. (2005) Treatment of human tumor xenografts with monoclonal
antibody 806 in combination with a prototypical epidermal growth factor receptor-
specific antibody generates enhanced antitumor activity. Clin Cancer Res 1 1(17):6390-
6399.
26. Friedman LM, et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by
combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci US
A 102(6):1915-1920.
86
27. Pedersen MW, et al. (2010) Sym004: a novel synergistic anti-epidermal growth factor
receptor antibody mixture with superior anticancer efficacy. Cancer Res 70(2):588-597.
28. Johns TG, et al. (2002) Novel monoclonal antibody specific for the de2-7 epidermal
growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells
containing amplification of the EGFR gene. Int J Cancer 98(3):398-408.
29. Chao G, Cochran JR, & Wittrup KD (2004) Fine epitope mapping of anti-epidermal
growth factor receptor antibodies through random mutagenesis and yeast surface display.
JMol Biol 342(2):539-550.
30. Johns TG, et al. (2004) Identification of the epitope for the epidermal growth factor
receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an
untethered form of the receptor. JBiol Chem 279(29):30375-30384.
31. Garrett TP, et al. (2009) Antibodies specifically targeting a locally misfolded region of
tumor associated EGFR. Proc Natl Acad Sci US A 106(13):5082-5087.
32. Scott AM, et al. (2007) A phase I clinical trial with monoclonal antibody ch806 targeting
transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U SA
104(10):4071-4076.
33. Ogiso H, et al. (2002) Crystal structure of the complex of human epidermal growth factor
and receptor extracellular domains. Cell 110(6):775-787.
34. Ettenberg SA, et al. (2010) Inhibition of tumorigenesis driven by different Wnt proteins
requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad
Sci USA 107(35):15473-15478.
35. Cochran JR (2010) Engineered proteins pull double duty. Sci Transl Med 2(17):17ps 15.
36. Muller D & Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy:
Current perspectives. BioDrugs 24(2):89-98.
37. Muller D & Kontermann RE (2007) Recombinant bispecific antibodies for cellular
cancer immunotherapy. Curr Opin Mol Ther 9(4):319-326.
38. Khambata-Ford S, et al. (2007) Expression of epiregulin and amphiregulin and K-ras
mutation status predict disease control in metastatic colorectal cancer patients treated
with cetuximab. J Clin Oncol 25(22):3230-3237.
39. Baeuerle PA (2011) Constructing bispecifics with improved properties. Seventh Annual
Protein Engineering Summit (PEGS).
87
40. Orcutt KD, et al. (2011) Engineering an antibody with picomolar affinity to DOTA
chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl
Med Biol 38(2):223-233.
41. Huang PH, et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks
reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U SA
104(31):12867-12872.
42. Kozak M (1977) Nucleotide sequences of 5'-terminal ribosome-protected initiation
regions from two reovirus messages. Nature 269(5627):391-394.
43. Huang HS, et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth
factor receptor common in human cancers is mediated by threshold levels of constitutive
tyrosine phosphorylation and unattenuated signaling. JBiol Chem 272(5):2927-2935.
44. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, & Sela M (2009) Persistent elimination of
ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies:
relevance of receptor endocytosis. Proc Natl Acad Sci USA 106(9):3294-3299.
45. Roovers RC, et al. (2011) A bi-paratopic anti-EGFR nanobody efficiently inhibits solid
tumour growth. Int J Cancer.
46. Simister NE & Mostov KE (1989) An Fc receptor structurally related to MHC class I
antigens. Nature 337(6203):184-187.
47. Harms BD, Bassi GM, Horwitz AR, & Lauffenburger DA (2005) Directional persistence
of EGF-induced cell migration is associated with stabilization of lamellipodial
protrusions. Biophys J 88(2):1479-1488.
88
4. Design of Downregulating Multispecific Antibody-Fibronectin Fusions
Introduction
Having successfully demonstrated the ability to synergistically downregulate surface EGFR
using a combination of antibodies targeting non-overlapping extracellular epitopes on this
receptor (1), we wished to enhance this effect by engineering multispecific molecules motivated
by our downregulation insights that would be capable of engaging multiple sites on the EGFR
extracellular domain. The concept of using bispecific antibodies has been around for the past
twenty years, but complications in production, stability, and immunogenicity have hindered their
development (2). As detailed in Chapter 3, improved manufacturing strategies and novel
recombinant formats have circumvented these obstacles and allowed for the pre-clinical
characterization and more recently the clinical development of bispecific therapeutics (3-8).
The canonical model for a bispecific antibody is a molecule with binding sites to two different
target antigens. Engaging multiple receptors allows for increased selectivity and specificity of
protein therapeutics and permits multi-step targeting strategies in which one site interacts with
target antigen and the other site recognizes a toxin, radionuclide, or contrast agent (9). In
addition, targeting multiple receptors can improve the affmity of an antibody through avidity
effects, improving therapeutic potency and potentially reducing manufacturing costs throughout
the drug characterization and commercial development processes.
Accumulating evidence argues for the use of multispecific antibodies targeting distinct epitopes
on a single receptor (10-13). In addition to enhancing affinity and specificity, the use of
multispecific antibodies against a single target can elicit receptor clustering and downregulation,
complementing inherent mechanisms of action of constituent monoclonal antibodies such as
ligand inhibition. Clustering is enhanced in the multispecific format compared to combination
treatment due to avidity effects. Furthermore, increased valency and functionality of the
multispecific format allows for efficient surface clustering with a single agent (See Figure 4.1).
An improvement in clustering efficiency may in turn enhance antibody-dependent cell-mediated
cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) through formation of
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large antibody-receptor complexes. In support of this hypothesis, enhanced CDC activity
function was observed following combination treatment with non-competitive EGFR-targeted
antibodies (11).
Rs
Numerous formats have been
employed in the development of
k G ke multispecific 
antibodies, as discussed
recR in Chapter 3. To create compounds
kd with two or more specificities, we
l E > 0 chose to use a full human IgG1 with
Figure 4.1. Modulation of EGFR trafficking via multispecific appended single-domain binding
antibody treatment. A basic model of receptor clustering and moieties to retain the benefits of the
trafficking following treatment with a bispecific antibody
targeting two non-overlapping epitopes on EGFR is shown. antibody format such as stability, lack
Note that in contrast to the requirement for two mAbs to
propagate crosslinking, a single bispecific antibody can of immunogenicity, and long serum
efficiently cluster surface receptor. Trafficking parameters and
species are indicated. EGFR can be surface-bound (Rs) or halflife. Indeed we showed robust
internal (R1). Receptor is synthesized with a rate P syn,
internalized with rate ke, recycled back to the surface with rate secretion of an IgG-scFv fusion in
krec, and degraded with rate kdeg. Chapter 3. An alternative approach
we pursued involved the design of IgG fusions to fibronectin domain variants. Our results with
combinations of EGFR-targeted antibodies suggested that a multispecific strategy that included
at least one ligand-competitive antibody would be optimal (1). We consequently fused the
clinically approved human mAb 225 (cetuximab) with variants of the tenth type III domain of
human fibronectin (Fn3) that recognize EGFR (14). Fn3 is a 94 amino acid (~10 kDa) soluble
beta-sandwich protein with three solvent-exposed variable loops, similar to an scFv. The domain
natively functions in molecular recognition and can be engineered to bind a variety of target
antigens (15). Head-to-tail fusion of Fn3 domains maintains them in their native conformation
(16, 17), allowing fusion to multidomain proteins to design multispecific constructs. We thus
fused Fn3 domains to full-length IgG to establish multispecific antibody-fibronectin fusions
(hereafter referred to as Ab-Fn3 fusions) that would induce downregulation of EGFR.
In previous work, Hackel et al used directed evolution on the yeast surface display platform to
isolate three non-competitive variants of the Fn3 domain that bind to EGFR on three different
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extracellular domains (See Figure 4.2, Tables 4.1, 4.2) (14). Clone A binds domain 1, clone B
binds domain 3, the ligand binding domain, and clone D binds at the domain 3/4 interface.
These Fn3 variants bind EGFR with nanomolar or sub-nanomolar affinity, as detailed in Table
4.2. When fused head-to-tail separated by a flexible linker to form heterobivalent constructs,
Fn3 clones induce moderate levels of EGFR downregulation in the absence of receptor or
downstream agonism. These clones also synergize with 225 to inhibit migration and
proliferation of cells that secrete autocrine EGF, simulating the tumor environment (18). In
particular, a fusion of clones A and D where A is N-terminal potently inhibits both migration and
proliferation (~80%) in the presence of 225 (14). Fusing these Fn3 constructs to the full 225 IgG
would capture this synergy and potentially enhance it via improvement in clustering and,
consequently, downregulation. Furthermore, the presence of the antibody Fc domain would aid
in the persistence of these fusions in the bloodstream via neonatal Fc receptor recycling (19) and
could facilitate immune cell recruitment, rendering Ab-Fn3 fusions superior to heterobivalent
fibronectin fusions as therapeutic compounds. The modular structure and design of these
constructs could allow for them to form the basis for a new generation of antibody-based
therapeutics against EGFR or other receptor targets.
A Clone 8 Clone A D -omain 1 B
225
2S EGF
CloneD
Figure 4.2. EGFR binding epitopes of engineered Fn3 domains. The binding locations of the three non-competitive
fibronectin clones were identified using yeast surface display-based fine epitope mapping (20). The epitopes of
clone A (magenta), clone B (violet), and clone D (brown) are depicted as spheres on the EGFR ectodomain in the
tethered monomeric (A) or active dimeric conformation (B). The 225 antibody epitope is shown in gray (21).
Domains 1 (orange), 2 (yellow), 3 (22), and 4 (cyan) of the EGFR extracellular domain are displayed, with the EGF
binding site shown in black on the dimeric receptor. The monomeric and dimeric structures are adapted from inql
(23) and livo (24), respectively. Epitopes were obtained from (14).
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Fn3 Clone A I L14, Q16, Y45, H69
Fn3 Clone B III 1327, V350M, F352V, W386R
Fn3 Clone D III/IV K430, S506
mAb 225 III Q384, Q408, H409, K443, K465, 1467, N473
Table 4.1. Binding epitopes of Fn3 moieties. Residues implicated in the binding of the EGFR targeted fibronectin
clones were identified using yeast surface display-based fine epitope mapping (20). The 225 epitope from the
published crystal structure of the bound Fab fragment is also listed (21). Data obtained from (14).
Sequence Kd [nMJ
Fn3 Clone BC Loop DE Loop FG Loop Framework A431, pH 7.4
A FDYAVTY GWIST DNSHWPFRST 190T 0.26 0.13
B YGFSLASS RSPWF SNDFSNRYSG - 30 3
D LHHRSDVRS GSRSL WGSYCCSN E47K 0.25 0.05
Table 4.2. Sequences and binding affinities of engineered Fn3 domains. Sequences of the three variable loops and
framework mutations for the three EGFR-targeted Fn3 clones are indicated. The affinity of each clone was
determined through titration on the surface of A431 cells at pH 7.4 (20). Data obtained from (14).
Results
Expression of Bispecific Ab-Fn3 Fusions
Bispecific Ab-Fn3 fusions were designed by conjugating a single Fn3 domain (A, B, or D) at the
four possible termini of the 225 human IgG1 backbone (heavy chain N or C terminus and light
chain N or C terminus), separated by a flexible (Gly4Ser)2 linker. The design of these modular
constructs is depicted in Figure 4.3. Constructs are named according to the position of Fn3
conjugation followed by the designation of the clone used (e.g. HN-A).
The 180 kDa Ab-Fn3 fusions were secreted from human embryonic kidney (HEK) 293 cells co-
transfected with the appropriate heavy and light chain expression plasmids. Sequences for these
plasmids in all four constuct orientations are provided in Appendix C. Antibodies were purified
via protein A affinity chromatography and analyzed via SDS-PAGE for purity. A representative
SDS-PAGE for Ab-Fn3 fusion constructs in the four bispecific orientations is shown in Figure
4.4A.
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EpitopeProtein EGFR Binding Domain(s)
HN HC LN LC
Figure 4.3. Bispecific Ab-Fn3 fusion orientations. The 225 human IgGI isotype backbone is used as a scaffold for
engineering Ab-Fn3 fusions. The heavy chain consists of three constant domains (CH1, CH2, and CH3) and one
variable domain (VH), whereas the light chain consists of one constant domain (CL) and one variable domain (VL).
The tenth type III domain of human fibronectin (Fn3), shown in green, is fused to the heavy or light chain at the N
or C terminus with a flexible linker and the fusion constructs are named as indicated. Antibodies are assembled in
vitro in two-to-two complexes of heavy and light chain moieties, linked by three disulfide bonds. The full
sequences of the plasmids used to prepare the heavy and light chains of bispecific Ab-Fn3 fusions are provided in
Appendix C.
Bispecific Ab-Fn3 yields ranged from 1 - 10,000 pg/L depending on antibody format and the
Fn3 clone used. In general, fusions in the HN orientation secreted the most robustly for all three
Fn3 moieties and fusions in the LN orientation secreted at the lowest levels. The HC and LC
fusions secreted equally well but yields were at least 100-fold less than those of HN fusions
(Figure 4.4B). In fact, Fn3 fusion in the HN orientation appeared to rescue secretion as HN
constructs secreted at five- to tenfold higher levels than the unconjugated 225 antibody.
Consequently, we selected HN fusions for extensive characterization and follow-up.
A B
250
100
60 -
50
40
30*
254
Figure 4.4. Bispecific Ab-Fn3 fusion yields. (A) SDS-PAGE analysis of a representative protein A-purified secreted
Ab-Fn3 fusion. The 225 mAb and the HN-D, HC-D, LN-D, and LC-D constructs were visualized in the non-
reduced (left) and reduced (right) states. Reference molecular weights in kDa are shown in the left lane. (B)
Summary of Ab-Fn3 bispecific fusion yields. The specified Fn3 clones (A, B, or D) were fused in the indicated
orientation and yield was quantified based on 280 nm absorbance. Yield of the base 225 IgG is marked with a
dashed line.
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Bispecific Ab-Fn3 Fusions Bind EGFR with Sub-Nanomolar Affinity
The interaction between Ab-Fn3 fusion constructs and their target antigen, EGFR, was
characterized by titration on the surface of A431 cells. The apparent equilibrium dissociation
constants (K1) for all secreted HN bispecific fusions are listed in Table 4.3. Note that the
affinities of the Ab-Fn3 fusions are five- to tenfold tighter than that of the unmodified 225
antibody, both at endosomal pH (6.0) and physiological pH (7.4). Insensitivity of binding to pH
reduction indicates that the constructs will remain bound to EGFR following internalization. The
measured Kd values fall in the tens to hundreds picomolar to hundreds of picomolar range,
corresponding with binding half-lives on the order of days.
Construct Kd, A431 H 6.0 Kd, A431 pH 7.4
225 3.7x10~10 M 1.2x10- M
HN-A 1.9x10~0 M 2.4x10~10 M
HN-B 2.4x10" M 6.1x10" M
HN-D 4.0x10" M 7.5x10"- M
Table 4.3. Bispecific Ab-Fn3 fusion binding kinetics. Due to avidity effects that emanate from the dual specificity
of the Ab-Fn3 fusion, these novel constructs generally have higher affinity for EGFR. Samples were titrated at the
indicated pH on the surface of A431 cells, which express 2.8x 106 EGFR per cell (1). Kd values from nonlinear least
squares regression fits to a 1:1 binding isotherm are listed.
Bispecific Ab-Fn3 Fusions Substantively Downregulate EGFR
To evaluate the ability of bispecific fusions to induce EGFR downregulation, we performed
downregulation assays on the seven cell lines used in our combination antibody screen described
in Chapter 2. Downregulation levels were compared to those induced by treatment with the most
active combination of antibodies, 225+Hl 1.
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Figure 4.5. Surface EGFR downregulation following bispecific Ab-Fn3 treatment. (A) Seven EGFR expressing cell
lines (listed in increasing order of receptor density) were treated with 20 nM of the specified constructs for 13 h at
37*C. Cells were then acid stripped, relabeled for EGFR, and analyzed via flow cytometry. Percent surface
receptor remaining relative to an untreated control is shown. (B) Relative surface receptor remaining plotted against
receptor density for each Ab-Fn3 fusion.
We found that HN, HC, and LC fusions induced appreciable levels of receptor downregulation,
but none were as potent as the 225+H11 combination, particularly on cell lines with high
receptor density (Figure 4.5A). In the case of HC and LC fusions, the extent of downregulation
was inversely correlated with receptor density, whereas HN fusion downregulation was
consistent across the panel of cell lines (Figure 4.5B). As expected, monovalent Fn3 domains did
not elicit EGFR downregulation; The multivalent fusion format was required.
Expression of Tri- and Tetraspecific Ab-Fn3 Fusions
To increase the valency and potentially enhance fusion-mediated clustering through avidity
effects, we conjugated additional Fn3 domains to the 225 IgG scaffold. Given three non-
competitive Fn3 domains plus the 225 variable domain, we have the ability to target four unique
epitopes on EGFR. We consequently designed both trispecific and tetraspecific molecules in the
four orientations shown in Figure 4.6. Cis-trispecifics fuse two Fn3 domains to the HN position,
trans-trispecifics consist of one HN and one LC Fn3 fusion, double HC trispecifics include one
HN and one HC Fn3 domain, and tetraspecifics contain one HN, one HC, and one LC Fn3
moiety. LN fusion was avoided due to low secretion levels. As with the bispecifics, tri- and
tetraspecific constructs were secreted from HEK 293 cells co-transfected with heavy and light
chain plasmids and purified via protein A affinity chromatography.
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Figure 4.6. Tri- and tetraspecific Ab-Fn3 fusion orientations. The 225 human IgGI isotype backbone (constant
dpmains in orange and variable domains in red) was fused to two or three Fn3 domains (green, magenta, and yellow)
at the positions shown. Three trispecific and one tetraspecific constructs were secreted from HEK 293 cells. The
full sequences of the plasmids used to prepare the heavy and light chains of these multispecific Ab-Fn3 fusions are
provided in Appendix C.
The yields of these 200-225 kDa antibodies varied from 5 to 5000 [g/L depending on both the
fusion format and the Fn3 clone position. SDS-PAGE analyses of protein A-purified constructs
from each orientation are shown in Figure 4.7A. Note the non-reduced Ab-Fn3 fusion constructs
run at higher molecular weights than unconjugated IgG, with heavy and light chain bands at the
expected molecular weights in the reduced samples. Based on the robust expression of fusions
with Fn3 domains at the heavy chain N terminus, we used HN fusions as a basis for all four
formats. The cis- and trans-trispecific fusions secreted best, whereas yields for the double HC-
trispecific and the tetraspecific formats were ten- to 100-fold lower. Notably, secretion of the
cis- and trans-trispecific fusions was superior to that of the unmodified 225 antibody by three- to
six-fold (Figure 4.7B).
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Figure 4.7. Tri- and tetraspecific Ab-Fn3 fusion yields. (A) SDS-PAGE analysis of a representative protein A-
purified secreted Ab-Fn3 fusion from each of the four categories: cis-trispecific (HN-AD); trans-trispecific
(HNA+LCD); double HC-trispecific (HNB+HCA); and tetraspecific (HNB+HCD+LCA). The 225 mAb is shown
for molecular weight comparison and a standards ladder is provided in the left lane. All constructs were visualized
under non-reducing (left) and reducing (right) conditions. (B) Summary of multispecific Ab-Fn3 fusion yields. The
specified Fn3 clones (A, B, or D) were fused in the indicated orientation and yield from HEK 293 cell secretion was
quantified based on 280 nm absorbance. Expression level of the base 225 IgG is marked with a dashed line.
Trans-Trispecific Ab-Fn3 Fusions Bind EGFR with Sub-Nanomolar Affinity
We characterized the binding kinetics of the two well-secreted classes of multispecific fusions,
the cis- and trans-trispecifics, on the surface of A431 cells (Table 4.4).
Construct Kd, A431 H 6.0 Kd, A431 H 7.4
225 3.7x10- M 1.2x10~ M
HN-AD 1.3x10~9 M 1.3xlO-9 M
HN-DB 1.2x10~' M 1.6x1O9 M
HNA+LCD 1.7x10- M 2.8 x10-W M
HND+LCA 3.9x10~' M 2.1x10' 0 M
HNB+LCD 2.1x10-'0 M 2.0x10-0 M
HND+LCB 1.2x1 0 ~ M 2.9x10- 0 M
Table 4.4. Trispecific Ab-Fn3 fusion binding kinetics. The binding kinetics of cis- and trans-trispecific Ab-Fn3
fusions were characterized on the surface of A431 cells. Fusions were titrated at the indicated pH and apparent Kd
values computed from a nonlinear least squares regression fit to a 1:1 binding isotherm are presented.
Surprisingly, cis-trispecifics bind EGFR with a slightly weaker affinity than the 225 base
antibody, perhaps due to impaired interaction in the presence of three proximal binding moieties.
In contrast, the trans-trispecifics had five- to tenfold tighter EGFR affinities than the base 225
antibody, with apparent equilibrium dissociation constant values in the hundreds of picomolar
range (half-lives on the order of days). Consistent with the bispecific constructs, the trispecific
Ab-Fn3 fusions bind with similar kinetics at physiological and endosomal pH, suggesting robust
receptor interaction both on the cell surface and in the cytoplasm. Interestingly, trispecific Ab-
Fn3 binding affinity does not depend on fibronectin clone orientation.
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Multispecific Ab-Fn3 Fusions Potently Downregulate Surface EGFR
To determine which tri- and tetraspecific constructs most effectively downregulate surface
receptor, we compared the performance of all secreted fusions on four different EGFR-
expressing cell lines. As demonstrated in Figure 4.8, the most effective fusions are in the trans-
trispecific and tetraspecific format. The cis- and double HC-trispecific fusions perform
approximately equivalently to the bispecific fusions. Within the trans-trispecific constructs,
HNA+LCD, HND+LCA, and HNB+LCD outperform HND+LCB and within the tetraspecific
fusions, those with clone B at the HN position elicit the most potent downregulation. The most
potent trans-trispecific and tetraspecifc downregulate as efficiently or better than the 225+Hl 1
mAb combination identified from downregulation screens described in Chapter 2.
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Figure 4.8. Surface EGFR downregulation following tri- and tetraspecific Ab-Fn3 treatment. Four EGFR expressing
cell lines (listed in order of increasing receptor density) were treated with 20 nM of the specified constructs from the
four engineered tri- and tetraspecific orientations. Incubation proceeded for 13 h at 37 0C. Cells were subsequently
acid stripped to remove surface-bound Ab-Fn3, re-labeled for EGFR, and analyzed via flow cytometry. Percent
surface receptor remaining relative to an untreated control is shown. Surface EGFR levels following incubation
with either mAb 225 or the potently downregulating 225+H11 mAb combination are provided for reference.
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Based on our multispecific downregulation screen, the two classes of constructs with the highest
downregulation capacity are the trans-trispecifics and the tetraspecifics. Due to secretion
limitations for tetraspecific compounds, we selected the trans-trispecifics for further
characterization and therapeutic evaluation.
The trans-trispecific fusions were comprehensively analyzed on a panel of 13 EGFR-expressing
cell lines of varying origins and receptor densities (Table 4.5). As demonstrated in Figure 4.9A,
three out of the four trans-trispecific constructs (HNA+LCD, HND+LCA, and HNB+LCD)
downregulate surface receptor by 80-90% in all cell lines examined, with the notable exception
of the most EGFR-dense cell line, A431, where downregulation stands at only 40-50%. Other
than the A431 anomaly, however, receptor density and downregulation are uncorrelated for
trans-trispecific treatment (Figure 4.9B). We also note that the HND+LCA construct
downregulates most actively and consistently across the examined cell lines while the
HND+LCB shows the weakest downregulation amongst the trans-trispecifics examined.
Cell Line Origin EGFR/cell
HT-29 Colorectal Carcinoma 1.1 E+05
Hela Cervical Carcinoma 1.7E+05
U87 Glioblastoma 1.9E+05
BT-20 Triple Negative Breast Cancer 2.4E+05
HCT- 116 Colorectal Carcinoma 2.4E+05
Hs578T Triple Negative Breast Cancer 3.OE+05
BT-549 Triple Negative Breast Cancer 4.1E+05
HMEC Human Mammary Epithelium 4.5E+05
MD-MBA-231 Triple Negative Breast Cancer 5.9E+05
A549 Lung Carcinoma 1.2E+06
CHO-EG Chinese Hamster Ovary 1.6E+06
U87-SH Glioblastoma 1.6E+06
A431 Epidermoid Carcinoma 2.8E+06
Table 4.5. EGFR surface expression levels of downregulation panel cell lines. Thirteen EGFR-expressing cell lines
of varying mammalian origins (both normal and transformed) were assessed for EGFR expression via quantitative
flow cytometry. The calculated number of receptors per cell is indicated for each line.
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BFigure 4.9. Surface EGFR downregulation following trans-trispecific Ab-Fn3 treatment. (A) Thirteen EGFR-
expressing cell lines (listed in order of increasing receptor density) were treated with 20 nM of trans-trispecifics or
the indicated mAbs for 13 h at 37*C. Cells were then acid stripped, re-labeled for EGFR, and analyzed via flow
cytometry. Percent surface receptor remaining relative to an untreated control is shown. (B) Relative surface
receptor remaining at steady state from (A) plotted against receptor density for each trans-trispecific Ab-Fn3 fusion.
Multispecific Ab-Fn3 Fusions Rapidly and Efficiently Cluster EGFR
As was done with 225+H1 1 combination mAb treatment, we examined Ab-Fn3 fusion treated
cells for evidence of clustering. Deconvolution microscopy images show a dramatic change in
receptor localization following Ab-Fn3 fusion treatment relative to 225 mAb treatment in two
EGFR-expressing tumor cell lines, indicative of receptor clustering.
In A431 cells, we find that clusters appear within 1 h of Ab-Fn3 treatment and to persist for at
least 6 h (Figure 4.1 0A). Also, based on isolation of 0.15 [tm z-sections through the cell
monolayer in HT-29 cells treated with the HND+LCA construct, we observe that receptor-Ab-
Fn3 fusion clusters are located both intracellularly and extracellularly (Figure 4.1OB). In A549
cells, we monitored the evolution of clusters over a 21-minute timecourse (Figure 4.10C). As
early as 9 minutes post-treatment, puncta are visible. These clusters increase in size and quantity
over time.
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Figure 4.10. Visual evidence of multispecific antibody-induced clustering. (A) A431 cells were treated with
fluorescently-labeled 225 or fluorescently-labeled trans-trispecific Ab-Fn3 fusion for the indicated time periods at
37*C. Cells were then washed to remove unbound antibody and imaged on a DeltaVision deconvolution microscope
for comparison of EGFR localization. Images reflect projections of deconvolved 0.15 pm thick z-sections through
the cell monolayer. Scale bars = 30 plm. (B) HT-29 cells were incubated with fluorescently-labeled HND+LCA for
6 h at 37*C. Cells were washed and imaged on a DeltaVision deconvolution microscope. Images represent
deconvolved 0.15 pm thick sections ranging from the bottom (left) to the top (right) of the cell with 1.5 pm spacing
between sections. Scale bars = 30 pm. (C) Fluorescently-labeled 225 or HND+LCA was added to live A549 cells
and cells were imaged over a 30 minute timecourse to track cluster formation. Images reflect projections of
deconvolved 0.15 pim thick z-sections through the cell monolayer. Scale bars = 30 stm.
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Ab-Fn3 Fusion Treatment Increases the Rate of EGFR Internalization
As detailed in Chapter 2 and Appendix A, antibody-mediated downregulation can occur by one
of three mechanisms: reduction of receptor synthesis rate; increase in receptor internalization
rate; or reduction in recycled fraction. Recall that in the case of monoclonal antibody
combination treatment, downregulation occurs as a result of recycling inhibition; Endocytosis
rate is not affected.
In the case of bispecific Ab-Fn3 fusion treatment (HN-D construct), internalization is
accelerated, as occurs upon the addition of EGF ligand (Figure 4.11 A). The endocytosis rate
enhancement increases for constructs of higher valency. As shown in Figure 4.1 1B-C, the trans-
trispecific fusions HNB+LCD and HND+LCA, respectively, elicit robust and rapid
downregulation of receptor in U87 cells.
A
C
Figure 4.11. Surface EGFR downregulation kinetics following Ab-Fn3 treatment. HeLa (A), U87 (B), or HT-29 (C)
cells were treated with the mAb combination 225+H1 1, the Ab-Fn3 fusion HN-D (A), HNB+LCD (B), HND+LCA
(C), or EGF at 37*C for the indicated time periods. Cells were then detached and acid stripped. Surface EGFR was
relabeled with murine 225 and quantified via flow cytometry. Percent surface receptor remaining relative to an
untreated control is shown (+SD; n=3). Data was fit to first-order exponential curves using nonlinear least squares
regression.
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Thus, in contrast to combination antibody treatment, Ab-Fn3 fusion treatment increases the
endocytic rate constant for EGFR. Notably, the acceleration of endocytosis for HN-D,
HNB+LCD, and HND+LCA is still less dramatic than that induced by EGF treatment (t1/2 , EGF
0.13 h, t1/2, HN-D = 0.74 h, and t1/2,225+H11= 2.12 h in HeLa cells; t1/2, EGF= 0.14 h, t1/2, HNB+LCD
0.56 h, and ti/2 , 225+H111 = 1.52 h in U87 cells; and t1/2 , EGF = 0.022 h, t1/2 , HND+LCA = 0.054 h, and
ti/2,225+H11 = 4.8 h in HT-29 cells). Note that in the case of both the HNB+LCD and the
HND+LCA trans-trispecifics, treatment results in a lower steady-state surface receptor level than
EGF or 225+H11 treatment, suggestive of the recruitment of additional downregulatory
mechanisms, such as recycling inhibition.
Ab-Fn3 Fusion Treatment Inhibits Endosomal Recycling of EGFR
In addition to enhancing endocytic rate,
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Figure 4.12. Trans-trispecific treatment inhibits that HNB+LCD treatment in the presence or
EGFR recycling. U87 cells were incubated with
PBS or 20 nM HNB+LCD in the presence or absence of monensin (25) elicits an equivalent
absence of 200 FLM monensin (a non-specific
inhibitor of receptor recycling) at 370C for the response to monensin treatment alone. Thus,
indicated time periods. Cells were then detached trans-trispecific fusions fully obstruct EGFR
and acid stripped to remove surface-bound Ab-Fn3.
Surface EGFR was labeled with murine 225 and recycling within 90 minutes of treatment,
analyzed by flow cytometry. Percent surface
receptor remaining relative to an untreated cells is shunting the receptor to lysosomal degradation
plotted (+SD; n=3). "-" indicates the absence and
"+" indicates the presence of monensin. (Figure 4.12).
Ab-Fn3 Fusions Exhibit Similar Distribution Kinetics to mAbs
Efficient penetration of antibody into solid tumors is critical for the efficacy of therapeutics
targeting cell surface antigens (26, 27). We consequently addressed transport considerations for
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our Ab-Fn3 fusion compounds compared to unconjugated IgG using tumor spheroid models
(28).
Recent work by Thurber et al established a Thiele modulus to describe antibody penetration.
This dimensionless parameter represents the ratio of antibody internalization rate to diffusion
rate (29). The Thiele modulus (<2) can be expressed as:
2 keR 2 [Ag]/E
D([Ablsur + K) (Equation 1)
where ke is the net endocytic uptake rate constant, R is the half-maximum intercapillary distance,
[Ag] is the antigen concentration per tumor volume, , is the drug-accessible tumor volume
fraction, D is the drug diffusivity in tumor tissue, [Ab]surf is the antibody concentration at the
capillary surface, and Kd is the equilibrium dissociation constant of the antibody. Antibody
penetration depth can be determined by setting the Thiele modulus equal to 1, resulting in the
following equation:
R D([Absurf + Kd)
keR2 g E(Equation 2)
If we assume that diffusivity and Kd of the IgG and Ab-Fn3 are approximately equivalent, the
only parameters that differ between mAb treatment and Ab-Fn3 treatment are ke and [Ag].
From our kinetic assays, we find that EGFR internalization is enhanced approximately threefold
compared to constitutive internalization following Ab-Fn3 administration. However, Ab-Fn3
treatment concurrently introduces a new steady state in which surface receptor levels are reduced
by 70-80% (three- to fivefold). As a result, the enhanced internalization rate precisely
counterbalances the reduction in surface antigen expression, leading us to predict from our
dimensional analysis that penetration of Ab-Fn3 fusions will be equivalent to that of mAbs.
To test this hypothesis, we formed hanging spheroids composed of A431 cells and visualized
antibody perfusion via confocal microscopy. As shown in Figure 4.13, treatment with equivalent
saturating concentrations of both mAb and Ab-Fn3 fusion (HN-D) resulted in a homogenous
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distribution of these constructs throughout A431 tumor cell spheroids, confirming that
conjugation of Fn3 domains to induce downregulation does not impair antibody delivery.
1 225 11 HN-D I
Figure 4.13. Ab-Fn3 fusions perfuse tumor cell spheroids at saturating concentrations. A431 spheroids were
incubated with 20 nM fluorescently-labeled mAb 225 or bispecific Ab-Fn3 fusion HN-D. Spheroids were then
washed and imaged on a Nikon confocal microscope to assess antibody penetration. All images were captured using
equivalent intensity settings and brightness and contrast have been normalized using the ImageJ software package.
Scale bars = 50 Rm.
Ab-Fn3 Fusions Downregulate EGFR without Agonizing Receptor or Downstream Signaling
Due to the parallel trafficking effects of Ab-Fn3 fusions and EGF, we considered the possibility
that our engineered molecules could be acting as receptor agonists and activating EGFR as
ligand mimics. In the presence of EGF, receptor dimerization enables kinase activity in trans, so
we sought to determine whether Ab-Fn3-induced receptor clustering elicits the same response.
As noted in Chapter 2, combination mAb-mediated clustering is not agonistic (1), but Ab-Fn3
fusion-mediated clustering differs in that it accelerates receptor endocytosis in addition to
obstructing receptor recycling, as does native ligand (30).
To test whether the most potently downregulating Ab-Fn3 fusions, the trans-trispecific
constructs, activate EGFR, we treated A431 cells with these constructs and monitored receptor
phosphorylation at eight known phosphosites in the EGFR intracellular domain including three
major tyrosine autophosphorylation sites (Y1068, Y1 148, and Y1 173) (31), one minor
autophosphorylation site (Y1086) (32), a Src tyrosine kinase target (Y845) (33), a Ca-
calmodulin-dependent kinase II target (S1046) (34), a target of protein kinase C (T654) (35), and
a MAPK phosphosite (T669) (36). As shown in Figure 4.14, all of these sites show some degree
of phosphorylation in response to EGF stimulation, but none are activated by engineered fusion
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treatment during the same 2 h timecourse. We conclude that despite its capacity to downregulate
surface EGFR, Ab-Fn3-induced clustering is not sufficient to instigate EGFR activation.
To ensure that the Ab-Fn3 fusions were not agonizing signaling cascades downstream of EGFR,
we examined the phosphorylation state of Akt, an effector in the P13K pathway and ERK, an
effector in the MAPK pathway. We focused specifically on the most actively downregulating
trans-trispecific compound, HND+LCA, which we pursued in animal studies discussed in
Chapter 5. As shown in Figure 4.15, in contrast to EGF treatment, Ab-Fn3 fusion treatment
induces receptor downregulation without activating Akt or ERK above background levels.
Taken together with the absence of EGFR agonism, this result motivates the therapeutic use of
trans-trispecific constructs.
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Figure 4.14. EGFR phosphorylation is not agonized by combination mAb treatment. In-cell western assays were
performed on A431 cells for eight known EGFR tyrosine, serine, and threonine phosphosites. Activation profiles
are shown for human IgG1 isotype control antibody (black), four trans-trispecific Ab-Fn3 fusions (shades of blue),
and EGF (red). Phosphoprotein fluorescence was normalized by DNA fluorescence and signal relative to that in
untreated cells is plotted versus time (±SD; n=3).
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Figure 4.15. Ab-Fn3 fusions do not agonize P13K or MAPK pathway signaling. Serum starved HT-29 cells were
incubated with 20 nM isotype control antibody, the trans-trispecific construct HND+LCA, or EGF for the indicated
time periods at 37*C. Cells were then lysed and phospho-Akt (A) or phospho-ERK (C) were quantified via
immunoblot assay. Beta actin levels are shown as a loading control. (B) & (D) Quantification of immunoblot
results presented in (A) & (C), respectively. Band intensities were normalized by beta actin levels and by the
intensity of a control lysate included on each blot.
Multispecific Ab-Fn3 Fusions Inhibit Migration and Proliferation of Autocrine Ligand-Secreting
Cell Lines
A major advantage of Ab-Fn3 fusions over current standard of care mAbs is their ability to
exploit multiple mechanisms to inhibit EGFR activity. The 225 base antibody directly competes
with EGF binding and antagonizes signaling by blocking ligand-mediated activation (21). In
addition to competitively inhibiting EGF binding through their 225 variable domains, Ab-Fn3
fusions decrease the total amount of EGFR available for signaling through downregulation,
compounding the antagonistic effects of 225.
The importance of recruiting multiple mechanisms to inhibit EGFR is highlighted in systems in
which ligand is dysregulated. EGF and other native EGFR ligands facilitate tumor growth
through a variety of autocrine and paracrine pathways (37-39). Specifically, activation of EGFR
stimulates the synthesis of angiogenic growth factors, resulting in the development and
expansion of vasculature to support tumor growth. Additionally, cancer cells often secrete EGF
and other similar growth factors that may act directly on endothelial cells or on the tumor cells
themselves. Secreted growth factors also act indirectly through modulation of protein expression
in ancillary cells. For example, EGFR ligands induce expression of osteoclastogenic factors in
bone marrow stromal cells that promote osteoclast maturation and activation, which ultimately
results in bone degeneration and establishment of bone metastases (40, 41).
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Autocrine expression or aberrant localization of receptor (42) can overwhelm exogenous
therapeutics by increasing the apparent concentration of ligand, resulting in resistance to EGF-
competitive mAbs. Consequently, the development of EGFR-targeted constructs that remain
effective in autocrine-driven environments could be instrumental in overcoming the limitations
of current clinically approved antibodies to increase the efficacy and applicability of anti-EGFR
therapeutics.
To test whether Ab-Fn3 fusions repress signaling activity and modify cell behavior in autocrine-
driven cells, we incubated the genotypically matched HMEC and TCT cell lines with various
constructs and observed migration via wound healing assay. The transfected TCT cell line was
engineered to express chimeric EGF at a rate of 0.6 h- per 106 cells, simulating the autocrine
ligand burden often observed in tumor cells (18). As expected, monovalent Fn3 domains do not
impact migration in normal HMEC or transformed TCT cells. The 225 mAb stifles HMEC
motility, but does not significantly affect that of TCT cells, presumably due to the autocrine
ligand challenge. Ab-Fn3 fusions showed no impact beyond the effects of 225 alone on the
migration of healthy HMEC cells, but significantly (P<0.05 or P<0.01 for all constructs)
restricted the movement of autocrine ligand-dependent TCT cells compared to 225 migration
levels (Figure 4.16). Taken together, these results indicate that Ab-Fn3 fusions significantly
inhibit motility of aberrantly activated cells without impacting healthy cells to a greater extent
than the base antibody, which exhibits minimal off-target toxicity in the clinic (43, 44).
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Figure 4.16. Autocrine ligand-secreting cell migration is reduced following Ab-Fn3 treatment. Migration of normal
HMEC (A) and autocrine ligand-secreting TCT (B) cells was assessed following incubation with 20 nM of the
indicated Fn3 domains (orange), mAbs (green), or Ab-Fn3 fusions (blue) using a scratch migration assay. Cell
monolayers were wounded and subsequently incubated with the indicated constructs at 37*C for 24 h (HMEC) or 16
h (TCT). Relative migration is presented as fractional wound replenishment compared to that of an untreated
control (+SD; n=3). The dashed lines indicate migration extent of untreated cells. *P<0.05 versus 225 cohort and
* *P<0.01 versus 225 cohort.
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Based on our promising migration results, we performed proliferation assays on the HMEC and
TCT cell lines, as well as on ECT cells (which express chimeric EGF at a rate of 0.3 h-1 per 106
cells) (18), HTGF-a cells (which express chimeric TGF-a at a rate of 1 ng per hour per 106 cells,
180-fold higher than endogenous levels), and HEPR cells (which express chimeric epiregulin at
quantities 140-fold higher than endogenous levels). All cell lines are derived from normal
mammary epithelial cells (HMEC) and simulate transformed cells that aberrantly express EGFR
ligands.
1.5 Figure 4.17. Cell proliferation is unaffected by
S1.2 monovalent Fn3 treatment. Proliferation of
HMEC and four HMEC-derived autocrine ligand-
I IPBS secreting cell lines were assessed via Wstl assay.
0.75 Fn3-A Cells were treated with PBS or 20 nM of the
0.5 Fn3-8 indicated Fn3 clones 72 h at 37 0 C. Relative
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Proliferation of the parental HMEC line and the derived cell lines was not inhibited by
monovalent Fn3 treatment, as expected (Figure 4.17). In HMEC cells, 225 moderately inhibited
cell growth and the four tested trans-trispecific Ab-Fn3 fusions stifled growth to the same extent
as the base mAb (Figure 4.18A, Table 4.6). In the ECT, TGF-a, and HNRG lines, 225 impaired
cell growth to varying extents (Figures 4.18B-D). In the more aggressive TCT line, which
expresses twice as much autocrine EGF as ECT, 225 was ineffective in inhibiting cell
proliferation (Figure 4.18E, Table 4.6). In contrast, in all four autocrine lines tested, three of the
four trans-trispecific Ab-Fn3 fusions substantially impaired cell proliferation at saturating
concentrations (Figure 4.18B-E, Table 4.6). The effective fusions corresponded with those that
downregulate the most actively (Figure 4.9). Specifically, the HND+LCB construct did not
show potency on the TCT cell line. Note that IC50 values for the antibody fusions are
predominantly in the range 3 to 30 nM, or ten- to 100-fold higher than the apparent Kd,
indicating that saturating concentrations of antibody are required to inhibit proliferation. Due to
their selective and efficient targeting of transformed cells, these constructs show strong promise
as potential cancer therapeutics.
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Figure 4.18. Autocrine ligand-secreting cell proliferation reduced following combination mAb treatment.
Proliferation of HMEC and four HMEC-derived autocrine ligand-secreting cell lines: HMEC (A) ECT (B); HTGF-a
(C); HEPR (D); and TCT (E) were assessed. Cells were treated with PBS or the indicated Fn3 clones for 72 h at
37 0 C. Proliferation by Wstl assay is depicted as viable cell count compared to that of untreated cells (±SD; n=6).
225 HNA+LCD HND+LCA HNB+LCD HND+LCB
Cell Line IC50 (nM) IC50 (nM) IC50 (nM) ICso (nM) IC50 (nM)
HMEC 3.5 8.2 3.5 5.3 2.9
ECT 16.7 31.0 20.9 30.9 15.7
HTGF-a 22.0 91.4 15.2 24.2 18.2
HEPR 14.3 3.7 2.6 7.9 3.8
TCT * 24.6 12.6 3.6 *
Table 4.6. IC50 values for inhibition of proliferation by Ab-Fn3 fusions. The proliferation data from Figure 14.18
were fit to IC50 curves using nonlinear least squares regression. The computed IC50 values for each treatment
condition on HMEC parental cells and the four HMEC-derived cell lines are presented. *225 and HND+LCB did
not inhibit proliferation of the TCT cell line.
Discussion
We have developed antibody-fibronectin domain fusion compounds targeting multiple non-
overlapping epitopes of a single receptor. These antibodies secrete stably from mammalian cells
and bind EGFR with sub-nanomolar affinity at both physiological (7.4) and endosomal (6.0) pH
(Tables 4.3, 4.4). These fusions benefit from avidity effects to improve upon the binding affinity
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of the unconjugated base 225 antibody and, surprisingly, fusions with N-terminal Fn3 domains
fused to the heavy chain secrete with higher yields than the 225 IgG (Figures 4.4, 4.7).
Ab-Fn3 fusions cluster and downregulate EGFR without agonizing the receptor or its
downstream effectors (Figures 4.8-4.10, 4.14, 4.15), ultimately leading to inhibition of the
growth and migration of transformed cells, as is true with combination mAb treatment (Figures
4.16, 4.18) (1). The key differences between the effects of combination mAb treatment and
those of Ab-Fn3 fusions are: (1) combination mAb-induced downregulation extent is inversely
correlated with receptor expression level, whereas trans-trispecific Ab-Fn3-induced
downregulation is insensitive to receptor number up to 1.6x 106 receptors/cell (Figure 4.9); (2)
combination mAb treatment abrogates recycling but does not enhance endocytosis rate, whereas
Ab-Fn3 fusion treatment blocks recycling and accelerates endocytosis (Figures 4.11, 4.12); and
(3) Cluster formation occurs much more rapidly (within 9 min of administration) in the case of
Ab-Fn3 fusion treatment (Figure 4.1 OC).
It is notable that we have achieved rapid receptor downregulation in the absence of agonism
since rapid endocytosis occurs exclusively through clathrin-coated pits. However, recruitment to
coated pits requires kinase activity, which suggests that the internalization we observe occurs
through basal membrane turnover or through lipid rafts (45-47). We hypothesize that although
the molecular rate of receptor internalization is not accelerated, clustered receptors are
internalized synchronously, resulting in an apparent increase in the bulk endocytic rate constant
following Ab-Fn3 administration.
The immediate application we anticipate for the Ab-Fn3 fusions we have designed is use as
targeted EGFR-directed therapeutics in solid tumors. However, the modular format of the Ab-
Fn3 fusion allows for the insertion of any Fn3 moiety with engineered specificity for an antigen
of interest, providing a generalized scaffold for targeting multiple proteins with a single IgG-
based compound. Furthermore, the successful secretion of tetraspecific Ab-Fn3 fusions with
three Fn3 domain conjugates allows for dual targeting and, potentially, simultaneous clustering
of two different receptors. This would be particularly significant for an EGFR-directed
therapeutic since EGFR interacts with a vast network of receptors and intracellular proteins,
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creating a vast array of potential multi-receptor cluster partners. Also, EGFR-targeted therapy
resistance has been found to be mediated through upregulation of ErbB3 and c-Met signaling
(48, 49). In particular, ErbB3 exhibits only transient responsiveness to tyrosine kinase inhibitors
and is aberrantly active in cetuximab-resistant lung cancer (50, 51). EGFR-directed drug
resistance through compensatory pathways directly motivates engagement of multiple receptors
in an inactive clustered conformation to inhibit growth signaling and enhance therapeutic
efficacy.
Like the IgG-scFv fusions presented in Chapter 3, a further application of Ab-Fn3 fusions could
be as delivery vehicles for toxins, siRNA, or other cell disruption agents. By forming pools of
clustered EGFR in the cytoplasm, these molecules could provide high local concentrations of
toxic agents that would selectively destroy transformed cells. Furthermore, by conjugating the
Ab-Fn3 fusions to fusogenic peptides, one could achieve high concentrations of receptors within
endosomes which could facilitate disruption of the endosomal membrane and allow for diffusion
of the toxic compound into the cytosol, enhancing therapeutic efficacy.
Finally, in addition to therapeutic potential, Ab-Fn3 fusions could prove useful in research and
detection, with applications in such areas as molecular recognition, delivery of contrast agents,
and diagnostics. With high affinity and specificity for EGFR, Ab-Fn3 fusions selectively and
tightly bind EGFR, providing accurate detection for imaging and diagnostic applications.
Our in vitro migration and proliferation results (Figures 4.16-4.18) strongly suggest that our
compound would inhibit tumor growth in vivo, based on previous findings with antibody
combinations and multispecific constructs (10, 12, 13). The antibody backbone allows for
superior retention in the bloodstream compared to small molecule drugs (19, 52) and the
molecular specificity of our multi-epitopic fusions will minimize off-target toxicity. Also, the
tumor penetration of our compound is not impaired by induced downregulation (Figure 4.13),
indicating that it effectively saturates tumor cells at equivalent doses to IgG. Based on our
promising in vitro results, the therapeutic efficacy of Ab-Fn3 fusions was extensively studied in
mouse tumor xenograft models, which are described in Chapter 5.
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Materials and Methods
Cell lines and antibodies
The transfected CHO-EG (53), U87-MGSH (54), and ECT (18) cell lines were established as
described previously and all other lines were obtained from ATCC (Manassas, VA). Cells were
maintained in their respective growth media (from ATCC unless otherwise indicated): DMEM
for A43 1, U87-MG, U87-MGSH, BT-20, Hs578T, BT-549, MDA-MB-23 1, and CHO-EG cells,
F-12K medium for A549 cells, McCoy's Modified 5A medium for HT-29 cells, EMEM for
HeLa cells, and HuMEC Ready Medium (Invitrogen, Carlsbad, CA) for HMEC and ECT cells.
U87-MG, U87-MGSH, and CHO-EG media were supplemented with 1 mM sodium pyruvate
(Invitrogen) and 0.1 mM non-essential amino acids (Invitrogen) and transfected lines U87-
MGSH and CHO-EG were selected with 0.3 mM Geneticin (Invitrogen). To prepare complete
culture media, ATCC media were supplemented with 10% fetal bovine serum (FBS) and IX
penicillin-streptomycin solution. All cell lines were maintained at 37*C with 5% ambient CO 2.
The 225 mAb was secreted from the commercially available hybridoma cell line (ATCC). H 11
was purchased through Lab Vision (Fremont, CA).
Unless otherwise noted, all washes were conducted in PBS containing 0.1% BSA and all
constructs were used at a concentration of 20 nM for single treatment and 10 nM each for
combination treatment. EGF (Sigma, St. Louis, MO) was dosed at 20 nM. Trypsin-EDTA
(Invitrogen) contains 0.05% trypsin and 0.5 mM EDTA.
Production ofAb-Fn3 fusions via HEK cell transfection
The human IgG1 heavy and light chains of each Ab-Fn3 fusion were inserted into the gWiz
mammalian expression vector (Genlantis). Constructs were verified by sequence analysis. All
plasmid sequences used for Ab-Fn3 constructs are provided in Appendix C. HEK 293F cells
(Invitrogen) were grown to 1.2 million cells per mL and diluted to one million per mL.
Miniprepped DNA and polyethyleneimine (Sigma) were independently diluted to 0.05 and 0.1
mg/mL in OptiPro medium and incubated at 220 for 15 min. Equal volumes of DNA and
polyethyleneimine were mixed and incubated at 22' for 15 min. 500 mL of cells and 20 mL of
DNA/polyethyleneimine mixture were added to a 2 L roller bottle and incubated at 370, 5% CO 2
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on a roller bottle adapter for seven days. The cell secretions were then centrifuged for 30 min at
15,000xg and the supernatant was filtered through a 0.22 tm bottle-top filter and purified via
affinity column chromatography using protein A resin (Thermo Fisher Scientific, Waltham,
MA). The eluted constructs were concentrated and transferred to PBS and then characterized by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
Affinity titrations
To characterize Ab-Fn3 binding affinities, A431 cells were trypsinized, washed in PBSA, and
incubated with various concentrations of Ab-Fn3 in a 96-well plate on ice. The number of cells
and sample volumes were selected to ensure at least tenfold excess Ab-Fn3 relative to EGFR.
All samples were assayed in triplicate. Cells were incubated on ice for sufficient time to ensure
that the approach to equilibrium was at least 99% complete. Cells were then washed and labeled
with 66 nM PE-conjugated goat anti-human antibody (Rockland Immunochemicals,
Gilbertsville, PA) for 20 min on ice. After a final wash, plates were analyzed on a FACS Calibur
cytometer (BD Biosciences, San Jose, CA). The minimum and maximum fluorescence and the
Kd value were determined by minimizing the sum of squared errors assuming a 1:1 binding
interaction (% Bound = [L]/([L]+Kj) where [L] is Ab-Fn3 concentration and Kd is the
equilibrium dissociation constant of the Ab-Fn3 construct. Curve fitting was implemented in
MATLAB (Mathworks, Natick, MA). Titrations were performed at both pH 6.0 (endosomal pH)
and pH 7.4 (physiological pH).
Deconvolution Microscopy
mAb 225 and Ab-Fn3 fusion constructs were labeled with Alexa 488 using a fluorescent labeling
kit (Invitrogen). A43 1, HT-29, or A549 cells were plated at 50,000 per well in 8-well
microscopy chambers and allowed to settle overnight. They were then serum-starved for 8-12 h
and incubated with the appropriate mAb or fusion construct for various time lengths at 370, 5%
CO 2. Cells were immediately washed and resuspended in phenol red-free medium (Invitrogen)
for imaging on a Delta Vision inverted deconvolution microscope at 60X magnification (oil
immersion lens). For A549 images, wells were not washed but rather dye was added and images
were captured over a 30 minute time course. Deconvolution and projection of 0.15 .tm z-slices
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and image analysis were performed using the Softworx software package. All compared images
were obtained using identical settings and brightness and contrast were normalized.
Receptor Downregulation Assays
Cells were seeded at 5x10 4 per well in 96-well plates, serum starved for 12-16 h, treated with the
indicated mAbs or Ab-Fn3 fusions in serum-free medium, and incubated at 37*C. At each time
point, cells were washed and treated with trypsin-EDTA for 20 min at 37*C. Trypsin was
neutralized with medium (10% FBS) and cells were transferred to v-bottom plates on ice. They
were then washed, acid stripped (0.2 M acetic acid, 0.5 M NaCl, pH 2.5), and washed again prior
to incubation with 20 nM 225 for 1 h on ice to label surface EGFR. Cells were then washed and
labeled with 66 nM PE-conjugated goat anti-mouse antibody (Invitrogen) for 20 min on ice.
After a final wash, plates were analyzed on a FACS Calibur cytometer (BD Biosciences, San
Jose, CA). Cell pelleting was conducted at 1000xg. Data was fit to a single exponential curve to
determine downregulation halftime (% Surface Receptor Remaining = Min + (Max - Min)*ekt).
Curve fitting was implemented in MATLAB (Mathworks).
Monensin Recycling Assays
U87 cells were seeded at 5x10 4 per well in 96-well plates and serum starved for 12-16 h. They
were then incubated in basal medium with or without 200 [tM monensin (Sigma, St. Louis, MO)
at 37*C for 20 min. The indicated Ab-Fn3 trans-trispecific constructs were then added and
incubation proceeded at 37*C. At each time point, cells were dissociated in trypsin, acid stripped,
and labeled for surface EGFR through incubation with 20 nM 225 for 1 h on ice. Cells were then
washed and labeled with 66 nM PE-conjugated goat anti-mouse antibody (Invitrogen) for 20 min
at 4*C. Cells were washed a final time and analyzed on a FACS Calibur cytometer (BD
Biosciences).
Confocal Microscopy
Spheroids were prepared by the hanging drop method (28, 55) in microwell trays (Nunc,
Rochester, NY). Five hundred A431 wells were seeded per well in a tray and incubated upside-
down for three days at 37*C and 5% CO2 to allow for spheroid formation. The spheroids were
then washed with PBS and transferred to 8-well microscopy chamber dishes and allowed to
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attach overnight at 370C. mAb or Ab-Fn3 fusions were labeled with Alexa 488 following the
manufacturer's protocol (Invitrogen) and added was added to the wells at a concentration of 20
nM for 1 h at 37*C. Labeled construct was then removed and cells were washed with PBS and
resuspended in phenol red-free DMEM. Images were acquired on a Nikon confocal microscope
(Zeiss, Thornwood, NY) using a 20X objective and are presented as overlays of 2.0 km-spaced
z-sections through the 100-200 nm spheroid diameter. Exposure conditions were consistent
across all images shown and z-stack projection and image analysis were performed in ImageJ.
In-Cell Western Assays
A431 cells were seeded at 4x 104 per well in 96-well plates and allowed to adhere for 24 h.
Following 12-16 h of serum starvation, cells were treated with the designated mAbs in serum-
free medium at 37*C for the specified time length. All subsequent incubations were performed at
room temperature. Cells were fixed for 20 min (PBS, 4% formaldehyde), permeabilized via four
5 min incubations (PBS, 0.1% triton), blocked for 1 h in blocking buffer (1:1 PBS:Odyssey
Blocking Buffer (Licor Biosciences, Lincoln, NE)), and labeled overnight at 4*C with 15 nM
anti-phosphosite antibodies (Genscript, Piscataway, NJ) in blocking buffer. Cells were then
washed three times with PBST (PBS, 0.1% Tween-20) and labeled with 66 nM 800-conjugated
goat anti-rabbit antibody (Rockland Immunochemicals) and 400 nM TO-PRO-3 DNA stain
(Invitrogen) in blocking buffer for 30 min. After three final PBST washes, wells were aspirated
dry for analysis on a Licor Odyssey infrared scanner (Licor Biosciences). Phospho-signal was
normalized to cell abundance by dividing 800 (phosphoprotein) by 700 (TO-PRO-3) channel
fluorescence.
Western Blots
HT-29 or HCT- 116 cells were cultured to confluence in 6-well plates and serum starved for 12 h.
Cells were subsequently incubated with 20 nM antibody or Ab-Fn3 fusion for the indicated
length of time at 370C.. Cells were then washed once with cold PBS and incubated with rotation
for 5 min in lysis buffer (50 mM Tris*HCl, 2% SDS, 5% glycerol, 5 mM EDTA, 1 mM NaF,
protease and phosphatase inhibitors (Thermo Fisher Scientific, Pittsburgh, PA), 10 mM P-GP, 1
mM PMSF and 1 mM Na3VO 4 ). Total protein levels were quantified via BCA assay (Thermo
Fisher Scientific) and lysates were normalized to a protein concentration of 3.5 mg/mL. Lysates
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were clarified by passage through centrifugal filter plates for 8-12 h at 4000xg. The lysates were
subsequently subjected to SDS-PAGE on 8% E-Page gels and blotted onto nitrocellulose via
iBlot apparatus (Invitrogen). The blotted membrane was then blocked in 1:1 PBS:Odyssey
Blocking Buffer (Licor Biosciences) for 1 h at room temperature. Blots were then incubated
with 1:1000 dilutions of either anti-phosphoAkt S473 rabbit antibody or anti-phosphoERK1/2
Y202/Y204 rabbit antibody overnight at 4*C (Cell Signaling, Danvers, MA). A 1:15,000
dilution of mouse anti-beta actin antibody was added the next morning and incubation proceeded
for 2 h. Following three washes, the membrane was incubated with goat anti-mouse (800 cw)
and anti-rabbit (700 cw) near IR dye conjugate antibodies. After four additional washes,
membranes were visualized on the Licor Odyssey infrared imaging system. Phospho-Akt and
phospho-ERK signals were normalized by beta actin signal for each lysate and all samples were
normalized to a control lysate to ensure consistent intensity between blots.
Migration Assays
HMEC and TCT cells were seeded at 5x10 4 per well in 96-well plates and grown to confluence.
Monolayers were wounded with a pipet tip, washed with PBS, and incubated in complete
medium with the indicated mAbs or Ab-Fn3 fusion constructs. Scratch area was measured
immediately and after 24 h incubation (HMEC cells) or 16 h incubation (TCT cells) at 37*C
using Image J software analysis of images from a Nikon confocal microscope (Nikon
Instruments, Melville, NY). Percent migration was calculated as the fractional reduction in
scratch area in the treated wells divided by that of untreated wells.
Cell Proliferation Assays
HMEC, ECT, TCT, HTGF-a, and HEPR cells were seeded at 3x 103 per well in 96-well plates
and allowed to adhere for 24 h. They were then treated with the indicated mAbs or Ab-Fn3
fusion constructs at the prescribed concentrations in complete medium and incubated at 37*C for
72 h. Cell viability (relative to an untreated control) was assessed using the Wstl tetrazolium
salt cleavage assay (Roche, Indianapolis, IN) (56, 57). Relative proliferation was calculated as
the 450 nm absorbance of treated wells relative to that of untreated controls. Data was then fit to
the equation: Relative Proliferation = Min+(Max-Min)(1-(x/(x+IC 5 o))) where x is the
concentration of Ab or Ab-Fn3 fusion and IC50 is the concentration required to achieve half-
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maximal inhibition of growth. A nonlinear least squares regression algorithm was implemented
in MATLAB (Mathworks).
Statistical Analysis
Heteroscedastic two-tailed student's t tests were performed on migration and proliferation assay
results to compare 225, Fn3, and Ab-Fn3 treatments. P values of less than 0.05 were deigned
significant.
References
1. Spangler JB, et al. (2010) Combination antibody treatment down-regulates epidermal
growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci US A
107(30):13252-13257.
2. Muller D & Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy:
Current perspectives. BioDrugs 24(2):89-98.
3. Gall JM, Davol PA, Grabert RC, Deaver M, & Lum LG (2005) T cells armed with anti-
CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and
bypass complement-mediated rituximab resistance in vitro. Exp Hematol 33(4):452-459.
4. Muller D & Kontermann RE (2007) Recombinant bispecific antibodies for cellular
cancer immunotherapy. Curr Opin Mol Ther 9(4):319-326.
5. Dreier T, et al. (2003) T cell costimulus-independent and very efficacious inhibition of
tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma
xenografts by a CD19-/CD3- bispecific single-chain antibody construct. JImmunol
170(8):4397-4402.
6. Friedman M, et al. (2009) Engineering and characterization of a bispecific HER2 x
EGFR-binding affibody molecule. Biotechnol Appl Biochem 54(2):121-131.
7. Fury MG, Lipton A, Smith KM, Winston CB, & Pfister DG (2008) A phase-I trial of the
epidermal growth factor receptor directed bispecific antibody MDX-447 without and with
recombinant human granulocyte-colony stimulating factor in patients with advanced solid
tumors. Cancer Immunol Immunother 57(2):155-163.
118
8. Kiewe P & Thiel E (2008) Ertumaxomab: a trifunctional antibody for breast cancer
treatment. Expert Opin Investig Drugs 17(10):1553-1558.
9. Cochran JR (2010) Engineered proteins pull double duty. Sci Transl Med 2(17):17ps15.
10. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, & Sela M (2009) Persistent elimination of
ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies:
relevance of receptor endocytosis. Proc Natl Acad Sci USA 106(9):3294-3299.
11. Dechant M, et al. (2008) Complement-dependent tumor cell lysis triggered by
combinations of epidermal growth factor receptor antibodies. Cancer Res 68(13):4998-
5003.
12. Roovers RC, et al. (2011) A bi-paratopic anti-EGFR nanobody efficiently inhibits solid
tumour growth. Int J Cancer.
13. Friedman LM, et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by
combinations of mAbs: implications for cancer immunotherapy. Proc Natl A cad Sci US
A 102(6):1915-1920.
14. Hackel BJ, Neil JR, White FM, & Wittrup KD (Submitted) Epidermal growth factor
receptor downregulation by small heterodimeric binding proteins.
15. Koide A & Koide S (2007) Monobodies: antibody mimics based on the scaffold of the
fibronectin type III domain. Methods Mol Biol 352:95-109.
16. Cota E & Clarke J (2000) Folding of beta-sandwich proteins: three-state transition of a
fibronectin type III module. Protein Sci 9(1):112-120.
17. Main AL, Harvey TS, Baron M, Boyd J, & Campbell ID (1992) The three-dimensional
structure of the tenth type III module of fibronectin: an insight into RGD-mediated
interactions. Cell 71(4):671-678.
18. Joslin EJ, Opresko LK, Wells A, Wiley HS, & Lauffenburger DA (2007) EGF-receptor-
mediated mammary epithelial cell migration is driven by sustained ERK signaling from
autocrine stimulation. JCell Sci 120(Pt 20):3688-3699.
19. Simister NE & Mostov KE (1989) An Fc receptor structurally related to MHC class I
antigens. Nature 337(6203):184-187.
20. Hackel BJ NJ, White FM, & Wittrup KD (Submitted) Epidermal growth factor receptor
downregulation by small heterodimeric binding proteins.
119
21. Li S, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor
by cetuximab. Cancer Cell 7(4):301-311.
22. Ettenberg SA, et al. (2010) Inhibition of tumorigenesis driven by different Wnt proteins
requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Nati Acad
Sci USA 107(35):15473-15478.
23. Ogiso H, et al. (2002) Crystal structure of the complex of human epidermal growth factor
and receptor extracellular domains. Cell 110(6):775-787.
24. Ferguson KM, et al. (2003) EGF activates its receptor by removing interactions that
autoinhibit ectodomain dimerization. Mol Cell 11(2):507-517.
25. Basu SK, Goldstein JL, Anderson RG, & Brown MS (1981) Monensin interrupts the
recycling of low density lipoprotein receptors in human fibroblasts. Cell 24(2):493-502.
26. Adams GP, et al. (2001) High affinity restricts the localization and tumor penetration of
single-chain fv antibody molecules. Cancer Res 61(12):4750-4755.
27. Saga T, et al. (1995) Targeting cancer micrometastases with monoclonal antibodies: a
binding-site barrier. Proc Natl Acad Sci USA 92(19):8999-9003.
28. Thurber GM & Wittrup KD (2008) Quantitative spatiotemporal analysis of antibody
fragment diffusion and endocytic consumption in tumor spheroids. Cancer Res
68(9):3334-3341.
29. Thurber GM, Schmidt MM, & Wittrup KD (2008) Factors determining antibody
distribution in tumors. Trends Pharmacol Sci 29(2):57-61.
30. Wiley HS (2003) Trafficking of the ErbB receptors and its influence on signaling. Exp
Cell Res 284(1):78-88.
31. Downward J, Waterfield MD, & Parker PJ (1985) Autophosphorylation and protein
kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine
kinase activity and ligand binding affinity. JBiol Chem 260(27):14538-14546.
32. Margolis BL, et al. (1989) All autophosphorylation sites of epidermal growth factor
(EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification
of a novel site in EGF receptor. JBiol Chem 264(18):10667-10671.
33. Sato K, Sato A, Aoto M, & Fukami Y (1995) c-Src phosphorylates epidermal growth
factor receptor on tyrosine 845. Biochem Biophys Res Commun 215(3):1078-1087.
120
34. Countaway JL, Nairn AC, & Davis RJ (1992) Mechanism of desensitization of the
epidermal growth factor receptor protein-tyrosine kinase. JBiol Chem 267(2):1129-1140.
35. Takishima K, Griswold-Prenner I, Ingebritsen T, & Rosner MR (1991) Epidermal growth
factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated
"MAP" kinase. Proc Natl Acad Sci USA 88(6):2520-2524.
36. Hunter T, Ling N, & Cooper JA (1984) Protein kinase C phosphorylation of the EGF
receptor at a threonine residue close to the cytoplasmic face of the plasma membrane.
Nature 311(5985):480-483.
37. Salomon DS, Brandt R, Ciardiello F, & Normanno N (1995) Epidermal growth factor-
related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol
19(3):183-232.
38. Normanno N, Bianco C, De Luca A, Maiello MR, & Salomon DS (2003) Target-based
agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Endocr Relat Cancer 10(1):1-21.
39. Normanno N, et al. (2005) The ErbB receptors and their ligands in cancer: an overview.
Curr Drug Targets 6(3):243-257.
40. Gupta D, et al. (2001) Adherence of multiple myeloma cells to bone marrow stromal
cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Leukemia 15(12):1950-1961.
41. De Luca A, et al. (2008) The role of the EGFR signaling in tumor microenvironment. J
Cell Physiol 214(3):559-567.
42. Kuwada SK, et al. (1998) Differential signaling and regulation of apical vs. basolateral
EGFR in polarized epithelial cells. Am JPhysiol 275(6 Pt 1):C1419-1428.
43. Saltz LB, et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal
cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201-
1208.
44. Cunningham D, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl JMed 351(4):337-345.
45. Sorkin A & Goh LK (2009) Endocytosis and intracellular trafficking of ErbBs. Exp Cell
Res 315(4):683-696.
121
46. Sigismund S, et al. (2005) Clathrin-independent endocytosis of ubiquitinated cargos.
Proc Natl Acad Sci U S A 102(8):2760-2765.
47. Zhu JX, et al. (2005) Decorin evokes protracted internalization and degradation of the
epidermal growth factor receptor via caveolar endocytosis. JBiol Chem 280(37):32468-
32479.
48. Schoeberl B, et al. (2009) Therapeutically targeting ErbB3: a key node in ligand-induced
activation of the ErbB receptor-PI3K axis. Sci Signal 2(77):ra3 1.
49. Schoeberl B, et al. (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-
dependent activation. Cancer Res 70(6):2485-2494.
50. Sergina NV, et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by
the kinase-inactive HER3. Nature 445(7126):437-441.
51. Wheeler DL, et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER
(ErbB) family members. Oncogene 27(28):3944-3956.
52. Roopenian DC & Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev
Immunol 7(9):715-725.
53. Harms BD, Bassi GM, Horwitz AR, & Lauffenburger DA (2005) Directional persistence
of EGF-induced cell migration is associated with stabilization of lamellipodial
protrusions. Biophys J 88(2):1479-1488.
54. Huang PH, et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks
reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U SA
104(31):12867-12872.
55. Kelm JM, Timmins NE, Brown CJ, Fussenegger M, & Nielsen LK (2003) Method for
generation of homogeneous multicellular tumor spheroids applicable to a wide variety of
cell types. Biotechnol Bioeng 83(2):173-180.
56. Ishiyama M, et al. (1996) A combined assay of cell viability and in vitro cytotoxicity
with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm
Bull 19(11):1518-1520.
57. Hamasaki K, Kogure K, & Ohwada K (1996) A biological method for the quantitative
measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-
soluble tetrazolium salt. Toxicon 34(4):490-495.
122
5. Therapeutic Evaluation of Engineered Multispecific Antibodies and Elucidation of the
Mechanistic Basis for Tumor Inhibition
Introduction
The two current clinically approved anti-EGFR monoclonal antibody drugs (cetuximab and
panitumumab) rely on ligand competition and are thus hindered by transport limitations, receptor
mutation, and autocrine secretion of stimulatory ligands (1-3). The multi-epitopic targeting
strategy we propose circumvents these issues by downregulating receptor to allow for further
antibody penetration into tumors, by effectively clustering both wild-type and mutant receptors
to permit efficacy in the presence of activating mutations, and by binding to sites on EGFR that
are not competitive with native ligand to retain therapeutic potency in autocrine-driven
environments. We thus sought to compare our multispecific EGFR-targeted antibody-based
constructs to currently approved therapies in established mouse xenograft models.
A particular challenge for EGFR-targeted antibodies is mutation of the receptor. In particular,
the EGFRvIII decouples signal activation from ligand stimulation, resulting in constitutive
activity that is resistant to ligand competitive treatments (5). The 806 antibody specifically
targets an epitope that is exposed in the mutant but not the wild-type form of EGFR (6) and has
been shown to control tumor growth in combination therapy studies with 528, a monoclonal
antibody that binds to extracellular domain 3 of the receptor (7).
Another major challenge in the use of EGFR therapeutics is that many tumors have mutations
downstream of EGFR, often in the KRAS or BRAF genes, which encode the ras and raf
proteins, respectively (8-11). Ras serves as a signal effector in both the mitogen-activated
protein kinase (MAPK) and phosphoinositide 3 kinase (P13K) pathways whereas Rafis an
effector in only the MAPK pathway. Both clinically approved EGFR-targeted antibodies are
ineffective against tumors with KRAS (12-17) or BRAF (18, 19) mutations, indicating that
EGFR ligand competition is insufficient to block downstream activation. One means of
overcoming this obstacle is enhancing immune effector function (20, 21), as has been achieved
with bispecific T cell-engaging (BiTE) variants of cetuximab (22).
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We hoped to address both the downstream signaling and mutational challenges with the novel
mechanism of multispecific antibody-induced clustering. We thus examined the performance of
our most active BS28 construct in a mouse tumor xenograft model of the EGFRvIII-transfected
U87-SH glioblastoma line (23). We also assess the efficacy of our most promising Ab-Fn3
fusion in three tumor models that vary in KRAS and BRAF mutational status. Our results show
strong efficacy of our engineered constructs and consistency between in vitro downregulation
extent and in vivo inhibition of tumor growth.
Results
Bispecific antibodies incorporating the 225 and 806 variable domains inhibit tumor growth
Of the four bispecific antibody orientations used to fuse the 806 scFv to the full 225 IgG, the C-
terminal fusion to the light chain (BS28-LC) downregulated surface EGFR levels the most
potently across a range of wild type and mutant EGFR-expressing cell lines. We thus compared
the ability of BS28-LC and its constituent antibodies (mAb 225, mAb 806, or both) to inhibit
growth of U87-SH tumor xenografts. U87-SH cells express 1.9x 105 copies of wild type EGFR
and 1.4x 106 copies of the mutant EGFRvIII (24). The in vitro surface EGFR downregulation
induced by each antibody treatment is shown in Figure 5.1 A.
U87-SH cells were injected subcutaneously into the left flank of 6-8 week old athymic mice and
tumors were grown for eight days. Beginning on day 8, twice weekly antibody injections at a
dosage of 5 mg/kg were commenced. As shown in Figure 5.1B, BS28-LC effectively controls
tumor growth for more than 20 days. Individual mAb treatment and combination treatment slow
tumor growth to a lesser extent, showing remarkable consistency with the extent of surface
downregulation induced by each treatment (Figure 5.1A). Growth profiles of the individual mice
in each cohort accentuate these trends (Figure 5.1C). At the termination of the experiment (day
23), tumor volume differed significantly (P<0.05) between the 225+806 combination and BS28-
LC treatment groups.
When the treatment dose was augmented to 7.5 mg/kg, BS28-LC therapy similarly inhibited
growth for 22 days (Figures 5.2A-B) compared to control tumors. Both the mean and individual
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tumor growth curves are shown in Figure 5.2. Tumor sizes were significantly different (P<0.05)
between the PBS and BS28-LC cohorts at the time of PBS group sacrifice (day 19).
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Figure 5.1. In vitro downregulation predicts in vivo performance of a bispecific antibody targeting wild type and
mutant EGFR. (A) U87-SH cells were treated with the indicated antibodies for 13 h at 37*C. Antibody was then
stripped and surface EGFR was relabeled and quantified via flow cytometry. Average surface EGFR levels
remaining from three independent experiments are shown (* SD). (B) U87-SH cells were injected subcutaneously
into the left flank of 6-8 week old female nude mice. Beginning on day 8 post-inoculation, mice were treated twice
weekly with either PBS or 5 mg/kg of the specified antibody. Average tumor volumes over the 23-day experiment
are shown (t SEM). On day 23, P<0.05 for the BS28-LC treatment group versus the 225+806 treatment group by
student's t test. (C) Individual mouse growth curves from the experiment shown in (B).
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Figure 5.2. Engineered bispecific antibody controls xenografted tumor growth of U87-SH glioblastoma cells. (A)
U87-SH cells were injected subcutaneously into the left flank of 6-8 week old female nude mice. Beginning on day
8 post-inoculation, mice were treated twice weekly with either PBS or 7.5 mg/kg of the BS28-LC bispecific
antibody. Average tumor volumes over the 22-day experiment are shown (± SEM). On day 19 (termination of PBS
cohort), P<0.05 for the PBS versus the BS28-LC treatment groups by student's t test. (B) Individual mouse growth
curves from the experiment shown in (A).
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Mice that were treated every three days with PBS or 7.5 mg/kg of either 225, 806, 225+806 in
combination, or BS28-LC were sacrificed on day 22 (24 hours post-treatment). Tumors were
dissected and immunofluorescently stained for antibody distribution. As shown in Figure 5.3,
antibody was well perfused throughout the small BS28-LC-treated tumors. Background
fluorescence is shown in the larger PBS-treated control tumor.
A B
Figure 5.3. Antibody is well perfused in an inhibited tumor. (A) U87-SH cells were injected subcutaneously into
the left flank of 6-8 week old female nude mice. Beginning on day 8 post-inoculation, mice were treated twice
weekly with PBS (left) or 7.5 mg/kg BS28-LC (25). Mice were administered a final injection on day 21 and
sacrificed 24 hours later. Tumors were then sectioned and immunofluorescently stained for both human IgGI
(green) and cell nuclei (blue). Tumors were imaged on the Delta Vision Spectris microscope and image intensities
were normalized. Scale bars = 1 mm. (B) Histogram of antibody pixel intensities for PBS-treated tumor (red) and
BS28-LC-treated tumor (blue).
The same tumor sections were then immunofluorescently stained for EGFR. Overall EGFR
expression in the tumor was decreased following two weeks of BS28-LC treatment compared to
saline-treated control tumors, presumably due to chronic downregulation (Figure 5.4).
A B
Figure 5.4. Tumor control correlates with downregulation of EGFR expression. U87-SH cells were injected
subcutaneously into the left flank of 6-8 week old female nude mice. Beginning on day 8 post-inoculation, mice
were treated twice weekly with PBS (left) or 7.5 mg/kg BS28-LC (25). Mice were administered a final injection on
day 21 and sacrificed 24 hours later. Tumors were then sectioned and immunofluorescently stained for both human
EGFR (green) and cell nuclei (blue). Tumors were imaged on the Delta Vision Spectris microscope and image
intensities were normalized. Scale bars = 1 mm. (B) Histogram of EGFR (26) pixel intensities for PBS-treated
tumor (red) and BS28-LC-treated tumor (blue).
Ab-Fn3 fusions exhibit equivalent pharmacokinetic properties to unconjugated antibody
Before evaluating the therapeutic efficacy of Ab-Fn3 fusions, we wished to determine their
clearance properties to establish an appropriate dosing regimen for these novel constructs. We
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injected cetuximab (225), the base antibody, or our most active trans-trispecific Ab-Fn3 fusion,
HND+LCA, into 6-8 week old female athymic
120 mice and measured blood plasma antibody
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- concentration over a 48 h time course. As shown
-60 in Figure 5.5, the pharmacokinetics of the Ab-
40 HFn3 fusion were identical to those of the
20 unmodified antibody. Fitting our data to biphasic
0 10 20 30 4 50 clearance curves of the equation:Time (h)
Y= Aeat + Be-bt
Figure 5.5. Ab-Fn3 fusion clears with same
pharmacokinetic profile as monoclonal antibody. where Y is relative antibody signal and t is time
The base 225 antibody or the trans-trispecific
fusion HND+LCA were injected into 6-8 week post-injection, we find that approximately 50%
old female athymic mice and blood plasma
antibody levels were measured for 48 h. The of the antibody is cleared in the a phase with a
fraction of initial signal at each timepoint is
displayed (±SD) with a fitted biphasic clearance halftime of 10 mi and 50% is cleared in the p
curve overlaid (three mice per cohort). phase with a halftime of 9 h. The full list of
parameters is provided in Table 5.1. Based on standard dosing regimens for IgG in mouse
xenograft models, we chose to dose animals every 3 days.
Parameter Description 225 HND+LCA
A a clearance fraction 53 50
B P clearance fraction 47 50
t1/ 2 ,a a clearance halftime 0.13 h 0.14 h
t1/2, p p clearance halftime 9.1 h 8.9 h
Table 5.1. Clearance parameters for 225 and HND+LCA constructs in nude mice. Parameters were obtained from a
least squares regression fit to the equation Y = Aee" + Be-bt where Y represents relative antibody signal and t
represents time post-injection. The t1 2 values were computed as tv2 ,=ln(2)/a and tli2,p=ln(2)/b.
Ab-Fn3 fusions exhibit superior efficacy to clinically approved cetuximab and in vitro
downregulation is predictive of in vivo tumor inhibition
To compare Ab-Fn3 efficacy to that of the base antibody, we performed tumor xenograft studies
on four different cell lines: A431 epidermoid carcinoma cells (2.8x106 EGFR/cell), HT-29
colorectal carcinoma cells (1.Ox 105 EGFR/cell), HCT- 116 colorectal carcinoma cells (2.4x 105
EGFR/cell), and U87 glioblastoma cells (1.9x105 EGFR/cell). Based on our in vitro
downregulation results and production considerations, we chose to characterize the cis-trispecific
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fusion HN-AD and the trans-trispecific fusion HND+LCA in tumor models. For all xenografts,
cells were injected into the flank of 6-8 week old female athymic mice. Tumors were grown for
one week, at which point the treatment with either PBS, 225, or an engineered trispecific
compound was initiated. Treatments continued every three days for three to five weeks,
depending on the tumor growth rate of the cell line.
We established that EGFR downregulation is inversely correlated with receptor density of a cell
line, making the A431 epidermoid carcinoma cell line the most challenging to target.
Consequently, we first examined the efficacy of Ab-Fn3 fusions in this most challenging
environment. Based on in vitro downregulation studies, 225 or the cis-trispecific fusion HN-AD
only reduces surface EGFR levels by 10-15% after 13 hour incubation at 37*C (Figure 5.6A).
Accordingly, in xenograft models, we observe no statistically significant tumor control via 225
or HN-AD treatment at a dose of 7.5 mg/kg (Figure 5.6B).
A B
1400
100 1200
S
80 1 00080
60800 -.@-PBS
~~600
> 600 -- 225
40 -4-HN-AD
400
20 200
0 0
PBS 225 HN-AD 5 10 15 20
Treatment Days Post-Injection
Figure 5.6. Monoclonal antibody 225 and a cis-trispecific Ab-Fn3 fusion fail to downregulate surface EGFR in vitro
and fail to inhibit tumor growth in vivo. (A) Cultured A431 cells were treated with the indicated antibodies for 13 h
at 37*C. Bound antibody was then stripped and surface EGFR was relabeled and quantified via flow cytometry.
Average surface EGFR levels remaining from three independent experiments are shown (±SD; n=3). (B) A431 cells
were injected subcutaneously into the left flank of 6-8 week old female nude mice. Beginning on day 7 post-
inoculation, mice were treated twice weekly with either PBS or 7.5 mg/kg of the specified antibody. Average tumor
volumes over the 21-day experiment are depicted (* SEM). No statistical significance was observed between the
groups by student's t test.
We subsequently assessed the performance of the HN-AD cis-trispecific Ab-Fn3 fusion in a
xenograft model of a less EGFR dense cell line, HT-29. In vitro, HT-29 cells were potently
downregulated by HN-AD but not by 225 (Figure 5.7A). This trend was paralleled in HT-29
xenograft tumors, with HN-AD effectively inhibiting tumor growth for 40 days (p<0.05 on days
18 through 29 and p<0.01 for days 30 through 34 for HN-AD compared to all other treatment
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groups by paired student's t test) while unmodified 225 did not significantly impact tumor
volume compared to the saline control during this period (Figure 5.7B)
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Figure 5.7. Cis-trispecific Ab-Fn3 fusion drastically downregulates surface EGFR in vitro and potently inhibits
tumor growth in vivo whereas the base 225 antibody does not. (A) Cultured HT-29 cells were treated with the
indicated antibodies for 13 h at 37*C. Bound antibody was stripped and surface EGFR was relabeled and quantified
via flow cytometry. Average surface EGFR levels remaining from three independent experiments are shown (± SD;
n=3). (B) HT-29 cells were injected subcutaneously into the left flank of 6-8 week old female nude mice.
Beginning on day 7 post-inoculation, mice were treated twice weekly with either PBS or 7.5 mg/kg of the specified
antibody. Average tumor volumes over the 40-day experiment are depicted (t SEM). From days 18 through 29,
p<0.05 and from day 30 to the termination of the study, p<0.01 for the HN-AD treatment group compared to each of
the other two cohorts by paired student's t test.
The HT-29 xenograft assay was recapitulated with the most potently downregulating trans-
trispecific fusion, HND+LCA. As was true of the HN-AD construct, HND+LCA significantly
reduced EGFR expression in vitro and tumor growth in vivo, whereas the unconjugated 225
antibody showed minimal efficacy using a 10 mg/kg dosing regimen. Similar results were
observed for the HCT- 116 and U87 cell lines (Figure 5.8). Using a one-way repeated measures
ANOVA algorithm, we find that for HT-29 and U87 xenograft models, p<0.01 for the
HND+LCA versus the PBS or 225 cohorts. For HCT-1 16 xenografts, p<0.01 for the HND+LCA
versus the PBS cohort and p<0.05 for the HND+LCA versus the 225 cohort.
Both Ligand Blocking and Effector Function Contribute to Ab-Fn3-Mediated Tumor Inhibition
The HT-29 and HCT- 116 cell lines carry genetic mutations that encode proteins downstream of
EGFR in the MAPK and P13K pathways. HT-29 carries the p.V600E BRAF mutation(27),
leading to hyperactivation of the rafprotein, which acts as an effector in the MAPK pathway.
HCT-1 16 carries the p.Gl3D KRAS mutation (27), leading to dysregulated signaling by ras, an
effector that mediates both the P13K and MAPK pathways. Consequently, it is surprising that
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our EGFR-targeted construct showed efficacy in these models. We examined three hypotheses
that could potentially explain the efficacy of our construct, both in the absence and presence of
BRAF or KRAS mutations.
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Figure 5.8. Trans-trispecific Ab-Fn3 fusion downregulates surface EGFR in vitro and inhibits tumor growth in vivo
whereas the unconjugated 225 antibody does not. For downregulation assays, cultured HT-29 (A), HCT- 116 (C), or
U87 cells (E) were treated with the indicated antibodies for 13 h at 37*C. Bound antibody was stripped and surface
EGFR was relabeled and quantified via flow cytometry. Average surface EGFR levels remaining from three
independent experiments are shown (t SD; n=3). For xenograft models, HT-29 (B), HCT-1 16 (D) or U87 cells (F)
were injected subcutaneously into the left flank of 6-8 week old female nude mice. Beginning on day 7 post-
inoculation, mice were treated every three days with either PBS or 10 mg/kg of the specified antibody. Treatment
spanned the duration of the experiment for HT-29 and HCT-1 16 xenografts whereas treatment was stopped on day
31 for U87 xenografts. Average tumor volumes from four mice are depicted (t SEM). For HT-29 and U87
xenografts, P<0.01 for the HND+LCA versus the PBS or 225 cohorts. For HCT-1 16 xenografts, P<0.01 for the
HND+LCA versus the PBS cohort and P<0.05 for the HND+LCA versus the 225 cohort. Statistical analyses were
performed using a one-way repeated measures ANOVA algorithm.
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The first hypothesis involved a recently discovered mechanism through which EGFR binds to
the SGL T1 glucose transporter to stabilize intracellular glucose levels, thereby preventing
autophagic death (28-30). We theorized that the overall reduction of EGFR induced by Ab-Fn3
fusion-mediated clustering would lead to a reduction in basal glucose levels, thus sensitizing the
cells to autophagy. To formally test this hypothesis, we performed a series of cell proliferation
assays in HT-29 and HCT-1 16 cells in the absence and presence of glucose. Cells were
incubated for 72 h at 370C with 20 nM antibody or Ab-Fn3 fusion and subsequently assessed for
viability via the Wst-1 proliferation assay. As shown in Figure 5.9, antibody treatment did not
affect HT-29 or HCT- 116 cell proliferation under high glucose (25 mM) or glucose starvation
(0.5 mM) conditions. Insensitivity to the glucose environment precludes the possibility that Ab-
Fn3 fusion-mediated tumor inhibition results from destabilization of intracellular glucose levels.
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0.0
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Figure 5.9. Glucose starvation does not affect survival of HT-29 or HCT-1 16 cells in presence of antibody
treatment. HT-29 (A) or HCT-1 16 (B) cells were seeded on 96-well plates and allowed to attach for 24 h.
Incubation in 20 nM antibody proceeded for 72 h at 37 0C and cells were then assessed for proliferation via Wst-1
assay. Proliferation relative to untreated cells (±SD; n=3) is depicted under glucose-rich (25 mM) and glucose
starvation (0.5 mM) conditions.
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An alternative hypothetical mechanism for Ab-Fn3 fusion-mediated inhibition of tumor growth
involves the obstruction EGFR signaling through the complementary strategies of ligand
inhibition (via the 225 base) and receptor
100 - ErbB1 downregulation (via multi-epitopic targeting of
.. v pERK the Fn3 domains). It was recently shown that
*pAkt
. 50- the response of MAPK and P13K signaling have
.. extreme sensitivity to the abundance of
0- phosphorylated EGFR (pErbB1) (4). As shown
11 I n q I 1nR Iu 1 nq I u 11qII in Figure 5.10 from Chen et al (4), the difference
-14 -13 -12 -11 -10 -9 -8 -7
Log [EGF(M)] between 99% and 99.9% inhibition of EGFR
Figure 5.10. EGF dose response profile of ErbB1 and activity translates into an 80% reduction in
downstream effectors. The response of ErbBl, Shc, activity of ERK (an effector in the MAPK
ERK, and Akt phosphorylation to a range of EGF
concentrations was measured five minutes after pathway) and Akt (an effector in the P13K
treatment via in-cell western assay. This figure is
reproduced with permission from (4). pathway).
This downstream amplification of input signal could account for the differential response to 225
versus the Ab-Fn3 fusion if the two-pronged mechanism of ligand inhibition plus
downregulation incrementally reduces residual EGFR signaling that occurs when only ligand
inhibition is employed (i.e. in the presence of unconjugated 225).
To examine whether or not ligand competition plays a role in the observed therapeutic effect, we
designed a version of the HND+LCA trans-trispecific fusion with two mutations in the variable
domain of the heavy chain to impair 225 binding. Specifically, residues Y102 and D103 of the
225 heavy chain, which are involved in hydrogen bond and salt bridge interactions with EGFR,
were mutated to alanine (2). As shown in Figure 5.11 A, mutation of D103 decreased the binding
affmity of 225 by nearly thirty-fold (Kd=1.Ox 1010 M for 225 versus 2.8x10-9 M for D103A),
whereas mutation of Y102 had a minimal effect. The two variable domain mutations were used
simultaneously in the HND+LCA construct to create the 225 binding defective mutant,
HND+LCAx. The reduction in binding from the 225 mutated construct was mitigated by the
presence of the two Fn3 domains, resulting in only about a tenfold difference in affinity between
HND+LCA (Kd=7.1x10~"M) and HND+LCAx (5.9x101 0 M) (Figure 5.11B).
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Figure 5.11. Introduction of two mutations in the variable domain of the 225 heavy chain impairs binding to EGFR.
(A) The indicated 225 variants (either wild type 225 or 225 with the Y102A, D103A, or both mutations) were
titrated on the surface of HMEC cells. The indicated concentrations of antibody were added to cell suspensions and
incubated for 3 h at 4*C. EGFR-bound antibody was detected with fluorophore-conjugated anti-human secondary
antibody. Signal relative to maximum fluorescence is plotted (*SD; n=3). (B) The indicated trans-trispecific
constructs were titrated on the surface of A431 cells. The indicated concentrations were added to cell suspensions
and incubated for 3 h at 4*C. Bound antibody was detected with fluorophore-conjugated anti-human secondary
antibody. Relative signal normalized to maximum fluorescence is plotted (±SD; n=3).
To verify that the competition with EGF was impaired by the mutations introduced into the 225
variable domain, we performed competition assays on the surface of A431 cells. As shown in
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Figure 5.12. Introduction of two mutations in the
variable domain of the 225 heavy chain impairs
antibody competition with EGF. (A) A431 cells were
incubated with the indicated concentration of
competitor antibody (either wild type HND+LCA or
225-mutated HND+LCAx) for 1 hour at 40C. Soluble
fluorescently labeled EGF was then added to the cells
and incubation proceded for 30 min. Fluorescent
signal was subsequently analyzed via flow cytometry.
Signal relative to the uncompeted control is presented
(*SD, n=3).
Figure 5.12, the mutated HND+LCAx
construct competes 7-fold less efficiently
with EGF than does the wild type HND+LCA
(K,=4.2x10~9 M for HND+LCAx versus
K,=5.9x 1010 M for HND+LCA).
The third hypothetical mechanism for Ab-Fn3
fusion efficacy that we considered was the
possibility that effector function was
enhanced by fusion-induced clustering. The
role of immune cell recruitment via Fcy
receptor interaction in antibody efficacy has
long been appreciated (20) and the 225
antibody is known to evoke ADCC in non-
small cell lung(3 1) and colorectal (32) cancers, mediated through natural killer (NK) cells or
macrophages.
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To parse the contribution of immune effector function to Ab-Fn3-mediated tumor inhibition, we
designed a mutant version of the HND+LCA trans-trispecific fusion (hereafter referred to as
HND+LCAf) with deficient Fc-y receptor binding. Specifically, the D265A mutation was
introduced into the constant region of the IgG heavy chain to drastically reduce immune cell
150 interaction (33, 34) and, consequently,
125 - ADCC. As demonstrated in Figure 5.13,
100 
_ this point mutation inhibits Fc-y receptor 4
7s . IHND+LCA
i HND+LCAf (which engages macrophages and NK
50 -
Z 25 - cells) binding by 96%. As expected, the
0 ,gI presence of this constant domain mutation
mFcgRI mFcgRII mFcgRIll mFcgRIV does not affect antibody affinity
Figure 5.13. Introduction of an Fc domain mutation in the (Kd=7.1x10~" M for HND+LCA and
225 IgG ablates binding to Fcy receptor IV. Yeast
displaying Fcy receptor I, II, III, or IV were incubated d=7.8x10" M for HND+LCAf) or EGF
with 20 nM either HND+LCA or HND+LCAf. Bound competition (K1=5.9x10~10 M forAb-Fn3 fusion was detected via flow cytometry with a
fluorophore-conjugated anti-human secondary antibody. HND+LCA and K 1=4.8x10-10 M forThe normalized fluorescent signal is plotted for each
receptor. This work was performed by Tiffany Chen. HND+LCAf).
Based on deconvolution microscopy analysis, Ab-Fn3 fusion-induced receptor clustering iss not
impacted by either the 225 variable domain or Fc region mutations. The punctate distribution of
EGFR is evident as early as 1 h after exposure to Ab-Fn3 fusion and does not differ noticibly
between HND+LCA, HND+LCAx, and HND+LCAf treatment (Figure 5.14).
225 HND+LCA HND+LCAx HND+LCAf
1 h
6h
Figure 5.14. Mutations in the 225 IgG variable domain and Fc domain do not impact receptor clustering. The
indicated constructs were labeled with fluorescent dye, incubated with HT-29 cells for 1 or 6 h at 37*C, and
subsequently washed and visualized on a DeltaVision Spectris microscope. Images were deconvolved and
normalized and represent projections of 0.15 pm slices through the full cell volume. Scale bars = 15 stm.
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To ensure that the 225 variable domain and Fc-domain mutations did not abrogate Ab-Fn3-
mediated EGFR downregulation, we compared the downregulation kinetics of HND+LCA,
HND+LCAx, and HND+LCAf. As shown in Figure 5.15, the kinetics of downregulation were
not significantly altered by either of the mutations relative to the wild type trans-trispecific
(ti/2 =0.05 h for HND+LCA, tu2=0. 11 h for HND+LCAx, and t 12=0.14 h for HND+LCAf). Also,
as expected, the steady-state surface EGFR levels were identical following HND+LCA and
HND+LCAf treatment. The steady-state level of surface EGFR in the HND+LCAx mutant was
slightly higher than that of HND+LCA due to the loss of trispecificity as a result of the 225
variable domain mutation.
To isolate the contributions of signal
100 'inhibition and effector function to in vivo
*HND+LCA tumor inhibition, we assessed the
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HND+LCAx performance of the HND+LCAx and40L40- OHND+LCAf
20 HND+LCAf mutants relative to the wild
type HND+LCA in HT-29, HCT-1 16, and
0 2 4 6 U87 xenograft models. As before, tumor
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Figure 5.15. IgG variable domain and effector function cells were injected subcutaneously into the
point mutations do not alter downregulation kinetics and flank of 6-8 week old nude mice and
only slightly affect downregulation extent. HT-29 cells
were treated with wild type HND+LCA trans-trispecific tumors were allowed to grow for 7 days.
Ab-Fn3 or variants of this construct with a 225 variable
domain mutation (HND+LCAx) or a CH2 domain Beginning on day 7 post-tumor inoculation,
mutation (HND+LCAf). Cells were dissociated at the
indicated time, acid stripped to eliminate bound antibody, 10 mg/kg of the prescribed construct was
and relabeled with murine 225 to detect surface receptor. inected eve three days. From Fiure
EGFR levels were quantified via flow cytometry and trdy g
normalized to those of untreated cells. 5.16, we find that the contributions of
ligand inhibition and effector function vary for the three cell lines tested. In the BRAF mutant
HT-29 cell line, both ligand inhibition and effector function are requisite for tumor control.
However, in the KRAS mutant HCT-1 16 cell line and the BRAF/KRAS wild type cell line U87,
ligand inhibition is sufficient for tumor control; although immune effector function may
contribute, it is not strictly required for the observed therapeutic effect. Statistical analysis via
one-way repeated measures ANOVA demonstrates significance (P<0.01) between the
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HND+LCA and the PBS, HND+LCAx, and HND+LCAf cohorts for HT-29 xenografts and
significance (P<0.01) between the HND+LCA and only the PBS and HND+LCAx cohorts for
HCT-1 16 and U87 cells.
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Figure 5.16. Trans-trispecific Ab-Fn3 fusion efficacy requires both intact 225 variable domain and, in some cases,
intact Fc effector function. For downregulation assays, cultured HT-29 (A), HCT- 116 (C), or U87 cells (E) were
treated with the indicated antibodies for 13 h at 37*C. Following treatment, antibody was stripped and surface
EGFR was relabeled and quantified via flow cytometry. Average surface EGFR levels remaining from three
independent experiments are shown (* SD). For xenograft models, HT-29 (B), HCT-1 16 (D) or U87 cells (F) were
injected subcutaneously into the left flank of 6-8 week old female nude mice. Beginning on day 7 post-inoculation,
mice were treated every three days with PBS or 10 mg/kg of the specified antibody. Average tumor volumes from
four mice are shown (* SEM). For HT-29 xenografts, P<0.01 for the HND+LCA versus the PBS, HND+LCAx, and
HND+LCAf cohorts. For HCT-116 and U87 xenografts, P<0.01 for the HND+LCA versus the PBS and
HND+LCAx cohorts. Statistical analyses were performed using a one-way repeated measures ANOVA algorithm.
As with the BS28-treated xenografts, HT-29 tumors were dissected and immunofluorescently
stained for total EGFR content at the termination of the experiment (day 38). Consistent with
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our findings from bispecific antibody-treated tumors, HND+LCA-treated tumors expressed
significantly less EGFR than untreated tumors. Notably, the HND+LCAx- and HND+LCAf-
treated tumors (which were not controlled by therapy) did not show evidence of EGFR
downregulation (Figure 5.17).
PBS HND+LCA HND+LCAx HND+LCAf
Figure 5.17. HT-29 tumor control coincides with downregulation of EGFR expression. HT-29 cells were injected
subcutaneously into the left flank of 6-8 week old female nude mice. Beginning on day 7 post-inoculation, mice
were treated twice weekly with PBS or 10 mg/kg of the indicated trans-trispecific Ab-Fn3 fusion. Mice were
administered a final injection on day 37 and sacrificed 24 hours later. Tumors were then sectioned and
immunofluorescently stained for both human EGFR (green) and cell nuclei (blue). Tumors were imaged on the
Delta Vision Spectris microscope and image intensities were normalized. Scale bars = 1 mm.
To further probe the role of signal inhibition in retarding tumor growth, we used western blot
analysis to determine the extent of Akt and ERK phosphorylation antagonism in HT-29 cells
following treatment with saturating concentrations of 225, HND+LCA, HND+LCAx, and
HND+LCAf. Note that ERK activity in these cells still responds to EGF stimulation despite the
downstream mutation in the raf protein. Cells were incubated with antibody or fusion constructs
for 13 h and subsequently pulsed with EGF, followed by cell lysis and phosphoprotein
quantification.
We first assessed Akt antagonism by trans-trispecific constructs compared to the 225 mAb. In
the BRAF mutant cell line HT-29, which has wild-type P13K signaling, Akt showed a rapid and
intense response to EGF stimulation, with peak stimulation at 1 min post-treatment (Figure 4.18).
Isotype control antibody did not impact signaling dynamics. However, the 225 mAb delayed and
attenuated the response to EGF, showing maximal activity 5 min post-treatment with a peak at
two-thirds the intensity of PBS-treated cells. Remarkably, all the trans-trispecific construct
HND+LCA and its ligand binding and effector function mutant counterparts completely blocked
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Akt activation in HT-29 cells. Thus, ligand blockade combined with downregulation effectively
inhibits signaling downstream of EGFR.
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Figure 5.19. Ab-Fn3 fusions block signaling through P13K pathway. (A) Serum starved HT-29 cells were treated
for 13 h at 37*C with PBS, or 20 nM of an isotype control antibody, 225, HND+LCA, HND+LCAx, or HND+LCAf.
They were then stimulated with 20 nM EGF for the indicated time intervals at 37*C. Cell lysis proceeded and pAkt
and beta actin were quantified via immunoblot assay. (B) Quantification of immunoblot results presented in (A).
Band intensities were normalized by beta actin levels and by the intensity of a control lysate included on each blot.
The activation threshold is set at 1.7-fold background.
Even more striking than the Akt inhibition is the differential ERK antagonism effected by trans-
trispecific constructs compared to 225. ERK phosphorylation is apparent within 1 min of EGF
stimulation and declines back to basal levels by 60 min post-treatment in the presence of PBS or
an isotype control antibody (Figure 5.19). Incubation with 225 delays ERK activation so that
maximum pERK signal is observed at 5 min post-EGF treatment. However, peak activation
levels still remain identical to those in untreated or isotype control-treated cells. Incubation with
HND+LCA, HND+LCAx, and HND+LCAf completely ablate ERK activation in the presence of
EGF. These results demonstrate that the combination of ligand inhibition and Ab-Fn3 -induced
receptor downregulation conspire to abrogate activity of the MAPK pathway although neither
mechanism alone is sufficient. These findings are consistent with our in vivo observation that
both downregulation capacity and intact ligand inhibition are vital for therapeutic efficacy.
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Figure 5.19. Ab-Fn3 fusions ablate signaling through MAPK pathway. (A) Serum starved HT-29 cells were
incubated for 13 h at 370C with PBS, or 20 nM of an isotype control antibody, 225, HND+LCA, HND+LCAx, or
HND+LCAf. They were subsequently stimulated with 20 nM EGF for the indicated lengths of time at 370C. Cells
were then lysed and the abundance of pERK and beta actin were analyzed via immunoblot quantification. (B)
Quantification of immunoblot results presented in (A). Band intensities were normalized by beta actin levels and by
the intensity of a control lysate included on each blot. The activation threshold is set at 1.7-fold background.
Discussion
Based on previous observations using combinations of antibodies directed against multiple
targets on EGFR (7, 35) or ErbB2 (36, 37), we predicted that our multi-epitopic antibodies would
effectively control tumor growth in mouse xenograft models of EGFR-expressing cancer.
In the case of the 225/806 bispecific antibody (BS28-LC), we achieve tumor inhibition that is
superior to that induced by combination therapy by enhancing avidity effects (Figures 5.1, 5.2).
The in vivo tumor control in the U87-SH model is strongly correlated with the in vitro
downregulation elicited by single, combination, or bispecific antibody treatment. Notably, the
effective dose of our bispecific construct (5 mg/kg) is tenfold below that of the 225 monoclonal
antibody (38). It is thus advantageous to re-format synergistic antibody combinations as
bispecific constructs, particularly in situations where the binding of one of the antibodies is
limited, as is the case for the 806 antibody (6, 39). Our immunofluorescent staining of the
excised tumors indicates that BS28-LC is well perfused in the tumor 24 h post-treatment and that
EGFR levels are reduced following two weeks of treatment with this construct (Figures 5.3, 5.4).
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We also establish the therapeutic efficacy of Ab-Fn3 fusion constructs in three different
xenograft tumor models (Figures 5.7, 5.8). These findings resonate with recent demonstration
that a camelid-derived single domain antibody that simultaneously binds two epitopes of EGFR
domain III retards the growth of solid tumors (40). Again, we observe that in vitro
downregulation is predictive of in vivo efficacy.
Surprisingly, two of the xenograft models we studied (HT-29 and HCT- 116) resist treatment
with the base 225 antibody via downstream mutations yet show sensitivity to Ab-Fn3 fusions.
While 225 induces significant inhibition of EGFR phosphorylation through ligand competition,
the incremental inhibition of EGFR activation by the complementary mechanism of receptor
clustering and downregulation results in potent obstruction of downstream signaling through the
Akt and MAPK pathways (Figures 5.18, 5.19). Furthermore, our results suggest a role for
ADCC in therapeutic efficacy in the HT-29 model (Figure 5.16). The rapid formation of
receptor-antibody clusters on the surface of tumor cells could enhance immune effector cell
recruitment, potentiating the immunological effects of 225 (31, 32). ADCC effects are known to
be mediated through NK cells, but there is growing evidence that macrophages may play a key
role in antibody-dependent tumor cell killing (41-44). Based on hematoxylin and eosin staining
of dissected tumor sections, we saw little evidence of NK cell infiltration in controlled tumors,
but we did observe an abundance of macrophages in these specimens. Although immune
effector function appears to contribute to the Ab-Fn3 mechanism of action, it is important to note
that immune effector function alone cannot account for the observed therapeutic effect as
constructs that lack ligand inhibition capacity but possess intact immune effector function fail to
substantively slow tumor growth.
Encouragingly, Ab-Fn3 fusion half-life parallels that of human IgG1 (Figure 5.5), suggesting
that like monoclonal antibodies, our fusions benefit from neonatal Fc receptor recycling in the
bloodstream (45). Thus, pharmacokinetic studies implicate a dosing schedule similar to that of
clinically approved IgGs, and potency at 10 mg/kg suggests that our construct may be effective
at lower doses than currently available monoclonal antibodies, which would reduce undesirable
side effects and cut manufacturing costs.
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The establishment of the strategy of multi-epitopic targeting holds exciting promise for
development of drugs targeting other ErbB family members or receptor tyrosine kinases in
general. By enhancing the avidity of antibody-based constructs and introducing the
complementary mechanism of cluster-induced downregulation, we may recover or improve the
efficacy of existing drugs as well as design novel therapeutics that benefit from a multi-epitopic
strategy. With the addition of a third fibronectin clone to the IgG scaffold, one can envision the
development of a tetraspecific Ab-Fn3 fusion that targets two receptors at two non-overlapping
epitopes, resulting in the clustering and consequent downregulation of multiple receptors from a
single construct. This would be particularly relevant for EGFR targeting, where cells often
evade EGFR therapy through compensatory signaling via other ErbB receptors (notably ErbB3)
or the c-MET receptor (46-50), as discussed in Chapter 4. Overall, the multi-epitopic strategy
we present introduces an effective means of targeting, clustering, and downregulating a receptor
to inhibit signaling and, ultimately, tumor growth.
Materials & Methods
Cell Culture
All cell lines and media were purchased from ATCC (Manassas, VA) unless otherwise specified.
Cells were grown at 370, 5% CO 2 in a humidified atmosphere. U87-SH cells (23) were cultured
in DMEM containing 10% FBS, 1% sodium pyruvate, 1% non-essential amino acids, and 0.2 g/L
G418 for selection. HT-29 and HCT-1 16 cells were cultured in McCoy's 5A medium
supplemented with 10% FBS and IX penicillin-streptomycin solution (PS). U87 cells were
cultured in DMEM with 10% FBS, 1% sodium pyruvate, 1% non-essential amino acids, and 1X
PS. HEK 293-F cells (Invitrogen, Carlsbad, CA) were maintained in suspension in FreeStyle
Expression medium (Invitrogen). Adherent cells were detached for subculture or assay use with
0.25% trypsin and 1 mM EDTA. For serum starvation, medium was removed by aspiration,
cells were washed with warm PBS, and fresh serum-free medium was added. Complete medium
refers to serum-rich medium.
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Unless otherwise noted, all washes were conducted in PBS containing 0.1% BSA and all
constructs were used at a concentration of 20 nM for single treatment and 10 nM each for
combination treatment. EGF (Sigma, St. Louis, MO) was dosed at 20 nM. Trypsin-EDTA
(Invitrogen) contains 0.05% trypsin and 0.5 mM EDTA.
Downregulation Assays
Cells were subcultured into 96-well plates at a density of 30,000 per well, incubated for 12-18 h
to allow attachment, and serum starved for 12 h. Subsequently, cells were treated with 20 nM of
the indicated antibody or Ab-Fn3 fusion for 13 h at 37*C. Medium was removed by aspiration
and cells were washed with PBS, detached with trypsin, and placed on ice for the remainder of
the assay. Bound antibody constructs were removed by 5 min acid strip with 0.2 M acetic acid,
0.5 M NaCl. Cells were washed with PBSA and incubated in mouse 225 antibody, washed
again, and labeled with R-phycoerythrin-conjugated anti-mouse secondary antibody (Invitrogen).
Cells were washed and analyzed using a FACS Calibur flow cytometer (BD Biosciences, San
Jose, CA). Mean fluorescence was normalized to PBS-treated control samples.
Production of Antibody-Fibronectin Fusions via HEK Cell Transfection
The human IgGI heavy and light chains of each antibody-fibronectin fusion construct were
inserted into the gWiz mammalian expression vector (Genlantis, San Diego, CA). Constructs
were verified by sequence analysis. HEK 293-F cells were grown in suspension to a density of
1.2x 106 per mL in 400 mL and diluted to 1x 106 per mL prior to transfection. Miniprepped DNA
and polyethyleneimine (Sigma, St. Louis, MO) were diluted separately to 0.05 and 0.1 mg/mL,
respectively, in 10 mL OptiPro medium and incubated at 22*C for 15 min. Equal volumes of
diluted DNA and polyethyleneimine were then mixed and incubated at 22*C for 15 min.
Subsequently, 500 mL of cells and 20 mL of DNA/polyethyleneimine mixture were added to a 2
L roller bottle and incubated at 370, 5% CO 2 on a roller bottle adapter for seven days. The cell
secretions were then centrifuged for 30 min at 15,000xg and the supernatants were filtered
through a 0.22 [m bottle-top filter and purified via affinity column chromatography using
protein A resin (Thermo Fisher Scientific, Waltham, MA). The eluted antibodies were
concentrated and transferred to PBS and then characterized by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
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Mouse Xenograft Studies
U87-SH glioblastoma cells (2x10 6), HT29 colorectal carcinoma cells (3x10 6 ), HCT-116
colorectal carcinoma cells (2x 106), or U87 glioblastoma cells (3x 106) were injected
subcutaneously into the right flanks of 6-8 week-old female Ncr nu/nu mice. By day 7 post-
injection (or day 8 post-injection for the U87-SH cell line), tumors had grown to a minimum
volume of 20 mm3 . Mice were randomized and a twice weekly or every three day retro-orbital
injection regimen of PBS or either 225 human IgG1, 806 human IgG1, bispecific antibody, or
Ab-Fn3 fusion was commenced (150 pg per treatment for 7.5 mg/kg dosing and 200 [tg per
treatment for 10 mg/kg dosing). Treatments continued for 3-5 weeks depending on tumor
growth rate and tumor volume was monitored daily with a digital caliper using the formula
Volume = 0.5x(Length)x(Width) 2. Throughout the experiment, mice were monitored for overall
health and activity in accordance with Massachusetts Institute of Technology Committee on
Animal Care protocol number 0509-048-12. Heteroscedastic two-tailed student's t tests were
performed to compare tumor growth between cohorts. Each cohort included three or four mice.
Tumor Immunofluorescence Studies
The xenografted U87-SH tumors were dissected on day 22, immersed in optimal cutting
temperature freezing medium, and flash frozen with liquid nitrogen in a bath of 2-methylbutane
(Sigma). Tumors were subsequently sectioned (7 [tm slices) in a cryostat and affixed to slides.
For immunofluorescent staining, slides were fixed with formalin for 10 min and then washed
three times with PBS. Cells were subsequently permeabilized in PBS containing 0.1% Triton X-
100 for 10 min and washed three additional times. Blocking with a 5% solution of goat serum
(Invitrogen) proceeded for 1 h at room temperature, followed by overnight incubation with either
polyclonal rabbit anti-EGFR antibody (Abcam, Cambridge, MA) or anti-human Fc antibody
(Invitrogen) in 5% goat serum at 4*C. Slides were rinsed three times and incubated with goat
anti-rabbit 488-conjugated antibody (Invitrogen) in PBS containing 0.1% Tween 20 for 1 h at
room temperature. Following four final PBS washes, the slides were incubated with the DNA
stain DAPI (Sigma) for one minute at room temperature, mounted with Vectashield (Vector
Laboratories, Burlingame, CA), and sealed with clear nail polish. Imaging was performed on a
DeltaVision Spectris microscope (Olympus, Center Valley, PA) at 10X magnification. Image
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acquisition and processing were conducted using the Applied Precision software package. All
images shown were acquired during a single session using identical intensity settings. The
images have been stitched from a series of panels acquired in a single plane of focus.
Pharmacokinetic Studies
Antibody or Ab-Fn3 fusion was labeled with Licor 800cw near-infrared dye (Licor Biosciences,
Lincoln, NE). A total of 200 [g per mouse (10 mg/kg) of labeled antibody or Ab-Fn3 fusion
suspended in 100 tL PBS was retro-orbitally injected into 6-8 week-old female Ncr nu/nu mice
(three mice per cohort). At each time point, 20 tL blood was collected from the tail vein and
maintained in a capillary tube. The blood was then centrifuged for 5 min at 1500xg to remove
red blood cells and the plasma layer was transferred to a fresh capillary tube for analysis. Near-
infrared signal was detected using the Licor Odyssey infrared imaging system at a wavelength of
800 nm. Signal was normalized to the first collection time point (immediately post-injection).
Cell Proliferation Assays
HT-29 or HCT- 116 cells were seeded at 3x 103 per well in 96-well plates and allowed to adhere
for 24 h. They were then treated with the indicated mAbs or Ab-Fn3 fusion constructs at the
prescribed concentrations in DMEM containing either 5 or 25 mM glucose and incubated at
37*C for 72 h. Cell viability (relative to an untreated control) was assessed using the Wstl
tetrazolium salt cleavage assay (Roche, Indianapolis, IN) (51, 52). Relative proliferation was
calculated as the 450 nm absorbance of treated wells relative to that of untreated control cells.
Affinity titrations
To characterize Ab-Fn3 binding affinities, HMEC or A431 cells were trypsinized, washed in
PBSA, and incubated with various concentrations of Ab-Fn3 in a 96-well plate on ice. The
number of cells and sample volumes were selected to ensure at least tenfold excess Ab-Fn3
relative to EGFR. All samples were assayed in triplicate. Cells were incubated on ice for
sufficient time to ensure that the approach to equilibrium was at least 99% complete. Cells were
then washed and labeled with 66 nM PE-conjugated goat anti-human antibody (Rockland
Immunochemicals, Gilbertsville, PA) for 20 min on ice. After a final wash, plates were analyzed
on a FACS Calibur cytometer (BD Biosciences, San Jose, CA). The minimum and maximum
144
fluorescence and the equilibrium dissociation constant (Kd) value were determined by
minimizing the sum of squared errors assuming a 1:1 binding interaction (% Bound =
[L]/([L]+Kd) where [L] is Ab-Fn3 concentration and Kd is the equilibrium dissociation constant
of the Ab-Fn3 construct. Curve fitting was implemented in MATLAB (Mathworks, Natick,
MA). Titrations were performed at physiological pH (pH 7.4).
Live Cell EGFR Imaging
Cells were plated at 20,000 cells/well in 8-well microscopy chambers (Nunc, Rochester, NY)
and allowed to attach overnight. Cells were then serum starved for 12 h and incubated with
Alexa 488-labeled (Invitrogen) monoclonal antibody or Ab-Fn3 fusion for 1 or 6 h at 37*C.
Wells were then washed to remove unbound constructs and cells were resuspended in phenol
red-free DMEM (Invitrogen). Cell monolayers were visualized using a DeltaVision Spectris
microscope (Olympus) at 60X magnification (oil immersion lens). During imaging, cells were
maintained at 37*C and 5% CO2 . Image acquisition and processing were conducted using the
Applied Precision and ImageJ software packages. All images shown were acquired during a
single session using identical intensity settings and brightness and contrast settings have been
normalized. These images represent projections from 0.15 [im sections spanning the full cell
monolayer.
Yeast-Displayed Fcy Receptor Binding Assay
Transformed yeast stably displaying the extracellular domain of Fcy receptor I (residues 25-297),
II (residues 30-207), III (residues 31-215), or IV (residues 21-203) followed by a cmyc tag were
incubated with 100 nM Ab-Fn3 fusion for 30 min at 22*C. Chicken anti-cmyc antibody
(Invitrogen) was also added to detect properly displayed receptor. Cells were then washed and
goat anti-human 488-labeled secondary antibody (Invitrogen) was added to detect bound IgG
fusion. Concurrently, goat anti-chicken 647-labeled secondary antibody (Invitrogen) was added
to detect cmyc. Cells were incubated at 4*C for 15 min, washed, and then analyzed on a FACS
Calibur flow cytometer (BD Biosciences) and mean Ab-Fn3 fluorescence is reported for
functionally displaying yeast (gated based on cmyc detection).
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Western Blots
HT-29 or HCT-1 16 cells were cultured to confluence in 6-well plates and serum starved for 12h.
Cells were then incubated with 20 nM antibody or Ab-Fn3 fusion for 13 h at 37*C.
Subsequently, 20 nM EGF was added and incubation proceeded at 37*C for the prescribed time
length. Cells were then washed twice with cold PBS and incubated with rotation for 5 min in
lysis buffer (50 mM Tris*HCl, 2% SDS, 5% glycerol, 5 mM EDTA, 1 mM NaF, protease and
phosphatase inhibitors (Thermo Fisher Scientific, Pittsburgh, PA), 10 mM s-GP, 1 mM PMSF
and 1 mM Na3VO 4). Total protein levels were quantified via BCA assay (Thermo Fisher
Scientific, Pittsburgh, PA) and lysates were normalized to a final concentration of 3.5 mg/mL.
Lysates were clarified by passage through centrifugal filter plates for 8-12 h at 4000xg. The
lysates were subsequently subjected to SDS-PAGE on 8% E-Page gels and blotted onto
nitrocellulose via iBlot apparatus (Invitrogen). The blotted membrane was then blocked in 1:1
PBS:Odyssey Blocking Buffer (Licor Biosciences) for 1 h at room temperature. Blots were then
incubated with 1:1000 dilutions of either anti-phosphoERK1/2 Y202/Y204 rabbit antibody or
anti-phosphoAkt S473 rabbit antibody overnight at 40C (Cell Signaling, Danvers, MA). A
1:15,000 dilution of mouse anti-beta actin antibody (Sigma) was added the next morning and
incubation proceeded for 2 h at room temperature. Following three washes, the membrane was
incubated with goat anti-mouse (800 cw) and anti-rabbit (700 cw) near IR dye conjugate
antibodies. After four additional washes, membranes were visualized on the Licor Odyssey
infrared imaging system. Phospho-ERK and phospho-Akt signals were normalized by beta actin
signal for each lysate and all samples were normalized to a control lysate to ensure consistent
intensity between blots. Images were normalized and quantified using ImageJ software (NIH).
Statistical Analysis
Heteroscedastic two-tailed student's t tests (for experiments shorter than 25 days) or one-way
repeated measures ANOVA (for experiments longer than 25 days with the exception of the HT-
29 HN-AD model for direct comparison to the A431 HN-AD model) were performed on mouse
xenograft data to compare 225, Fn3, and Ab-Fn3 treatments. Both algorithms were implemented
in MATLAB (Mathworks).
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6. Conclusions and Future Perspectives
Conclusions
We have taken the idea of antibody-induced characterization from conception and preliminary
characterization to mechanistic elucidation and application to the development of two novel
classes of cancer therapeutics. In the process, we have gained important insights into EGFR
kinetics that could form the basis for development of new drugs that target and downregulate this
receptor.
As discussed in Chapter 2, we establish that combinations of non-competitive EGFR-targeted
antibodies can cluster and downregulate surface in a range of cell lines. Interestingly, we find
that a combination of two mAbs targeting extracellular domain 3: (1) The murine form of the
clinically approved cetuximab and (2) The N-terminal domain 3-targeted mAb H 11 induce the
greatest extent of downregulation. More generally, combinations of domain 3-targeted mAbs
show more synergism than combinations targeting two different domains. Also, we find that
unlike EGF-mediated downregulation, combination mAb-mediated downregulation exclusively
obstructs recycling and does not accelerate endocytosis. In contrast to EGF, combination
treatment does not activate the receptor or downstream signaling pathways. We establish that
downregulation requires two bivalent mAbs and that it is coincident with dramatic receptor
clustering. To motivate use of antibody combinations as a therapeutic strategy, we demonstrate
that mAb-induced downregulation selectively and efficiently inhibits the migration and
proliferation of cells that aberrantly secrete autocrine ligand, mimicking the dysregulated tumor
environment.
We then apply these insights to the development of bispecific antibodies targeting both the wild
type and the mutated or activated forms of EGFR. As detailed in Chapter 3, these bispecific
constructs enhance the apparent affinity of antibody-receptor interaction and effectively
downregulate receptor on both wild-type and mutant EGFR-expressing cell lines. This particular
case illustrates the advantage of the bispecific format, which enables avidity-mediated synergy
that is not observed with combination treatment.
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Another approach we pursue in engineering antibodies that engage multiple epitopes on EGFR is
the conjugation of Fn3 domains to the cetuximab IgG, creating the bispecific, trispecific, and
even tetraspecific constructs described in Chapter 4. We determine that the optimal format in
terms of both secretion and downregulation efficacy is the trans-trispecific fusion, which
involves one heavy chain N-terminal and one light chain C-terminal Fn3 moiety. We establish
that these constructs accelerate endocytosis and block recycling in the absence of receptor or
downstream signaling activation. Like antibody combinations, trans-trispecific mutants
selectively antagonize migration and growth of autocrine-driven cells.
Prompted by our promising in vitro results, we evaluated the therapeutic efficacy of our lead
bispecific antibody and Ab-Fn3 fusion in mouse tumor xenograft models of EGFR-expressing
cancer. As discussed in Chapter 5, we observe significant inhibtion of tumor growth following
administration of multispecific therapeutics, which correlates well with our in vitro
downregulation studies and coincides with an overall decrease in EGFR expression.
Surprisingly, we achieve strong tumor control in cell lines that resist treatment with the base
cetuximab antibody due to mutations in downstream effector proteins. Manipulation of our
antibody fusions allows us to implicate ligand inhibition, downregulation, and effector function
in the therapeutic mechanism of these constructs. In particular, the combined effects of
multispecific antibody-mediated downregulation and ligand competition ablate signaling through
both the P13K and MAPK pathways in a cell line with a mutation downstream of EGFR in the
MAPK cascade. The efficacy observed our pre-clinical studies provides motivation for further in
vivo characterization and pre-clinical development of these multispecific molecules as potential
therapeutic agents for cancer treatment.
Future Perspectives
The efficacy of our multispecific fusions may extend to other tumor cell lines representing
cancers of diverse origins that overexpress EGFR. Evaluation of these fusions in a breadth of
systems will characterize the robustness of response and will prove informative for the
therapeutic indications of our constructs. Further studies in non-immune deficient mice will be
essential in the pre-clinical development of our molecules to ensure the absence of
immunogenicity. In addition, although the relatively low effective doses compared to the less
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potent unconjugated IgG of our antibody could mollify off-target effects, rigorous
characterization of the toxicity of our compounds must be performed. We predict based on our
HMEC-derived autocrine cell line data that our constructs would exhibit similar toxicity
behavior to the base cetuximab antibody, which has been well-tolerated in the clinic (1, 2).
However, skin rashes are frequently observed in cetuximab-treated patients, with rash severity
correlating strongly to drug response (3). In the downstream development of our engineered
constructs, it will be important to determine whether conjugation of scFv and Fn3 domains to the
cetuximab IgG exacerbates or mitigates toxic side effects.
In addition to realization of the exciting therapeutic potential for our constructs in the treatment
of epithelial-based cancers, we envision the extension of our multi-epitopic clustering strategy to
create novel more effective EGFR-targeted constructs. In particular, isolation of additional non-
competitive domain 3-targeted antibodies could incrementally improve downregulation, based on
the epitope bias discovered from our pairwise downregulation screen. It would be of particular
utility to engineer antibodies that more efficiently downregulate receptor on A431 cells, as this
cell line resists downregulation and, consequently, therapeutic intervention. Additionally, other
topologies for a tetraspecific Ab-Fn3 fusion could be explored that extend the cis-trispecific by
fusing an additional Fn3 domain at the HC or LC position for comparison with the HN+HC+LC
format used in our downregulation panel. In addition to enhancing receptor clustering, the
ability to target four epitopes introduces the possibility of engaging multiple receptors in clusters
and thereby simultaneously preventing their active signaling. This would be particularly relevant
for the EGFR system, as compensatory signaling via ErbB3 and c-Met have been shown to
confer resistance to EGFR therapies via P13K pathway activation (4-8). The frequent co-
expression and colocalization of EGFR and interacting RTKs would facilitate multi-receptor
clustering and allow for robust and widespread efficacy of engineered tetraspecific therapeutics.
We find that the multispecific antibody-induced downregulation mechanism is effective even in
systems involving receptor mutation (EGFRvIII) and ligand dysregulation (HMEC-derived
autocrine cell lines), making this strategy a promising candidate for drug synergism. In
particular, targeting EGFR downregulation could be a useful tool for circumventing secondary
resistance to existing therapies, for instance the T790M receptor mutation which appears in
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>90% of patients who develop acquired resistance to the TKIs gefitinib or erlotinib (9-12). It
will thus be useful to characterize how our drugs would complement existing therapies, for
instance through sensitization to TKIs (13) or cell disruptive agents (13, 14). Also, it has
recently been reported that EGFR promotes survival through signal-independent mechanisms
(15, 16), motivating the use of our agents to decrease the overall EGFR burden through
antibody-mediated downregulation.
In addition to its utility in systems involving EGFR mutation and ligand upregulation, multi-
epitopic antibody action lends itself to multi-step targeting strategies and delivery applications
due to its remarkable specificity and affinity for target antigen as well as its induction of rapid
clustering and internalization of receptor in the absence of agonism. The high concentrations of
clustered receptor-antibody complexes achieved by multispecific constructs could render them
powerful vehicles for acute presentation of destructive agents or fusogenic peptides that facilitate
endosomal escape. In addition, surface-localized clustered antibody-receptor complexes could
serve as active immune effector cell recruitment sites, eliciting extensive ADCC or CDC (17).
The enhancement of effector function via Fc engineering or introduction of T cell-engaging
moieties could potentiate these immune effects (18, 19).
Finally, the modularity of multi-epitopic targeting design makes our strategy readily extensible
to other receptor networks of therapeutic interest. Design of multispecific fusions directed to
other RTKs and combination of two or more multi-epitopic therapies with distinct targets present
exciting new directions in drug development.
In conclusion, we have gained extensive insight into the phenomenon of antibody-mediated
receptor downregulation and used our findings to engineer therapeutics that employ this
mechanism to inhibit tumor growth. The constructs we have developed hold powerful potential
in cancer therapy and pave the way for a new wave of antibody-based drugs and combination
treatments that exploit receptor clustering and downregulation to achieve therapeutic efficacy.
155
References
1. Saltz LB, et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal
cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201-
1208.
2. Cunningham D, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl JMed 3 51(4):337-345.
3. Lenz HJ, et al. (2006) Multicenter phase II and translational study of cetuximab in
metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and
fluoropyrimidines. J Clin Oncol 24(30):4914-4921.
4. Sergina NV, et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by
the kinase-inactive HER3. Nature 445(7126):437-441.
5. Wheeler DL, et al. (2008) Mechanisms of acquired resistance to cetuximab: role of HER
(ErbB) family members. Oncogene 27(28):3944-3956.
6. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science 316(5827):1039-1043.
7. Schoeberl B, et al. (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-
dependent activation. Cancer Res 70(6):2485-2494.
8. Schoeberl B, et al. (2009) Therapeutically targeting ErbB3: a key node in ligand-induced
activation of the ErbB receptor-PI3K axis. Sci Signal 2(77):ra3 1.
9. Balak MN, et al. (2006) Novel D761Y and common secondary T790M mutations in
epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance
to kinase inhibitors. Clin Cancer Res 12(21):6494-6501.
10. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer
to gefitinib. N Engl JMed 352(8):786-792.
11. Kosaka T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in
patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer
Res 12(19):5764-5769.
12. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib
is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73.
156
13. Regales L, et al. (2009) Dual targeting of EGFR can overcome a major drug resistance
mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119(10):3000-
3010.
14. Xu S & Weihua Z (2011) Loss of EGFR induced autophagy sensitizes hormone
refractory prostate cancer cells to adriamycin. Prostate.
15. Weihua Z, et al. (2008) Survival of cancer cells is maintained by EGFR independent of
its kinase activity. Cancer Cell 13(5):385-393.
16. Yao Y, et al. (Mitochondrially localized EGFR is independent of its endocytosis and
associates with cell viability. Acta Biochim Biophys Sin (Shanghai) 42(11):763-770.
17. Dechant M, et al. (2008) Complement-dependent tumor cell lysis triggered by
combinations of epidermal growth factor receptor antibodies. Cancer Res 68(13):4998-
5003.
18. Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal
antibodies. Curr Opin Biotechnol 20(6):685-691.
19. Lutterbuese R, et al. (2010) T cell-engaging BiTE antibodies specific for EGFR potently
eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA
107(28):12605-12610.
157
Appendix A: Basic Trafficking Model
From the diagram:
dR~~-kR
s dt 
_ Y Rsk, + Rjkedt Se I
dRI~~ R
dt = Rske - Rkec - Rk
RTotal = Rs + R,
dRTotal. p 
- R k
dt '
Assume steady state.
dRotal 
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dt dt
0= P,, - Rkdeg
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Let t=treated and u=untreated.
Further assume that:
1) kdeg,t kdeg,u kdeg
2) Psyn, u = Psyn,u = Psyn
3) kre,t = 0
% Receptor Remaining = sU _
P
P +S"" k
kdeg rect + krec,t
kect ke,u kdeg
P ke kre~
syn syn re
deg kdeg
ke,u
% Receptor Remaining = 1+
ke,t 4 rec,u
I degj
From literature values (Lauffenburger & Linderman (1993). Receptors. New York:
Oxford University Press):
krecu 10-2 10-1 min' (5.8x10-2 min-1)
kdeg ~10 - 10-2 min-1 (2.2x10-3 min-)
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Now consider krec,u/kdeg.
Max krec" = 1  -1 =100
kdeg 10~' min
in k ' ) _ 10~2 min-'
keg. 10-2 min- 1
=>1 k'' s100
kdeg
Using the exact values from Lauffenburger & Linderman: krec,2/kdeg ~ 26.4
Based on experimental results, endocytosis accelerates or stays constant following treatment, so:
ke,u
ket
Assume that endocytosis is unaffected by treatment, so ke,u= ke,t.
R_ 1
% Receptor Remaining = RSu _ 1
kdeg
Using the exact parameter values:
% Receptor Remaining = s,' 1
1+26.4
The upper and lower bounds on downregulation are thus as follows:
1 1
s % Receptor Remaining s
1+100 1+1
1.0% s % Receptor Remaining s 50%
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Dependence of downregulation extent on antibody clone used implies:
1) Variable ke,t
2) Variable krec,t
OR BOTH
We can constrain ke,t based on our experimental results from Chapter 2:
Normal metabolic turnover ~ 36 h => ln(2)/ke,u= 36 h => ke,u= 3.2x10-4 min-
Fastest downregulation halftime ~ 2 h => ln(2)/ke,t= 4 h => ke,t = 0.006 min1
Slowest downregulation halftime ~ 11 h = ln(2)/ke,t= 11 h => ke,t= 0.001 min1
Thus, assuming surface downregulation is a result of an endocytic rate change ONLY, the lower
bound for ke,u/ke,t is:
k 3.2 x 10-4 min- = 0.055
e,"~ 1 .5
ke,t 0.006 min-
The ratio of the endocytic rates is thus bounded by:
0.055s ke,
ke,t
We may now estimate the limitations on downregulation extent:
R (ke) 1
% Receptor Remaining = RSu ke,u
RS'u e,t + krec,u
kdeg
0.2-0.4 0.11-1 0.01-0.5
. s Receptor emainng s
Thus, steady-state downregulation level is bounded and depends on the acceleration of
endocytosis as well as the endogenous rates of recycling and degradation in a given cell line.
161
Appendix B: Comprehensive Phosphotyrosine Mass Spectrometry Dataset
The full mass spectrometry dataset from our global phosphotyrosine screen described in Chapter
2 (Figure 2.15B) included 28 proteins from the 15' timepoint and 48 proteins from the 60'
timepoint. Phosphoprotein activity in A431 cells treated with an isotype control antibody, 225,
HI 1, 225+H11, or EGF is shown in Figure B.1. Proteins and the phosphopeptide sequences are
identified in Table B. 1.
Consistent with the Akt and ERK effectors
proteins to varying extents, but none of the
detected proteins based on a threshold of 1
shown in Figure 2.1 5B, EGF stimulates effector
single or combination treatments activates the
.7-fold background.
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Figure B.1. Global mass spectrometry analysis of mAb-treated cells. Serum-starved A431 cells were incubated with
single mAbs, the 225+H1 1 mAb combination, or EGF for 15 min (left) or 60 min (1) at 37 0C. EGF stimulation was
held constant at 15 min for both screens. Cells were then subjected to an iTraq-based mass spectrometry assay to
identify and quantify phosphorylated peptides. Phosphoprotein signal was normalized to total protein concentration
for each condition and relative phosphorylation levels (compared to an isotype control) are shown for all detected
peptides. The 60 min screen was performed twice with strong agreement between phosphorylation levels for
proteins observed in both biological replicates.
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15'
Number Abbreviation Protein Name Site Sequence
1 EGFR epidermal growth factor receptor Y1173 K.GSTAENAEyLR.V
isoform a
2 EGFR epidermal growth factor receptor Y1 148 K.GSHQISLDNPDyQQDFFPK.
isoform a E
3 PDLIM1 PDZ and LIM domain 1 Y321 R.VTPPEGyEVVTVFPK.-
myeloid/lymphoid or mixed-lineage
4 AF6 leukemia (trithorax homolog, Y1214 R.EyFTFPASK.SDrosophila); translocated to, 4
isoform 2
5 PTK6 PTK6 protein tyrosine kinase 6 Y447 R.LSSFTSyENPT.-
6 PKP3 plakophilin 3 Y175 R.ADyDTLSLR.S
7 Erbin ERBB2 interacting protein isoform Y1 104 R.AQIPEGDyLSYR.E
8 ERKI mitogen-activated protein kinase 3 Y204 R.IADPEHDHTGFLTEyVATR.isoform 2 W
9 Paxillin paxillin Y118 R.VGEEEHVySFPNK.Q
10 ERK2 mitogen-activated protein kinase 1 Y187 R.VADPDHDHTGFLTEyVATR.W
SHC (Src homology 2 domain
11 SHC1 containing) transforming protein 1 Y318 R.ELFDDPSyVNVQNLDK.A
isoform p52Shc
12 PKP4 plakophilin 4 isoform a Y1 168 K.STTNyVDFYSTK.R
13 EphA2 ephrin receptor EphA2 Y575 R.QSPEDVyFSK.S
14 P3PBP3 phosphoinositol 3-phosphate- Y492 R.SEDIyADPAAYVMR.Rbinding protein-3
dual-specificity tyrosine-(Y)-
15 DYRKIA phosphorylation regulated kinase Y320 R.IYQyIQSR.F
1A isoform 3
16 PRP4K serine/threonine-protein kinase K.LCDFGSASHVADNDITPyLPRP4K VSR.F
17 CDK1 cell division cycle 2 protein isoform Y14 K.IGEGTyGVVYK.G
18 EphA2 ephrin receptor EphA2 Y772 R.VLEDDPEATyTTSGGKIPIR
19 Na+/K+ - Na+/K+ -ATPase alpha 1 subunit Y260 R.GIVVyTGDR.TATPase al isoform a proprotein
20 GSK3b glycogen synthase kinase 3 beta Y216 R.GEPNVSyICSR.Y
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60'
Number Abbreviation Protein Name Site Sequence
K.IGTAEPDyGALYEGR.N +
1 PLCg phospholipase C gamma 1 isoform b Y771 Phospho (Y)
2 EGFR epidermal growth factor receptor Y1 173 K.GSTAENAEyLR.V +isoform a Phospho (Y)
3 EGFR epidermal growth factor receptor Y1148 K.GSHQISLDNPDyQQDFFPK.isoform a E + Phospho (Y)
4 PKP3 plakophilin 3 Y175 ADYDTLSLR.S + Phospho
_________(Y)
SHC (Src homology 2 domain R.ELFDDPSyVNVQNLDK.A +5 SHC1 containing) transforming protein 1 Y318 Phospho (ST)isoform p52Shc
6 ERK1 mitogen-activated protein kinase 3 Y204 R.IADPEHDHTGFLTEyVATR.isoform 2 W + Phospho (Y)
7 Cortactin a cortactin isoform a Y421 R.LPSSPVyEDAASFK.A +Phospho (Y)
8 ERK2 mitogen-activated protein kinase 1 Y187 R.VADPDHDHTGFLTEyVATR.W + Phospho (Y)
9 ANX2 annexin A2 isoform 2 Y30 K.AyTNFDAER.D + Phospho(Y)
10 SHP2 protein tyrosine phosphatase, non- Y580 R.VyENVGLMQQQK.S +
receptor type 11 Phospho (Y)
11 BCAR1 breast cancer anti-estrogen Y249 R.HLLAPGPQDIyDVPPVR.G
resistance 1 + Phospho (Y)
12 HSP90b heat shock 90kDa protein 1, beta Y276 K.yIDQEELNK.T + Phospho(Y)
13 TYK2 tyrosine kinase 2 Y292 R.LLAQAEGEPCyIR.D +Phospho (Y)
14 TIM rho guanine nucleotide exchange Y665 R.DySTVSASPTALSTLK.Q +factor 5 Phospho (Y)
15 LISCH3 LISCH protein isoform 3 Y518 R.SGDLPyDGRLLEEAVR.K +Phospho (Y)
16 Integrin bI integrin beta 1 isoform 1A precursor Y783 K.WDTGENPIyK.S + Phospho
__________________________(Y)
17 CAV1 caveolin 1 Y1l4 K.YVDSEGHLyTVPIR.E +Phospho (Y)
18 MPP5 membrane protein, palmitoylated 5 Y242 R.VyESIGQYGGETVK.I +
_______ __________ _____________Phospho (Y)
19 Syntaxin 4 syntaxin 4 Y251 NILSSADyVER.G + Phospho
____ ___ ___ ___ ____ __ ___  ___ 
____ ___ ____ ___(Y)
20 EphB3 ephrin receptor EphB3 precursor Y792 FLEDDP PTyTSSLGGK.I
21 Cofilin 1 cofilin 1 (non-muscle) Y89 R.YALYDATyETK.E +Phospho (Y)
22 SHP2 protein tyrosine phosphatase, non- Y62 K.IQNTGDyYDLYGGEK.F +
receptor type 11 Phospho (Y)
23 Cortactin a cortactin isoform a Y446 R.GPVSGTEPEPVySMEAADYR.E + Phospho (Y)
24 EphA2 ephrin receptor EphA2 Y772 R.VLEDDPEATyTTSGGKIPIRI_ I_  .W + Phospho (Y)
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25 p38 MAPK mitogen-activated protein kinase 14isoform 1 Y182
R.HTDDEMTGyVATR.W +
Phospho (Y)
26 PI3K p85 phosphoinositide-3-kinase, Y464 R.EYDQLYEEYTR.T +
regulatory subunit 2 (beta) Phospho (Y)
27 PYK2 PTK2B protein tyrosine kinase 2 Y819 K.QMVEDyQWLR.Q +beta isoform a Phospho (Y)
28 EphB2 ephrin receptor EphB2 isoform 2 71 R.FLEDDTSDPTyTSALGGK.Iprecursor + Phospho (Y)
29 ANX1 annexin I Y216 K.QAWFIENEEQEyVQTVK.S
+ Phospho (Y)
R.SLEATDSAFDNPDyWHSR.30 ErbB3 erbB-3 isoform 1 precursor Y1328 L + Phospho (Y)
31 Erbin ERBB2 interacting protein isoform Y1 104 R.AQIPEGDyLSYR.E +2 Phospho (Y)
32 PKP4 plakophilin 4 isoform a Y1 168 K.STTNYVDFYSTK.R +
Phospho (ST)
dual-specificity tyrosine-(Y)-
33 DYRKIA phosphorylation regulated kinase lB Y320 R.IYQyIQSR.F + Phospho (Y)
isoform a
34 RAK fyn-related kinase Y46 R.HGHyFVALFDYQAR.T +Phospho (Y)
35 PZR myelin protein zero-like 1 isoform a Y263 K.SESVVyADIR.K + Phospho
____ ____ ___ __ ____ ___ _______ (Y)
36 P3PBP3 phosphoinositol 3-phosphate- Y492 R.SEDIyADPAAYVMR.R +binding protein-3 Phospho (Y)
37 a-Catenin catenin, alpha 1 Y619 R.LVYDGIR.D + Phospho (Y)
R.LLDDFDGTyETQGGKIPIR.
38 EphA1 ephrin receptor EphA1 Y281 W + Phospho (Y)
39 PRPK4 serine/threonine-protein kinase K.LCDFGSASHVADNDITPyLPRP4K VSR.F + Phospho (Y)
40 CDK1 cell division cycle 2 protein isoform 4 K.IGEGTYGVVyK.G +1 Phospho (Y)
41 Yes Yamaguchi sarcoma viral (v-yes-1) Y316 R.EEPIyIITEYMAK.G +
oncogene homolog isoform A Phospho (Y)
42 GSK3b glycogen synthase kinase 3 beta Y216 R.GEPNVSyICSR.Y + Phospho
_______I (Y)
43 XB130 kin of IRRE like Y560 R.TPYEAyDPIGK.Y + Phospho
I (Y)
44 Src/Fyn/Yes protein-tyrosine kinase fyn isoform Y420 R.LIEDNEYTAR.Q + Phospho
a (Y)
R.VGEEEHVySFPNK.Q +45 Paxillin paxilhin Y118 Phospho (Y)
46 Na+/K+ - Na+/K+ -ATPase alpha 1 subunit Y260 R.GIVVyTGDR.T + PhosphoATPase al isoform a proprotein (Y)
47 RPTPa protein tyrosine phosphatase, Y791 K.VVQEYIDAFSDYANFK.- +
receptor type, A isoform 1 precursor Phospho (Y)
48 FYB-120/130 FYN binding protein (FYB- Y561 K.TTAVEIDyDSLK.L +120/130) isoform 2 Y Phospho (Y)
Table B. 1. Peptide sequences and corresponding proteins detected in 15 and 60 min A431 phosphotyrosine mass
spectrometry screens. Lowercase residues in the sequences denote phosphorylated amino acids (either Y, S, or T).
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Appendix C: DNA Sequences
All secreted constructs were based on the gWiz backbone (Genlantis, San Diego, CA) with the
heavy and light chain of each antibody fusion. For the first construct (gWiz 225 HC), the full
vector is shown. For subsequent constructs, only the engineered region from the Pstl to the Sall
sites from the gWiz polylinker region are shown.
The 225 and 806 variable sequences were obtained from the information contained in their
respective patents.
The constructs described herein are:
1) Unconjugated Antibodies
2) Bispecific 225/806-Containing Antibodies (BS28)
3) Antibody-Fibronectin Fusions (Ab-Fn3 Fusions)
Abbreviations
HC=Heavy Chain
LC=Light Chain
VH=Heavy Chain Variable Domain
VL=Light Chain Variable Domain
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1) Unconjugated Antibodies
gWiz 225 HC (225 variable domain on human IgGi Scaffold)
TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGC1'GTCTGTAAGCGGATGCCGG
GAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTG'ITGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAGAGCAGATTGT
ACTGAGAGTGCACCATATGCGGTGTGAAATACCGCACAGATGCGTAAG3AGAAAATACCGCATCAGATTGGCTATTGOCCATTGC
ATACGTTGTATCCATATCATAATATGTACATTATATTG43CTCATGTCCAACATTACCGCCATGTTGACATfGATTATTGACTAGTT
ATTAATAGTAATCAATTACGGGGTCATTAGnrCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCT
GGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTCCATTGAC
GTCAATGGOTGGAGTATTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTC
AATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGT
CATCGCTATTACCATGGTGATGCGGTTTJGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGA1TTCCAAGTCTCC
ACCCCATTGACGTCAATGGOAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACG
CAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT-rTAGTGAACCGTCAGATCGCCTGGAGACGCCATC
CACGCTG1TrGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCG
TGCCAAGAGTGACGTAAGTACCGCCTATAGACTCTATAGGCACACCCCTTTGGCTCTUATGCATGCTATACTGTTrTTGGCTTGGG
GCCTATACACCCCCGCTTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTTATGACCATTATTGACCACTCCC
CTATTGGTGACGATACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAACTATCTCTATTGGCTATATGCCAATACTCTGTC
CTTCAGAGACTGACACGGACTCTGTATFI=rACAGGATGGGGTCCCATTTA1TATTrACAAATTCACATATACAACAACGCCGTCC
CCCGTGCCCGCAGTrTTMATTAAACATAGCGTcXXIATCTCCACGCGAATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGT
AGCGQCGQAGCTTCCACATCCGAGCCCTGGTCCCATGCCTCCAGCGGCTCATGGTCGCTCGGCAGCTCCTTGCTCCTAACAGTGGA
GGCCAGACTrAGGCACAGCACAATGCCCACCACCACCAGTGTGCCGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAATGA
GCGTGGAGATTGGGCTCGCACGGCTGACGCAGATGGAAGACTTAAGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGT
ATTCTGATAAGAGTCAGAGGTAACTCCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAG.TCTGAGCAGTACTCGTTGCTGCC
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TTTTTGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTrGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGQAAGGTGCCACT
CCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGTGGcJTGGGGcCA
GCACAGCAAGGGGAGGATTGGAAGACAATAGCAGCATGCTGGGATGCGGTGGGCTCTATGGTACCTCTCTCTCTCTCTCT
CTCTCTCTCTCTCTCTCTCTCTCTCGTACCTCTCTCTCTCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCGGTACCAGTGCTGAAGA
ATTGACCCGGTTCCTCCTGGGCCAGAAAGAAGCAGGCACATCCCCTTCTCTGTGACACACCCTGTCCACGCCCCTGGTTCTTAGTT
CCAGCCCCACTCATAGGACACTCATAGCTCAGGAGGGCTCCGCCTTCAATCCCACCCGCTAAAGTACTTGGAGCGGTCTCTCCCTC
CCTCATCAGCCCACCAAACCAAACCTAGCCTCCAAGAGTGQGAAGAAATTAAAGCAAGATAGGCTATTAAGTGCAGAGGGAGAG
AAAATGCCTCCAACATGTGAGGAAGTAATGAGAGAAATCATAGAATTTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTC
GTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG3TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAAC
ATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTc3CGTTITCCATAcGCTCCGCcCCCCCTGACG
AGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGcjCGTTTCeCCCTGQAAGCT
CCCTCGTGCGCTCTCCTGT-rCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTfTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAAT
GCTCACGCTGTAGOTATCTCAGTTCGGTGTAGOTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGC
TGCGCCTTATCCGTAACTATCGTCTUGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGCAGCAGCCACTGGTAACAGGA
TTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTrCTTGAAGTGGTGGCCTAACTACG%3CTACACTAGAAcGiACAGTATTTGG
TATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTfGATCCGGCAAACAAACCACCGCTGQTAGCGJT
GGTT=rTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTCTACGG3GTCTGACGC
TCAGTGGAACGAAAACTCACGTTAAGGGATTTrGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTAAATrAAAAAT
GAAG1TTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCG
ATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCGGGGGGGGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGcJTGTTGCTGACT
CATACCAGGCCTGAATCGCCCCATCATCCAGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTT
GGTGA=mGAACTTrTGCTTTGCCACGGAACGGTCTGCGTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCAAAAGTTC
GATTTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCAATTAACCAATTCTGATTAGAAAA
ACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAA
GGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAAC
CTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGQTGAGAATGCAAALG
CTTATGCATTTCTTTCCAGACTTGTJ7CAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCAT
TCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGOCGCAG
GAACACTGCCAGCGCATCAACAATATrTTCACCTGAATCAGGATATTCTCTAATACCTGGAATGCTG=rTCCCGMJQATCGCAG
TGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGcITCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCT
GACCATCTCATCTGTAACATCATTGGCAACGCTACCTTrGCCATGTTTCAGAAACAACTCTGGCGCATCGQ(JCTTCCCATACAATC
GATAGATTGTCGCACCTGATL'GCCCGACATrATCGCGAGCCCATTrATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGC
GGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCAT
GATGATATATTTTATCTTGTGCAATGTAACATCAGAGAT=rGAGACACAACGTGGCTTTCCCCCCCCCCCCATTATTGAAGCATT
TATCAGGGTrATTGTCTCATGAGCGGATACATATTTGAATGTATrTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTrCCCCG
AAAAGTGCCACCTGACGTCTAAGAAACCATrATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAM3CCCTTTCGTC
gWiz 225 LC (225 variable domain on human IgGi Scaffold)
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gWiz 806 HC (806 variable domain on human IgGi Scaffold)
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2) Bispecific 225/806-Containing Antibodies (BS28)
gWiz BS28-HN (Secreted with gWiz 225 LC)
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gWiz BS28-LN (Secreted with gWiz 225 HC)
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gWiz BS28-LC (Secreted with gWiz 225 HC)
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3) Antibody-Fibronectin Fusions (Ab-Fn3 Fusions)
The three EGFR-targeted Fn3 domain clones used in engineered fusions have the following
sequences (from Hackel BJ Neil JR, White FM, & Wittrup KD (Submitted) Epidermal growth
factor receptor downregulation by small heterodimeric binding proteins):
Fn3 Clone A
GTTTCCGATGTTCCGAGGGACCTGGAGGTTGTTGCTGCGACCCCCACCAGCCTACTG
ATCAGCTGGTTCGACTACGCTGTGACTTATTACAGGATCACTTACGGAGAAACAGGA
GGAAATAGCCCTGTCCAGGAGTTCACTGTGCCTGGTTGGATCTCCACTGCTACCATC
AGCGGCCTTAAACCTGGAGTTGATTATACCATCACTGTGTATGCTGTCACTGACAAC
TCTCGTTGGCCTTTTCGCTCTACTCCAATTTCCACTAATTACCGAACAGAAATTGACA
AACCACCCCAG
Fn3 Clone B
GTTTCTGATGTTCCGAGGGACCTGGAAGTTGTTGCTGCGACCCCCACCAGCCTACTG
ATCAGCTGGTACGGTTTTTCGCTTGCGAGCTCTTACAGGATCACTTACGGAGAAACA
GGAGGAAATAGCCCTGTCCAGGAGTTCACTGTGCCTCGTTCGCCCTGGTTTGCTACC
ATCAGCGGCCTTAAACCTGGAGTTGATTATACCATCACTGTGTATGCTGTCACTTCTA
ACGACTTTTCTAATCGTTACTCTGGTCCAATTTCCATTAATTACCGAACAGAAATTGA
CAAACCATCCCAG
Fn3 Clone D
GTTTCTGATGTTCCGAGGGACCTGGAAGTTGTTGCTGCGACCCCCACCAGCCTACTG
ATCAGCTGGCTTCACCATCGCTCTGACGTGCGCTCTTACAGGATCACTTACGGAGAA
ACAGGAGGAAATAGCCCTGTCCAGAAGTTCACTGTGCCTGGGTCGCGCTCCCTGGCT
ACCATCAGCGGCCTTAAACCTGGAGTTGATTATACCATCACTGTGTATGCTGTCACT
TGGGGGTCTTACTGTTGCTCTAATCCAATTTCCATTAATTACCGAACAGAAATTGAC
AAACCATCCCAG
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gWiz HN-A (N-terminal heavy chain fusion)
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gWiz HC-A (C-terminal heavy chain fusion)
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gWiz LN-A (N-terminal light chain fusion)
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gWiz LC-A (C-terminal light chain fusion)
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gWiz RN-AD (Representative cis trispecific fusion chain)
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gWiz HNA+HCB (Representative double HCfusion chain)
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